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ABSTRACT OF DISSERTATION

MECHANISMS AND POTENTIAL THERAPY ON DISRUPTED BLOOD PRESSURE
CIRCADIAN RHYTHM IN DIABETES
Arterial blood pressure (BP) undergoes a 24-hour oscillation that peaks in the
active day and reaches a nadir at night during sleep in humans. Reduced nocturnal BP
fall (also known as non-dipper) is the most common disruption of BP circadian rhythm
and is associated with increased risk of untoward cardiovascular events and target
organ injury. Up to 75% of diabetic patients are non-dippers. However, the mechanisms
underlying diabetes associated non-dipping BP are largely unknown. To address this
important question, we generated a novel diabetic db/db-mPer2Luc mouse model
(db/db-mPer2Luc) that allows quantitatively measuring of mPER2 protein oscillation by
real-time mPer2Luc bioluminescence monitoring in vitro and in vivo. Using this model, we
demonstrated that the db/db-mPer2Luc mice have a diminished BP daily rhythm. The
phase of the mPER2 daily oscillation is advanced to different extents in explanted
peripheral tissues from the db/db-mPer2Luc mice relative to that in the control mice.
However, no phase shift is found in the central oscillator, the suprachiasmatic nucleus
(SCN). The results indicate that the desynchrony of mPER2 daily oscillation in the
peripheral tissues contributes to the loss of BP daily oscillation in diabetes.
Extensive research over the past decades has been focused on how the
components of food (what we eat) and the amount of food (how much we eat) affect
metabolic diseases. Only recently has it become appreciated that the timing of food
intake (when we eat), independent of total caloric and macronutrient quality, is also
critical for metabolic health. To investigate the potential effect of the timing of food
intake on the BP circadian rhythm, we simultaneously monitored the BP and food intake
profiles in the diabetic db/db and control mice using radiotelemetry and BioDAQ
systems. We found the loss of BP daily rhythm is associated with disrupted food intake
rhythm in the db/db mice. In addition, the normal BP daily rhythm is altered in the
healthy mice with abnormal feeding pattern, in which the food is available only during
the inactive-phase. To explore whether imposing a normal food intake pattern is able to

prevent and restore the disruption of BP circadian rhythm, we conducted active-time
restricted feeding (ATRF) in the db/db mice. Strikingly, ATRF completely prevents and
restorers the disrupted BP daily rhythm in the db/db mice. While multiple mechanisms
likely contribute to the protection of ATRF on the BP daily rhythm, we found that ATRF
improves the rhythms of energy metabolism, sleep-wake cycle, BP-regulatory hormones
and autonomic nervous system (ANS) in the db/db mice. To further investigate the
molecular mechanism by which ATRF regulates BP circadian rhythm, we determined the
effect of ATRF on the mRNA expressions of core clock genes and clock target genes in
the db/db mice. Of particular interest is that we found among all the genes we
examined, the mRNA oscillation of Bmal1, a key core clock gene, is disrupted by
diabetes and selectively restored by the ATRF in multiple peripheral tissues in the db/db
mice. More importantly, we demonstrated that Bmal1 is partially required for ATRF to
protect the BP circadian rhythm.
In summary, our findings indicate that the desynchrony of peripheral clocks
contributes to the abnormal BP circadian pattern in diabetes. Moreover, our studies
suggest ATRF as a novel and effective chronotherapy against the disruption of BP
circadian rhythm in diabetes.

KEYWORDS: Diabetes, Blood pressure circadian rhythm, Clock genes, Time-restricted
feeding, Sympathetic nervous system, db/db mice
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CHAPTER I. INTRODUCTION
1.1 Diabetes
1.1.1 Background
The prevalence of diabetes is increasing steadily over the decades, from 4.3% in 1980 to
8.5% in 2014 worldwide. This accounts for a total of 422 million adults (9% of men and
7.9% of women) that year (2016). This number exceeds the previous projection that 439
million adults will have diabetes in 2030 (Shaw, Sicree et al. 2010). The newest
International Diabetes Federation (IDF) diabetes atlas projects that the number of adults
affected by diabetes is expected to rise to 521 to 829 million by 2040, which accounts
for 10.4% of adults globally (Ogurtsova, da Rocha Fernandes et al. 2017).
Diabetes is classified into four general categories: 1) type 1 diabetes (T1D); 2)
type 2 diabetes (T2D); 3) gestational diabetes and 4) specific types of diabetes due to
other causes, such as monogenic diabetes syndromes, diseases of the exocrine
pancreas, and drug- or chemical-induced diabetes (2018). Among the different forms of
diabetes, T2D accounts for 90-95% of all diabetes in the US (Prevention 2017). T2D,
previously known as “non-insulin dependent diabetes mellitus”, is a chronic metabolic
disease and results from the progressive loss of -cell insulin secretion; it is
characterized by hyperglycemia, insulin resistance and relative insulin deficiency
(Chatterjee, Khunti et al. 2017).

1

1.1.2 Complications of type 2 diabetes
People with T2D are more susceptible to various forms of short- and long-term
complications, which can lead to their premature death. The Centers for Disease Control
and Prevention (CDC) of US reported that diabetes is the seventh leading cause of death
in the US (Prevention 2017). The world Health Organization (WHO) projects that
diabetes will be the seventh leading cause of death in 2030 in the whole world (Mathers
and Loncar 2006). The short-term, or acute complications associated with T2D include a
hyperglycemic hyperosmolar state (HHS) due to acute hyperglycemia (Pasquel and
Umpierrez 2014) as well as coma due to hypoglycemia, resulting from an adverse effect
of diabetes treatment using insulin and sulfonylureas (Frier 2014). The long-term, or
chronic complications of diabetes include microvascular diseases (due to the damage to
small vessels, e.g. retinopathy, nephropathy, and neuropathy) and macrovascular
diseases (due to the damage to the arteries, e.g. coronary artery disease leading to
angina or myocardial infarction and cerebrovascular disease contributing to stroke)
(Forbes and Cooper 2013). In addition, T2D has also been found to be associated with
cancer (Tsilidis, Kasimis et al. 2015), depression (Semenkovich, Brown et al. 2015),
dementia (Biessels, Strachan et al. 2014), tuberculosis (Jeon and Murray 2008) and
sexual dysfunction (Isidro 2012). The incidence and mortality rate of the short-term
complications is relatively low in T2D. The most devastating consequence of T2D is the
long-term complications, among which cardiovascular disease (CVD) is the leading cause
of mortality and morbidity associated with T2D (Organization 2014). In 1979, Kannel et
al used the data from the Framingham Heart Study (FHS), which includes 13,861 men
2

and 18,928 women of 45 to 74 years of age at the time of the study, first identified that
people with diabetes are two to three times more likely to have CVD than those without
(Kannel and McGee 1979). Several decades later, due to effective prevention and
treatment, the incidence of CVD has declined in people with diabetes (Fox, Coady et al.
2004, Dale, Vatten et al. 2008), which is in accordance with the overall reduction of CVD
(Rosamond, Chambless et al. 1998, Cooper, Cutler et al. 2000). Despite this, diabetes is
still associated with 2-fold higher incidence in the rate of CVD (Fox, Coady et al. 2004,
Collaboration 2010) . A recent systematic literature review demonstrated that CVD
affects more than 30% of persons with T2D and accounts for approximately half of all
death among people with diabetes between the year 2007 to 2017 (Einarson, Acs et al.
2018).
1.1.3 Hypertension in type 2 diabetes
The mechanisms linking T2D with CVD are not well understood currently.
Researchers have demonstrated there are several risk factors for developing CVD in
people with T2D. Studies have shown that hyperglycemia (Klein 1995, Gerstein and
Yusuf 1996, Lehto, Ronnemaa et al. 1996, Turner, Millns et al. 1998, Stratton, Adler et al.
2000), hypertension (1993, Stamler, Vaccaro et al. 1993, Lehto, Ronnemaa et al. 1996,
Turner, Millns et al. 1998), increased low density lipoprotein (LDL) cholesterol and
decreased high density lipoprotein (HDL) cholesterol (Stamler, Vaccaro et al. 1993,
Turner, Millns et al. 1998), and smoking (Stamler, Vaccaro et al. 1993, Turner, Millns et
al. 1998, Qin, Chen et al. 2013, Pan, Wang et al. 2015) significantly increase the
incidence and mortality of CVD. However, the contribution of each risk factor to the
3

development of CVD is not equal. The population attributable fraction (PAF) is a widely
used epidemiologic measure to assess the impact of exposures to the public health in
populations (Mansournia and Altman 2018). It is equivalent to the reduction of
mortality with reduced risk factor exposured. For ischaemic heart disease, the PAF for
hyperglycemia, high cholesterol, hypertension and smoking is 21%, 45%, 47% and 12%,
respectively (Danaei, Lawes et al. 2006). And for stroke, the PAF for hyperglycemia is
13%, which is equal to high cholesterol, for hypertension is 54% and for smoking is 8%
(Lopez, Mathers et al. 2006). Therefore, hypertension has the highest PAF value in CVD.
Indeed, a comparative risk assessment showed that hypertension is the leading risk
factor for deaths for CVD, chronic kidney disease and diabetes and causes more than
40% deaths from these diseases worldwide (2014).
Hypertension and T2D often coexist. Hypertension occurs twice as often in
people with diabetes than in those without diabetes (El-Atat, McFarlane et al. 2004).
The prevalence of hypertension in T2D is 40 to 60 percent (1993, Kabakov, Norymberg
et al. 2006, Colosia, Palencia et al. 2013). When people have both hypertension and
T2D, their risk for CVD increases

(Gomes 2013). Multiple studies report that

antihypertensive treatment lowers the incidence of cardiovascular events among
diabetic patients (Curb, Pressel et al. 1996, Group 1998, Hansson, Zanchetti et al. 1998).
The UK Prospective Diabetes Study Group (UKPDS) found that each 10 mm Hg decrease
in updated mean systolic blood pressure was associated with reductions in risk of 12%
for any complication related to diabetes (95% confidence interval 10% to 14%,
P<0.0001), 15% for deaths related to diabetes (12% to 18%, P<0.0001), 11% for
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myocardial infarction (7% to 14%, P<0.0001), and 13% for microvascular complications
(10% to 16%, P<0.0001) (Adler, Stratton et al. 2000). A recent meta-analysis showed
that a 10-mmHg reduction in systolic blood pressure was significantly associated with
lower risk of all-cause mortality (RR, 0.87 [95% CI, 0.78-0.96]) and cardiovascular events
(RR, 0.89 [95% CI, 0.83-0.95]) (Emdin, Rahimi et al. 2015).
Accumulating studies have shown that diabetic patients have not only an
increased prevalence of high blood pressure, but also the incidence of abnormal BP daily
variation is elevated compared to nondiabetic people. In addition, the abnormal BP
variation is independently associated with increased risk of cardiovascular events and
target organ injury.

1.2 Blood pressure circadian rhythm
1.2.1 Background
Arterial blood pressure (BP) displayed distinct diurnal variation, characterized by
lowest value during sleep (around 3 a.m.), a slow increase during late sleep, an abrupt
rise upon morning awakening, and two daytime peaks (first one around 9 a.m. and
second one around 7 p.m.); the latter are separated by a small mid-afternoon drop
(around 3 p.m.), and a gradual decline thereafter till the nadir during sleep (Millar-Craig,
Bishop et al. 1978, Hermida, Ayala et al. 2007, Smolensky, Hermida et al. 2017). The 24hr BP in humans can be measured using a device called ambulatory blood pressure
measurement (ABPM); this is a noninvasive and autonomic BP monitor that measures
BP at regular intervals. The BP during the nighttime mean is normally 10-20% lower
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compared to the daytime mean, which is also called a dipping pattern. Abnormal BP
rhythm patterns include: non-dipping (nocturnal BP fall is less than 10% of daytime BP
mean), reverse dipping (nocturnal BP mean is higher than daytime BP mean), and
extreme dipping (nocturnal BP fall is greater than 20% of daytime BP mean).
In the general population, 50.3% of people are dippers, 23.5% are non-dippers,
20.3% are extreme-dippers and 5.9% are reverse-dippers as assessed by the
International Database on Ambulatory blood pressure monitoring in relation to
Cardiovascular Outcomes (IDACO). This study was based on the ABPM data of 7458
individuals (Boggia, Li et al. 2007). The prevalence of circadian BP patterns in
hypertensive patients has been assessed by the Spanish Society of Hypertension ABMP
Registry. Based on the results of 42947 hypertensive patients, dippers accounts for
50.2% of previously untreated patients (n=8384), extreme dippers, non-dippers and
risers (reverse-dippers) account for 8.8%, 35% and 6% respectively of this population (de
la Sierra, Redon et al. 2009). In patients receiving antihypertensive treatment (n=34563),
39.9%, 7.2%, 39.4% and 13.5% are dipper, extreme dippers, non-dippers and risers (de
la Sierra, Redon et al. 2009). Therefore, non-dipping BP is the most prevalent abnormal
BP circadian pattern in both the general population and in hypertensive patients.
1.2.2 Circadian variation of BP and CVD
Many cardiovascular events follow a well-defined frequency in their onset
throughout the day; this pattern is closely related to the diurnal variation of BP. For
example, the frequency of acute myocardial infarction onset is lowest during the
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nighttime sleep and highest during the awake time, between 6 AM to noon (Muller,
Stone et al. 1985, Hjalmarson, Gilpin et al. 1989, Willich, Linderer et al. 1989, Gilpin,
Hjalmarson et al. 1990, Hansen, Johansson et al. 1992, Behar, Halabi et al. 1993, Boari,
Salmi et al. 2007). Sudden cardiac death also exhibits 24-hour variation in the
occurrence, with trough onset during the night and peak onset during the morning
hours (Muller, Ludmer et al. 1987, Willich, Levy et al. 1987, Levine, Pepe et al. 1992,
Aronow and Ahn 1993, Aronow, Ahn et al. 1994). Stoke is another cardiovascular events
that is shown to be more frequent during the morning hours (Tsementzis, Gill et al.
1985, Marler, Price et al. 1989, Kelly-Hayes, Wolf et al. 1995, Manfredini, Gallerani et al.
1997, Casetta, Granieri et al. 2002). Meta-analyses of the three cardiovascular events
demonstrated that there is a 40%, 29% and 49% excess risk of acute myocardial
infarction, sudden cardiac death and stroke, respectively, that happen between 6 AM to
noon (Cohen, Rohtla et al. 1997, Elliott 1998). In addition, both the aortic rupture and
dissection happen more frequently during the early morning hours (Gallerani,
Portaluppi et al. 1997, Manfredini, Portaluppi et al. 1999, Manfredini, Boari et al. 2004,
Lasica, Perunicic et al. 2006, Killeen, Neary et al. 2007). The apparent time-of-day
difference in CVD onsets suggests there may be an association between the circadian
pattern of BP and CVD.
In 1988, O’Brien et al reported for the first time that hypertensive patients with a
less marked decrease in nighttime BP had a greater prevalence of stroke incidents and
named these patients non-dippers, in contrast to the normal dippers (O'Brien, Sheridan
et al. 1988). Since then, numerous studies have investigated the importance of
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nighttime BP and the circadian variation of BP. The majority of these studies found that
blunted nighttime BP fall and abnormal night-to-day ratio of BP is associated with
increased risk of CVD (Verdecchia, Schillaci et al. 1993, Verdecchia, Porcellati et al. 1994,
Zweiker, Eber et al. 1994, Staessen, Thijs et al. 1999, Ohkubo, Hozawa et al. 2002,
Kikuya, Ohkubo et al. 2005, Sega, Facchetti et al. 2005, Ingelsson, Bjorklund-Bodegard et
al. 2006, Boggia, Li et al. 2007, Mancia, Bombelli et al. 2007, Fagard, Celis et al. 2008,
Fagard, Thijs et al. 2009, Muxfeldt, Cardoso et al. 2009, Bastos, Bertoquini et al. 2010,
Hansen, Li et al. 2011, de la Sierra, Banegas et al. 2012) and target organ damage in
heart, kidney and brain, including greater ventricular mass index or left ventricular
hypotrophy (Kuwajima, Suzuki et al. 1992, Palatini, Penzo et al. 1992, Suzuki, Kuwajima
et al. 1992, Mayet, Shahi et al. 1995, Verdecchia, Schillaci et al. 1995, Cuspidi, Macca et
al. 2001, Hoshide, Kario et al. 2003, Hoshide, Kario et al. 2003, Cuspidi, Meani et al.
2004), albumin excretion or albuminuria (White 1992, Lurbe, Redon et al. 1993, Lindsay,
Stewart et al. 1995, Timio, Venanzi et al. 1995, Equiluz-Bruck, Schnack et al. 1996), and
silent cerebrovascular damage (Kario, Matsuo et al. 1996, Kario, Pickering et al. 2001).
Results from the Ohasama study showed that on average, each 5% decrease in the
decline in nocturnal systolic/diastolic BP was associated with an approximately 20%
greater risk of cardiovascular mortality in the Japanese general population (Ohkubo,
Hozawa et al. 2002). In addition, the nighttime BP was demonstrated to be a better
predictor of future cardiovascular events than daytime or office BP (Staessen, Thijs et al.
1999, Dolan, Stanton et al. 2005, Kikuya, Ohkubo et al. 2005, Boggia, Li et al. 2007,
Fagard, Celis et al. 2008, Hansen, Li et al. 2011, O’brien, Parati et al. 2013). Fan et al in
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2010 published results from a large prospective study in 8711 individuals from 10
populations for a mean follow-up of 10.7 years and found that the isolated nocturnal
hypertension, defined as daytime BP <135/85 mmHg and night-time BP ≥120/70 mmHg,
predicts cardiovascular outcomes in patients, even though their office or daytime
ambulatory BP is at normal range (Fan, Li et al. 2010). A recent review of nine cohorts
from Europe, Brazil and Japan of 13844 individuals also supports the claim that
nighttime BP better predicts cardiovascular outcomes than daytime and clinic BP
(Roush, Fagard et al. 2014).
Despite massive evidence supporting the prognostic role of nighttime BP in
predicting cardiovascular events, the relationship between the dipping status of BP and
cardiovascular outcomes is not consistent. For example, a few prospective studies with
relatively small sample size found that the nocturnal fall of BP is not associated with
increased left ventricular mass index or left ventricular hypotrophy (Roman, Pickering et
al. 1997, Cuspidi, Lonati et al. 1999, Yi, Shin et al. 2014). The results from meta-analyses
also showed inconsistent conclusions. For example, Fagard et al reported that night-today ratio of arterial BP only predicts all-cause mortality but is not associated with
cardiovascular risk (Fagard, Celis et al. 2008). On the contrary, Hansen reported that
night-to-day ratio predicts total cardiovascular events but not mortality after adjusting
for the 24-hour BP (Hansen, Li et al. 2011). Such discrepancy may be possibly because of
differences in sample size, study population, end point, the low-reproducibility of a
single 24-hour ABPM data and the definition of day and night periods (fixed or diary
time) that may significantly affect the classification of BP dipping pattern (Henskens,
9

Kroon et al. 2008). Therefore, the Ambulatory Blood Pressure Collaboration in Patients
with Hypertension (ABC-H) recently published a largest known meta-analysis on ABPM
database from 3 continents; the study consists of a total of 17312 hypertensive
individuals for follow-up of 4 to 8 years and found that after adjusting for 24-hour
systolic blood pressure (SBP), the systolic night-to-day ratio predicts all outcomes. In
particular, reduced nocturnal BP fall is associated with a significant 27% higher incidence
of all cardiovascular events compare to normal nocturnal BP fall (Salles, Reboldi et al.
2016). This largest meta-analysis confirmed the prognostic significance of BP dipping
status on CVD.
Among the different abnormal circadian BP patterns, reverse-dipping, in which
the nighttime BP is higher than the daytime BP, seems to have the worst cardiovascular
prognosis. In particular, the Ohasama study showed that reverse-dippers have the
highest mortality risk, followed by non-dippers (Ohkubo, Imai et al. 1997). Kario et al
found that the incidence of stoke is 6.7% in dipper, 7.6% in non-dippers, 12% in
extreme-dipper and 22% in reverse-dippers for an average duration of 41 months (Kario,
Pickering et al. 2001). In addition, intracranial hemorrhage was also more common in
reverse-dippers (29% of strokes) than in other subgroups (7.7% of strokes, P=0.04)
(Kario, Pickering et al. 2001). In another study Eguchi et al found that reverse-dippers
have the highest cardiovascular events rate, followed by non-dippers; these findings are
associated with approximately 150% increased risk of CVD (Eguchi, Pickering et al.
2008).

10

1.2.3 Circadian variation of BP in diabetes
Previous studies have demonstrated that type 2 diabetes is significantly
associated with abnormal BP circadian rhythm in both the general population (Boggia, Li
et al. 2007) and in hypertensive patients (de la Sierra, Redon et al. 2009). Impaired BP
circadian rhythm is found to be more common in people with diabetes than those
without, although the exact prevalence various among different studies. Fogari et al
found that an abnormal circadian BP pattern is detected in 30% of the normotensive
and 31% of the hypertensive diabetic patients compared to 6% of the normotensive and
6.4% of the hypertensive nondiabetic subjects (Corradi, Zoppi et al. 1993). However,
Pistrosch et al observed non-dipping BP in 73% of hypertensive diabetic patients
(Pistrosch, Reissmann et al. 2007), while Oh et al found non-dipping BP occurs in 58.2%
vs. 48.2% of hypertensive patients with and without diabetes (Oh, Han et al. 2015). The
reasons for the discrepancy of the prevalence of an abnormal BP circadian pattern in
diabetic patients are probably similar to the reasons that lead to inconsistent
conclusions between the relationship of BP dipping status and cardiovascular outcomes,
such as relatively small sample size, low-reproducibility of a single 24-hour ABPM data
and the definition of daytime and nighttime periods. In addition, the complications of
diabetes may also affect the BP dipping status. For example, Equiluz-Bruck et al
observed non-dipping BP in 80% of the macroalbuminuric, 74% of the microalbuminuric,
and 43% of the normoalbuminuric T2D patients compare to 37% of nondiabetic subjects
(Equiluz-Bruck, Schnack et al. 1996). Therefore, Ayala et al evaluated the influence of
diabetes on the circadian pattern of BP from the data of Hygia project, where 12765
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hypertensive patients (2954 T2D patients) were maintained on a diary listing times of
going to bed at night and awakening in the morning and their ABPM were monitored for
48-hours. They found that the prevalence of non-dipping BP was detected in 62.1% of
hypertensive diabetic patients compared to 45.9% hypertensive nondiabetic patients
(Ayala, Moya et al. 2013). In addition, the largest difference between diabetic and
nondiabetic patients is the prevalence of the riser pattern (19.9% in diabetes vs. 8.1% in
nondiabetes), which is also shown to be associated with the worst cardiovascular
prognosis (Ohkubo, Imai et al. 1997, Kario, Pickering et al. 2001, Eguchi, Pickering et al.
2008).
In patients with diabetes, reduced nocturnal BP fall is also associated with
increased risk of CVD and target organ damage. In a 4-year prospective study, the
incidence of fatal and nonfatal vascular (cerebrovascular cardiovascular, peripheral
vascular arteries, and retinal artery) events is higher in T2D patients with reversedipping BP than in those with dipping BP (Nakano, Fukuda et al. 1998). The intimamedia thickness and left ventricular mass index, which are found to be increased in nondippers, are also greater in diabetic non-dippers than dippers (Di Flaviani, Picconi et al.
2011). The nocturnal fall in systolic blood pressure (SBP), independent of 24-hour BP, is
negatively associated with pulse wave velocity (PWV), lower albumin: creatinine ratio
(ACR) and positively associated with glomerular filtration rate (GFR) in T2D patients
(Jennersjo, Wijkman et al. 2011). The rate of decline of creatinine clearance is higher in
diabetic non-dippers than in dippers (-7.9 vs. -2.9 ml/min/year) over a 6-year period
(Farmer, Goldsmith et al. 1998). The prevalence of non-dipping BP is highest in diabetic
12

patients with macroalbuminuria compared to diabetic patients with microalbuminuria
and normoalbuminuria (Equiluz-Bruck, Schnack et al. 1996). There are conflicting results
on the relationship of BP dipping status and the progression of diabetic nephropathy.
Knudsen et al found the night: day BP ratio is an independent predictor of nephropathy
progression in T2D patients (Knudsen, Laugesen et al. 2009) while Palmas et al
concluded nocturnal non-dipping, if not with nocturnal BP rise, is not an independent
predictor of nephropathy (Palmas, Pickering et al. 2008). However, Pierdomenico et al
analyzed the results of both studies and demonstrated that the overall risk ratio (RR) for
nephropathy progression in non-dippers was 1.73, 95% CI: 0.97–3.06, P=0.061
(Pierdomenico and Cuccurullo 2010).
1.2.4 Mechanisms of BP circadian rhythm
1.2.4.1 Role of hemodynamics
BP is determined by total peripheral resistance (TPR) cardiac output (CO), in
which the CO equals heart rate (HR)stroke volume (SV). Several human studies have
investigated the daily variations of TPR and CO and found the CO has an oscillation
pattern parallel to that of BP, whereas TPR remains unchanged throughout the day or
increases during the night (Khatri and Freis 1967, Miller and Horvath 1976, Mori 1990,
Idema, van den Meiracker et al. 1994, Veerman, Imholz et al. 1995). Veerman et al
concluded the nocturnal decrease of CO is mainly due to nocturnal fall of HR as the
nighttime SV is comparable to daytime (Veerman, Imholz et al. 1995); while Miller et al
found the decreased SV leads to nocturnal fall of CO as HR is not different between day
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and night (Miller and Horvath 1976). The discrepancy may be due to differences in
physical activity as the day and night changes in HR and CO are found to be correlated
with physical activity (Cavelaars, Tulen et al. 2004). In non-dippers, an increment in
nighttime TPR or a smaller decline in nocturnal CO and SV are found as compared to
dippers. (Takakuwa, Ise et al. 2001, Cavelaars, Tulen et al. 2004).
1.2.4.2 Role of sleep
The sleep-wake cycle is the most evident circadian rhythm of life and is also a
significant determinant of BP circadian rhythm. As reviewed by Smolensky et al
(Smolensky, Hermida et al. 2007), the stages of sleep have a profound effect on the BP
24-hour oscillation. The sleep stage 3 and 4, which are the deepest sleep stage,
correspond to the lowest BP levels during sleep, whereas the less deep sleep stage 1
and 2 and the rapid eye movement (REM) sleep, coincide with higher BP levels, although
these values are still lower than the awake BP levels. Human study has shown that the
levels of BP decline significantly from wakefulness to stage 4 of non-rapid eye
movement (NREM) sleep in normotensive subjects (Somers, Dyken et al. 1993). Another
influence of sleep on the BP 24-hour oscillation is exerted through the variation of
respiration. During the NREM sleep, the breathing is regular and the BP declines.
Whereas during REM sleep, the breathing and HR are irregular; central apneas or
hypopneas occur sporadically, and the peaks of BP, sometimes as great as 30–40 mmHg
from baseline, happen abruptly during the whole REM episode. The relationship
between sleep and BP circadian rhythm has been investigated mainly in patients with
obstructive sleep apnea (OSA). Studies have shown that 43% to 84% of OSA patients,
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either hypertensive or normotensive, are non-dippers (Suzuki, Guilleminault et al. 1996,
Loredo, Ancoli-Israel et al. 2001). Severe OSA, compared to mild OSA or habitual
snorers, is associated with greater BP night-to-day ratio (Pankow, Nabe et al. 1997) and
the severity of sleep apnea is demonstrated to be an independent predictor for BP
circadian rhythm (Nabe, Lies et al. 1995).
1.2.4.3 Role of autonomic nervous system
It is well-known that the autonomic nervous system (ANS) is an important
regulator of BP homeostasis. The ANS is also critical to the BP circadian rhythm. The
activity of the sympathetic and parasympathetic nerve system (SNS and PNS), two
efferent arms of ANS, exhibit day and night difference. The sympathetic nerve activity,
in accordance with BP, is typically higher during the active or awake period and lower
during sleep. In human studies, the concentrations of plasma norepinephrine (NE) and
epinephrine (EPI) peak during the awake and reach a nadir at night during sleep in
normal men (Prinz, Halter et al. 1979, Stene, Panagiotis et al. 1980, Lightman, James et
al. 1981, Sowers and Vlachakis 1984, Linsell, Lightman et al. 1985). The low- to highfrequency ratio (LF: HF), a value that is calculated from the frequency domain method of
heart rate variability (HRV) and considered as an indicator of sympatho-vagal balance in
some studies, is significantly higher in the morning than in the evening (Huikuri, Niemelä
et al. 1994, Kawano, Tochikubo et al. 1994, Nakagawa, Iwao et al. 1998, Massin, Maeyns
et al. 2000). Using microneurography, which provides a direct measurement of efferent
sympathetic nerve activity related to muscle blood vessels, Somers et al demonstrated
that the mean amplitude of bursts of sympathetic nerve activity decreased significantly
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from wakefulness to deep sleep in normal subjects (Somers, Dyken et al. 1993). In
laboratory animals, the plasma (McCarty, Kvetnansky et al. 1981, De Boer and Van der
Gugten 1987) and urinary (Fu, Patel et al. 2005) NE and EPI concentrations are higher
during the active phase than rest phase. The LF: HF also displays day and night
difference, with significantly greater LF: HF in the active phase than rest phase
(Hashimoto, Kuwahara et al. 1999, Kuwahara, Suzuki et al. 1999, Matsunaga, Harada et
al. 2001, Kuwahara, Tsujino et al. 2004). Direct measurement of stellate ganglion nerve
activity in dogs revealed that there is a higher sympathetic outflow to stellate ganglia
during the daytime (Jung, Dave et al. 2006). The direct measurement of sympathetic
nerve activity in rodents can be obtained by measuring renal sympathetic nerve activity
(RSNA) (Ling, Cao et al. 1998). However, whether the RSNA exhibits circadian variation
in rodents has not been examined. On the other hand, the parasympathetic nerve
activity, which is mostly demonstrated by the HF power of HRV, has an opposite diurnal
pattern as the sympathetic nerve activity. An increased HF of HRV during the night has
been found in several human studies (Furlan, Guzzetti et al. 1990, Lombardi, Sandrone
et al. 1992, Huikuri, Niemelä et al. 1994, Yamasaki, Kodama et al. 1996, Nakagawa, Iwao
et al. 1998, Massin, Maeyns et al. 2000). The HRV can also be calculated using a time
domain method, in which the square root of the mean of the sum of squares of
differences between adjacent RR intervals (rMSSD), and the percentage of differences
between adjacent RR intervals that are greater than 50 msec (pNN50), correlate with
the HF of HRV (Sztajzel 2004). In humans, the rMSSD and pNN50 increase at night and
decrease during the day (Massin, Maeyns et al. 2000). In animals, a 24-hour variation of
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HF was found in rats (Hashimoto, Kuwahara et al. 1999), dogs (Matsunaga, Harada et al.
2001) and miniature swine (Kuwahara, Suzuki et al. 1999, Kuwahara, Tsujino et al. 2004)
and the pattern of HF is opposite to LF: HF in these animals.
The circadian variation of ANS activity is altered in non-dippers as compared to
normal individuals. The difference (nocturnal dip) of the excretion rate of both NE and
EPI between the awake and asleep period was reduced in non-dippers compare to
dippers (Sherwood, Steffen et al. 2002). In addition, the normal difference of the urinary
NE between work and nonwork periods in day shift workers is absent in evening+night
shift workers, who also have a higher prevalence of non-dipping BP (Yamasaki, Schwartz
et al. 1998). Direct measurement of muscle sympathetic nerve activity (MSNA) showed a
close inverse association between the degree of sympathetic activation and the
magnitude of nighttime BP falls. The most severe form of non-dipping BP pattern, the
reverse-dipping, has the highest level of MSNA in hypertensive subjects (Grassi,
Seravalle et al. 2008). These studies suggest that the nighttime sympathetic activity is
increased in non-dippers vs. dippers. On the other hand, the normal increase of
parasympathetic activity during nighttime, as assessed by power spectral analysis of
HRV, is significantly blunted in non-dippers compare to dippers (Kohara, Nishida et al.
1995). The ANS contributions to BP circadian rhythm are further demonstrated in
sinoaortic denervated (SAD), guanethidine sulfate-induced sympathectomized, and
atropine-induced parasympathetic blockade rats (Makino, Hayashi et al. 1997). The
findings from the SAD rats showed that the MAP daily rhythm was lost due to increased
MAP during the light phase. The daily rhythm of MAP in sympathectomized rats was
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also diminished because of decreased MAP during the dark phase, although the
decrease was not significant. The parasympathetic blockade induces compromised MAP
daily rhythm in rats by increasing MAP only during the light phase. In summary, both
human and animal studies indicate that increased sympathetic activity and/or
decreased parasympathetic activity at night participate in BP circadian rhythm
disruption.
1.2.4.4 Role of baroreflex
The baroreflex is a rapid mechanism to buffer acute BP sudden change. The
baroreflex reflects the reciprocal responses between SNS and PNS: when the BP
increases, baroreceptors activate and trigger the inhibition of SNS and the activation of
PNS, resulting in decreased HR and TPR, and thus lower BP. An inversed reflex will be
triggered when BP decreases. The baroreflex sensitivity (BRS), defined as the change in
inter beat interval (IBI) of HR in milliseconds per unit change in BP, is used to quantify
baroreflex function. The BRS has a daily rhythm that is opposite to BP rhythm in both
humans (HOSSMANN, FITZGERALD et al. 1980, Takakuwa, Ise et al. 2001) and mice (Xie,
Su et al. 2015). The role of the baroreflex in BP circadian variation is not clear. Some
studies investigated BRS between dippers and non-dippers but did not find a significant
difference (Vaile, Stallard et al. 1996, Takakuwa, Ise et al. 2001, Myredal, Friberg et al.
2010). Myredal et al calculated the baroreflex effectiveness index (BEI), defined as the
number of SBP ramps that are followed by the respective reflex RR interval ramps
fulfilling the BRS criteria, divided by the total number of SBP ramps and found the BEI is
decreased in non-dippers compared to normal dippers, indicating the baroreflex
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function might be impaired in non-dippers (Myredal, Friberg et al. 2010). In mice with
smooth muscle-specific deletion of the clock gene Bmal1, diminished BP daily rhythm is
found to be associated with abolished BRS daily rhythm (Xie, Su et al. 2015).
1.2.4.5 Role of hormonal systems
BP is regulated by multiple hormones, among which the renin-angiotensinaldosterone system (RAAS) is the most important hormonal system for BP homeostasis.
The RAAS regulates BP through modulating vasoconstriction and extracellular fluid
volume. Interestingly, the components of the RAAS all exhibit circadian rhythm. Renin is
the rate-liming enzyme of the RAAS and is secreted by the kidney. It hydrolyzes
angiotensinogen (AGT) to angiotensin I (Ang I). In humans, numerous studies have
demonstrated an apparent circadian rhythm of plasma renin activity (PRA),
characterized by peak in the early morning, and nadir around midnight (Gordon, Wolfe
et al. 1966, KATZ, ROMFH et al. 1975, Modlinger, Sharif-Zadeh et al. 1976, Cugini,
Manconi et al. 1980, Beilin, Deacon et al. 1983, Cugini, Salandi et al. 1983, Kawasaki,
Uezono et al. 1983, Stern, Sowers et al. 1986, Kawasaki, Cugini et al. 1990, Portaluppi,
Bagni et al. 1990, Brandenberger, Follenius et al. 1994). Despite the massive evidence of
PRA circadian rhythm, the relationship of the PRA and BP circadian rhythm is vague. PRA
is comparable in dippers, non-dippers and extreme dipper in both the supine and tilting
positions (Kario, Mitsuhashi et al. 2002). No significant correlation of PRA and the
night/day ratio of MAP has been found (Fukuda, Urushihara et al. 2012). However PRA
increases less in non-dippers during tilting as compared to dippers and to extreme
dippers (Kario, Mitsuhashi et al. 2002). The BP circadian rhythm is inverted in transgenic
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TGR (mREN2)27 rats that harbor the mouse salivary gland renin gene (mREN2) (Mullins,
Peters et al. 1990), (Lemmer, Mattes et al. 1993, Lemmer, Witte et al. 2003). AGT is
mostly produced and secreted by the liver and is the only known substrate of renin.
Recent studies suggest urinary AGT is a biomarker of the intrarenal RAAS activity (Kobori
and Navar 2011). However, the urinary AGT levels are not significantly different
between day and in healthy people (Nishijima, Kobori et al. 2014, Isobe, Ohashi et al.
2015); but it is significantly higher during the daytime in patients with chronic kidney
disease, who also exhibit a riser pattern of BP (Isobe, Ohashi et al. 2015). The renal
proximal tubular AGT is found to be significantly higher in non-dippers than dippers and
correlate with the night/day ratio of BP (Fukuda, Urushihara et al. 2012). A recent
animal study demonstrated that deletion of AGT in brown adipose tissue (BAT) leads to
decreased BP only during the rest phase (Chang, Xiong et al. 2018). Angiotensinconverting enzyme (ACE) is found predominantly in the lung and converts Ang I to Ang
II. An ACE inhibitor is a widely used pharmaceutical drug to treat hypertension. Only a
few studies have reported a circadian rhythm of ACE activity, probably because the ACE
rhythm is not apparent due to the low amplitude (Veglio, Pietrandrea et al. 1987, Cugini,
Letizia et al. 1988). Ang II acts on multiple tissues to increase BP. Plasma Ang II peaks in
the early morning and is lowest in the evening (Kala, Fyhrquist et al. 1973). The effects
of Ang II on BP circadian rhythm are revealed in rats with chronic low dose Ang II
infusion, which inverts the circadian pattern of BP (Baltatu, Janssen et al. 2001, da Silva
Lemos, Braga et al. 2005). The effect of Ang II on BP circadian rhythm is likely mediated
by brain RAS as TGR(ASrAOGEN) rats with low brain AGT levels are resistant to Ang II
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induced BP circadian alternation (Baltatu, Janssen et al. 2001). In the TGR (mREN2)27
rats, which exhibit inverted BP circadian rhythm, the levels of Ang II are significantly
elevated and the rhythm of Ang II is lost (Schiffer, Pummer et al. 2001). In vitro study
demonstrated that Ang II can induce clock gene expression in vascular smooth muscle
cells (VSMCs) via the Ang II type 1 (AT1) receptor (Nonaka, Emoto et al. 2001).
Aldosterone plays a critical role in maintaining electrolyte balance by promoting sodium
reabsorption and potassium secretion.

In humans, aldosterone is highest in the

morning and lowest around midnight (Liddle 1966, Kem, Weinberger et al. 1973, GRIM,
WINNACKER et al. 1974, Armbruster, Vetter et al. 1975, KATZ, ROMFH et al. 1975,
Ryoyu, Isamu et al. 1984, Portaluppi, Bagni et al. 1990). The effects of aldosterone on BP
circadian rhythm are controversial. Several studies reported that the BP circadian
rhythm is disrupted in patients with primary aldosteronism (Tanaka, Natsume et al.
1983, Middeke and Schrader 1994, Rabbia, Veglio et al. 1997), while others found no
significant change (Imai, Abe et al. 1992, Penzo, Palatini et al. 1994). This discrepancy is
probably

due

to

pathogenesis

of

aldosteronism

(adenoma

or

idiopathic

hyperaldosteronism) and the dietary sodium intake. Uzu et al demonstrated that in
patients with unilateral adenoma, BP circadian rhythm is diminished during normal
sodium diet but not low sodium diet; and both sodium restriction and adrenalectomy
are able to restore BP dipping (Uzu, Nishimura et al. 1998).
Besides RAAS, BP is also regulated by other hormones, such as cortisol, thyroid
and atrial natriuretic peptide (ANP). Cortisol, the major form of human glucocorticoid,
regulates BP homeostasis through multiple mechanisms (Saruta 1996). Cortisol is
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produced in the adrenal gland and the release of cortisol is stimulated by
adrenocorticotropic hormone (ACTH) from the pituitary gland. Excessive cortisol,
commonly seen in people with Cushing's syndrome, is associated with hypertension
(Whitworth, Williamson et al. 2005). Plasma cortisol has a 24-h oscillation with highest
level around awakening and lowest level shortly after sleep (Bridges and Jones 1966,
ORTH, ISLAND et al. 1967, Weitzman, Fukushima et al. 1971, Désir, Van Cauter et al.
1980, Ockenfels, Porter et al. 1995). The circadian rhythm of BP is blunted or reversed in
excessive glucocorticoid conditions, either endogenous (Cushing’s disease due to
pituitary adenoma) or exogenous (patients with glomerulonephritis (CGN) and systemic
lupus erythematosus (SLE) who received glucocorticoid treatment) (Imai, Abe et al.
1988, Imai, Abe et al. 1989, Imai, Abe et al. 1990). Glucocorticoid is considered as a
zeitgeber of circadian rhythm as it can entrain the rhythm of the circadian clock
(Dickmeis 2009). Therefore, the effects of glucocorticoid on BP circadian rhythm may be
also mediated through regulation of clock genes. Thyroid has complex effects on BP
(Danzi and Klein 2003). Hypertension is observed in both hyper- (Merillon, Passa et al.
1981) and hypo- (Streeten, Anderson Jr et al. 1988) thyroidism. A graded independent
relation is found between lower levels of free thyroid 3 (FT3) and the risk of non-dipping
BP (Kanbay, Turgut et al. 2007). ANP is a peptide hormone synthesized and secreted by
cardiac muscle cells of the atria and works to decrease BP (Laragh 1985). ANP has an
apparent circadian rhythm that is almost antiphase to BP oscillation: highest level during
sleep and lowest level in the afternoon and evening (Winters, Sallman et al. 1988,
Portaluppi, Montanari et al. 1989, Portaluppi, Bagni et al. 1990). A temporal inverse
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relationship is found between the rhythm of ANP and BP (Sothern, Vesely et al. 1995). In
addition, in patients with chronic renal failure (CRF), the loss of nocturnal BP fall is
associated with loss of circadian variation of ANP (Portaluppi, Montanari et al. 1992).
1.2.4.6 Role of vasculature
Blood vessels are the major organ in maintaining BP. Studies have demonstrated
that the vascular tone exhibits circadian variation. The vascular contractile responses to
various agonists have been investigated extensively in isolated aortas and mesentery
arteries in rodents. Results from these studies have demonstrated there is a time-of-day
variation in the in vitro VSM contractile responses to phenylephrine (PE, α1-agonist),
Ang II, high K+ and 5-hydroxytryptamine (5-HT); this variation is characterized by
generally higher responses during the rest phase and lower responses during the active
phase (Keskil, Gorgun et al. 1996, Gorgun, Keskil et al. 1998, Witte, Hasenberg et al.
2001, Su, Xie et al. 2011). In addition, the in vivo MAP responses to intravenous PE and
Ang II injection also exhibit similar variations in rodents (Masuki, Todo et al. 2005, Su,
Xie et al. 2011). In humans, the BP response to L-noradrenaline infusion is lowest at
0300 (HOSSMANN, FITZGERALD et al. 1980). On the other hand, the vascular responses
to vasodilators also exhibit daily rhythm. Keskil et al found both the endotheliumdependent and -independent relaxations are more pronounced in rats aorta at ZT19
than the other times of the day (Keskil, Gorgun et al. 1996). Witte et al found higher
endothelium-dependent relaxation at ZT2 than at ZT14 (Witte, Hasenberg et al. 2001).
However, Witte et al did not examine vascular relaxation at ZT19, so they may have
missed the peak response. In humans, both endothelium-dependent vasodilation
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induced by acetylcholine (ACh) and flow-mediated dilation is lower in the morning than
in the afternoon (Etsuda, Takase et al. 1999, Elherik, Khan et al. 2002). The results of
endothelium-independent vasodilation induced by sodium nitroprusside (SNP) are not
consistent: Panza et al did not find significant difference of vasodilation in response to
SNP at 0700, 1400 and 1700 (Panza, Epstein et al. 1991) while Elherik et al found the
response peaks at 1600 and lowest at 0400 and 0800 (Elherik, Khan et al. 2002). Again,
the difference may due to limited sampling time points.
Studies have demonstrated that altered circadian variation in vascular tone is
associated with abnormal BP circadian rhythm. Blunted time-dependent variations in
vascular contraction to Ang II and endothelium-dependent relaxation by ACh are found
in TGR(mREN2)27 rats, who have an inverted BP circadian rhythm (Witte, Hasenberg et
al. 2001). Deletion of smooth muscle specific Bmal1 in mice resulted in attenuated BP
circadian

rhythm

and

abolished

time-of-day

variation

in

agonist-induced

vasoconstriction of the mesenteric arteries (Xie, Su et al. 2015). Mice lacking
Cryptochrome (Cry), one of the clock genes, also exhibit diminished MAP circadian
rhythm, which is accompanied by blunted day and night difference in MAP responses to
PE (Masuki, Todo et al. 2005). Mutation of clock gene Period 2 (Per2) in mice leads to
attenuated BP circadian rhythm (Vukolic, Antic et al. 2010) and diminished diurnal
variation in endothelium-dependent relaxations (Viswambharan, Carvas et al. 2007). In
subjects with non-dipping BP, the dose needed to increase the MAP to 25 mmHg using
PE is lower than subjects with dipping BP, suggesting heightened α1-adrenergic receptor
(α1-AR) responsiveness in non-dippers (Sherwood, Steffen et al. 2002). In addition, a
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long-acting α1-AR blocker, doxazosin, lowers the nighttime SBP only in non-dippers but
not in dippers (Ebata, Hojo et al. 1995). In non-dippers, endothelium-dependent
vasodilation is reduced compared to dippers (Higashi, Nakagawa et al. 2002). In people
with coronary artery disease, blunted BP circadian rhythm is associated with diminished
variation in ACh induced vasodilation (Shaw, Chin-Dusting et al. 2001).
1.2.4.7 Role of kidney
The kidney regulates BP homeostasis through modulating extracellular fluid
volume and electrolyte concentrations. It has long been known that the urine flow and
excretion of sodium, potassium and chloride electrolyte are lower during sleep than
when awake (Manchester 1933, Sirota, Baldwin et al. 1950). Such rhythms persist with
the same amounts of food and water consumption at certain intervals throughout the
24 hours (Simpson 1924, Nom 1929, Borst and De Vries 1950, Mills and Stanbury 1952).
The water and electrolyte variations are in phase with the variation of glomerular
filtration rate (GFR) and antiphase with tubular reabsorption rhythm (Koopman,
Koomen et al. 1989). As reviewed by Burnier et al (Burnier, Coltamai et al. 2007),
changes in GFR and/or tubular reabsorption lead to increased daytime sodium
retention, which results in elevated nighttime BP via the pressure-natriuresis
mechanism. The pressure-natriuresis mechanism is a long-term regulator of BP, in which
increased renal perfusion pressure increases sodium excretion and decreases sodium
reabsorption (Ivy and Bailey 2014). The nocturnal BP needs to increase to excrete
excessive sodium in order to reach sodium balance. Indeed, daytime urinary sodium is
found to be independently associated with nocturnal SBP fall (Nishijima and Tochikubo
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2003, Bankir, Bochud et al. 2008). People with high-sodium sensitivity have a diminished
nocturnal BP fall (Uzu, Kazembe et al. 1996, Kimura 2001). In people with chronic kidney
disease (CKD), the GRF is reduced and the sodium reabsorption is enhanced. Increased
prevalence of abnormal BP circadian rhythm is observed in people with CKD (Farmer,
Goldsmith et al. 1997, Mojón, Ayala et al. 2013). In addition, such prevalence increases
with the progression of CKD (Farmer, Goldsmith et al. 1997, Mojón, Ayala et al. 2013).
Renal transplantation normalizes non-dippers to dippers (Gatzka, Schobel et al. 1995),
suggesting a critical role of kidney in BP circadian rhythm.
In summary, BP circadian rhythm is regulated by multiple factors and pathways.
And these factors and pathways are interconnected and cannot be separated. For
instance, sleep deprivation leads to derangement of CNS and endothelial dysfunction
(Tobaldini, Costantino et al. 2017). There is a close interaction between SNS and RAAS:
SNS stimulate renin and aldosterone release (Gordon, Küchel et al. 1967) while Ang II
activates SNS and modulates baroreflex control of HR (Reid 1992). Both the vascular
tone and kidney function are influenced by SNS, RAAS, glucocorticoid and thyroid
hormones (Dibona and Kopp 1997, Mangos, Whitworth et al. 2003, Brewster and
Perazella 2004, Danzi and Klein 2004, Yang and Zhang 2004, van Hoek and Daminet
2009, Cat and Touyz 2011, Amiya, Watanabe et al. 2014).
1.2.5 Mechanisms of diabetes associated BP circadian rhythm disruption
As described above, BP circadian rhythm is influenced by multiple factors,
including the sleep-wake cycle, the ANS, the hormonal systems (RAAS, glucocorticoid,
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thyroid and atrial natriuretic peptide), the vasculature and the kidney. These factors
interact with each other and work together to determine BP circadian rhythm.
Alternations of these factors and pathways have been observed in diabetes. For
example, people with diabetes have increased TPR compared to nondiabetic subjects
(Sole, Lucas et al. 2014). Findings from the Sleep Heart Health Study (SHHS) showed that
diabetes is associated with periodic breathing (Resnick, Redline et al. 2003). Over 86% of
obese patients with T2D have OSA (Foster, Sanders et al. 2009). Diabetic patients are
known to have sympatho-vagal imbalance, in which the vagal activity is impaired while
the SNS is overactive (Perin, Maule et al. 2001). In people with T2D, increased nighttime
sympathetic nerve activity (Spallone, Maiello et al. 2001, Perciaccante, Fiorentini et al.
2006)

and decreased nighttime vagal activity (Bernardi, Ricordi et al. 1992) are

observed. In addition, there is a positive relationship between the nocturnal BP change
and the nocturnal plasma NE change in T2D patients with neuropathy (Nielsen, Hansen
et al. 1999). The diurnal variations of plasma PRA, aldosterone and ANP are altered in
diabetic patients, especially in those with reversed BP rhythm (Nakano, Uchida et al.
1994). Diabetic nephropathy is a major compilation of diabetes (Gross, De Azevedo et al.
2005). In patients with T2D, there is a positive correlation between urinary albumin
excretion rate (UAER) and non-dipping BP (Equiluz-Bruck, Schnack et al. 1996, Nakano,
Ishii et al. 1996). In diabetic animal models, such as db/db mice (Hummel, Dickie et al.
1966) and SHRcp rats (Takaya, Ogawa et al. 1996), non-dipping BP circadian rhythm is
observed (Su, Guo et al. 2008, Sueta, Kataoka et al. 2013). In db/db mice, the LF
component of the SBP variability, indicative of sympathetic input to the vasculature
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(Stauss 2007), loss the circadian variation (Senador, Kanakamedala et al. 2009) and the
HRV linked to sympathetic control is altered at different time of day (Stables, Auerbach
et al. 2016). The diurnal rhythm of plasma corticosterone is also altered db/db mice
(Saito and Bray 1983). In addition, the time-of-day variations in VSM contractile
responses and MAP responses to PE and Ang II are attenuated in db/db mice (Su, Xie et
al. 2011). In SHRcp rats, the day and night difference in LF of HRV is lost (Sueta, Kataoka
et al. 2013).
In addition to the above factors, diabetes is a metabolic disorder that is
associated with obesity, hyperglycemia and insulin resistance. The metabolic
abnormalities are also implicated in BP regulation and may contribute to diabetes
associated BP circadian rhythm disruption.
Obesity is known to be associated with increased BP (Mikhail, Golub et al. 1999).
Whether obesity is associated with the abnormal BP circadian rhythm is controversial.
The incidence of non-dipping BP is significantly higher in obese subjects (Kotsis, Stabouli
et al. 2005). In obese children and adolescents, the nighttime BP are higher than in
healthy controls (Hvidt, Olsen et al. 2014). The results from both the Oman family study
and Spanish Society of Hypertension registry demonstrated increased BMI or obesity is
associated with non-dipping BP (Hassan, Jaju et al. 2007, de la Sierra, Redon et al. 2009).
In addition, the body weight loss induced by gastric bypass surgery has been shown to
restore the normal BP rhythm in morbidly obese hypertensive subjects (Czupryniak,
Strzelczyk et al. 2005). In contrast, Diamantopoulos et al. did not find any difference in
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the BMI between dipper and non-dippers (Diamantopoulos, Andreadis et al. 2006). The
result from the Korean Ambulatory Blood Pressure Monitoring Registry also
demonstrated the central obesity has no influence on the BP dipping patterns (Kang,
Pyun et al. 2013). In an animal study, the BP dipping pattern was also not significantly
different between diet-induce obese and lean mice (Prasai, Mughal et al. 2013).
High blood glucose is the major diagnostic criteria of diabetes and plays an
important role in the pathogenesis of the micro- and macro-complications of diabetes
(Ohkubo, Kishikawa et al. 1995) (1998). The 24-h variation in fasting blood glucose is
disrupted in people with prediabetes or T2D (Gubin, Nelaeva et al. 2017). In diabetic
db/db mice, the daily rhythm of blood glucose is almost antiphase to that of control
mice (Grosbellet, Dumont et al. 2015). Both the diabetic and non-diabetic non-dippers
have greater postprandial glucose levels and are more glucose intolerant than dippers
(Pistrosch, Reissmann et al. 2007) (Chen, Jen et al. 1998). In addition, the postprandial
glucose is considered as an independent predictor for non-dipper BP in diabetes
(Pistrosch, Reissmann et al. 2007).
Various studies have investigated the roles of insulin in the BP regulation. More
than 40% of hypertensive patients have hyperinsulinemia (Zavaroni, Mazza et al. 1992,
Vanhala, Pitkajarvi et al. 1998). Insulin resistance is associated with hypertension, even
in the absence of obesity and diabetes and there is a protective association between
greater insulin sensitivity and lower BP (Goff, Zaccaro et al. 2003). The effects of insulin
on BP regulation are through multiple pathways, including induction of vasodilation by
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stimulating the release of nitric oxide (NO) in the endothelial cells (Scherrer, Randin et
al. 1994), regulation of sodium handling by enhancing sodium absorption in the diluting
segment of the distal nephron (DeFronzo, Cooke et al. 1975) and increases in
sympathetic nervous activity (Rowe, Young et al. 1981). Studies have shown that nondippers have a greater degree of insulin resistance and a delayed insulin secretion phase
during oral glucose tolerance test (OGTT) (Chen, Jen et al. 1998, Pistrosch, Reissmann et
al. 2007). In addition, the insulin sensitivity, measured by the steady-state plasma
glucose (SSPG) method, is negatively associated with the nocturnal BP fall (Suzuki,
Kimura et al. 2000). In the diabetic db/db mice, non-fasting plasma glucose and insulin
only correlate with the light-phase BP but not the dark-phase BP (Su, Guo et al. 2008).
1.2.6 Therapies for abnormal BP circadian rhythm
1.2.6.1 Chronotherapy
Since the abnormal BP circadian rhythm is usually characterized by inadequate
decrease of sleep BP, it is not surprising to speculate that different treatment times of
antihypertensive drugs yield different results on the pattern of BP variation. A great
number of clinical trials have been done to test possible relationship between timing of
antihypertensive medicine and nocturnal BP . The results demonstrated that single
evening dose of calcium channel blockers (CCB), AngII receptor blocker (ARB) or
angiotensin-converting enzyme inhibitors (ACEIs), compare to single morning dose,
significantly reduce asleep BP in individuals with essential hypertension (Umeda, Naomi
et al. 1994, Kohno, Iwasaki et al. 1997, Hermida, Calvo et al. 2003, Hermida, Ayala et al.
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2007, Hermida and Ayala 2009, Hermida, Ayala et al. 2009, Hermida, Ayala et al. 2010).
A similar effect is also observed in patients with T2D receiving olmesartan at bedtime
(Tofé Povedano and García De La Villa 2009). In addition, the bedtime administration of
antihypertensive drugs also reduces microalbuminuria (Hermida, Calvo et al. 2005,
Kario, Hoshide et al. 2010), plasma fibrinogen (Hermida, Ayala et al. 2005, Hermida,
Ayala et al. 2009), cholesterol (Hermida, Ayala et al. 2005) and CVD morbidity and
mortality (Hermida, Ayala et al. 2010, Hermida, Ayala et al. 2011). In people with T2D,
the CVD morbidity and mortality is also significantly decreased with treatment of ≥1
hypertension medications at bedtime (Hermida, Ayala et al. 2011).
1.2.6.2 Targeting sodium handling
Since the salt sensitivity is associated with BP dipping (Uzu, Kazembe et al. 1996,
Kimura 2001), studies have investigated whether decreasing salt intake in salt-sensitive
hypertension or reducing salt sensitivity can restore BP dipping.

The results

demonstrated that salt restriction can shift non-dippers to dippers in patients with saltsensitive hypertension (Uzu, Ishikawa et al. 1997) and in patients with primary
aldosteronism, a typical salt-sensitive secondary hypertension (Uzu, Nishimura et al.
1998, Takakuwa, Shimizu et al. 2002). In addition, diuretics, which lower BP by reducing
sodium sensitivity (Saito and Kimura 1996), restore BP from the non-dipping to the
dipping pattern (Uzu and Kimura 1999, Uzu, Harada et al. 2005). ARB also restores
normal BP circadian rhythm (Fukuda, Yamanaka et al. 2008) by suppressing tubular
sodium reabsorption (Fukuda, Wakamatsu-Yamanaka et al. 2011). In patients with T2D,
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combination therapy of diuretic and ARB, but not monotherapy of ARB, restores
nocturnal BP fall (Uzu, Sakaguchi et al. 2009).

1.3 Circadian rhythm
1.3.1 Background
Almost all the physiological processes in living organisms have a daily oscillation
that is thought to adapt to the 24-hour environmental light-dark cycle. The circadian
oscillation in mammals is generated by cell autonomous transcription-translational
negative feedback networks. As shown in Figure 1.3.1 (Golombek, Bussi et al. 2014), the
core of the clock networks is composed of the Bmal1-Clock/Per-Cry loop: the brainmuscle arnt-like protein 1 (BMAL1) and circadian locomotor output cycles kaput
(CLOCK), which form a heterodimer that activates the transcription of their repressors
Period (Per1 and Per2) and Cryptochrome (Cry1 and Cry2). The PER and CRY proteins
accumulate and form a complex that translates into the nucleus and, in turn, suppresses
Bmal1 and Clock; this results in a rhythmic expression of the loop (Gekakis, Staknis et al.
1998, Jin, Shearman et al. 1999, Kume, Zylka et al. 1999, Bunger, Wilsbacher et al.
2000).The cycle of the loop takes about 24 hours. There are additional feedback loops
interacting with Bmal1, among which the Rev-erb and Ror loop is the most
prominent one. The REV-ERB competes with ROR and directly represses the
transcription of Bmal1 while ROR promotes its transcription (Preitner, Damiola et al.
2002, Sato, Panda et al. 2004).
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Figure 1.3.1 The molecular mechanisms of circadian clock.
The circadian system in mammals consists of the central and peripheral oscillators. The
central oscillator is located in the hypothalamus suprachiasmatic nucleus (SCN), which
acts as a master pacemaker and generates behavioral rhythms (locomotor activity and
feeding). With the observation of rhythmic expression of clock genes and proteins in
cells and tissues throughout the body, circadian oscillators are realized to ubiquitously
exist in peripheral tissues (Balsalobre, Damiola et al. 1998, Yamazaki, Numano et al.
2000, Yoo, Yamazaki et al. 2004). The circadian system is regulated in a hierarchical
manner with the SCN being the master pacemaker that controls the clocks of peripheral
tissues. Animals with SCN lesions are missing the circadian rhythmicity in behavioral
and endocrine oscillations (Moore and Eichler 1972, Stephan and Zucker 1972),
including the rhythm of BP (Sano, Hayashi et al. 1995, Witte, Schnecko et al. 1998).
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Tissue-specific gene expression is regulated by both the local clock and by the signals
from the SCN. As demonstrated in mice with an intact SCN clock and conditionally
inactive liver clock (Kornmann, Schaad et al. 2007), the rhythmic transcription of most
hepatic genes becomes arrhythmic when the liver oscillator is arrested, but some genes,
including the core clock gene, Per2, still oscillate robustly. In contrast, in liver explant
culture, the rhythms in PER2 can only be observed in the liver with functional oscillators.
The peripheral clocks are also regulated by SCN, which synchronizes peripheral clocks
through several signals, including the autonomic innervation; hormonal signals (such as
glucocorticoid), body temperature and behavioral processes (such as feeding) (reviewed
in (Mohawk, Green et al. 2012)). Briefly, the sympathetic innervation from the SCN to
the liver and adrenal gland regulates the daily rhythm of plasma glucose (Kalsbeek, La
Fleur et al. 2004, Cailotto, La Fleur et al. 2005, Kalsbeek, Bruinstroop et al. 2010) and
modulates adrenal sensitivity to adrenocorticotropic hormone (ACTH) and the release of
glucocorticoid (Buijs, Wortel et al. 1999). Glucocorticoid is a hormone that can shift the
phase of peripheral tissues as demonstrated by the glucocorticoid analog,
dexamethasone (Balsalobre, Brown et al. 2000). This may be accomplished by the
regulation of clock genes transcription as the glucocorticoid-response elements (GREs)
are found in the regulatory regions of the core clock genes Per1 and Per2 (Yamamoto,
Nakahata et al. 2005, So, Bernal et al. 2009). The daily rhythm of body temperature is
under the control of the SCN. Peripheral oscillators are sensitive to temperature
changes (Abraham, Granada et al. 2010) and can be reset by a low temperature pulse
(Brown, Zumbrunn et al. 2002, Buhr, Yoo et al. 2010). The peripheral clocks can also be
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entrained by the feeding activity generated by the SCN. Rodent studies have shown that
the rhythms of liver clock genes and protein expression rapidly shift their phase
following the time of feeding (Damiola, Le Minh et al. 2000, Stokkan, Yamazaki et al.
2001). The feeding cue is of particular interest, given that scheduled, time-restricted
feeding is capable of resetting the circadian outputs and organizing the peripheral clocks
in the absence of SCN (Stephan, Swann et al. 1979, Hara, Wan et al. 2001). More
importantly, recent studies have demonstrated that time-restricted feeding is closely
related to the metabolic health.
1.3.2 Time-restricted feeding
Extensive research over the past decades has focused on how the components
of food (what we eat) and the amount of food (how much we eat) affect metabolic
diseases. Only recently has it become appreciated that the timing of food intake (when
we eat), independent of total caloric and macronutrient quality, is also critical for
metabolic health. Results from animal and human studies demonstrated that it is
beneficial to the organism when the feeding time is in alignment with the endogenous
circadian clock and vice versa. In mice fed normal diet ad libitum, the food intake
pattern has a daily rhythm, with most of the food (~80%) consumed during the darkphase, which is the active period in nocturnal mice. The high-fat fed mouse is a
commonly used animal model of obesity and diabetes. Close monitoring of food intake
reveals that when mice are fed a high-fat diet ad libitum, their food intake pattern is
altered as the percentage of daily food intake during the light-phase (rest period) is
increased (Kohsaka, Laposky et al. 2007). Importantly, the change in feeding pattern
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exceeds the onset of weight gain. Accompanied with the changes in food intake pattern,
the 24-h profiles of circulation metabolic markers, including leptin, glucose, insulin, free
fatty acids (FFA), and corticosterone are also altered (Kohsaka, Laposky et al. 2007).
These results suggest a critical role in the timing of food intake on metabolic health.
Arble et al (Arble, Bass et al. 2009) first reported that nocturnal mice fed a high-fat diet
only during the 12-hour dark-phase gain significantly less weight than the mice fed only
during the 12-hour light-phase without changing the calories intake. Later studies have
confirmed the effects of time-restricted feeding on the body weight. They found activetime (dark-phase in nocturnal animals) restricted feeding (ATRF) prevents high-fat diet
induced obesity in animals (Hatori, Vollmers et al. 2012, Sherman, Genzer et al. 2012,
Tsai, Villegas-Montoya et al. 2013, Chaix, Zarrinpar et al. 2014, Yasumoto, Hashimoto et
al. 2016). Other metabolic profiles, including total cholesterol, triglyceride, glucose
intolerance, insulin and insulin resistance, are also improved under ATRF in high-fat fed
animals (Hatori, Vollmers et al. 2012, Sherman, Genzer et al. 2012, Tsai, VillegasMontoya et al. 2013, Adamovich, Rousso-Noori et al. 2014, Chaix, Zarrinpar et al. 2014).
In addition to metabolism, the inflammatory biomarkers, such as Interleukin-6 (IL-6),
tumor necrosis factor-alpha (TNFα), Interleukin 1 Beta (IL1) and C-reactive protein
(CRP) are also reduced with ATRF (Sherman, Frumin et al. 2011, Hatori, Vollmers et al.
2012, Sherman, Genzer et al. 2012, Chaix, Zarrinpar et al. 2014). The daily fluctuation of
the gut microbiome composition is dampened with high-fat diet and ATRF partially
restores the fluctuation (Chaix, Zarrinpar et al. 2014).
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In humans, a late eating pattern correlates with increased incidence of metabolic
syndromes. Epidemiological studies demonstrate that night eating syndrome,
characterized by delayed time of eating, is positively associated with BMI (Colles, Dixon
et al. 2007). More daily energy intake consumed in the evening is associated with higher
risk of obesity compared to a schedule where more energy is consumed at midday
(Wang, Patterson et al. 2014). People who ate lunch after 1500 hours lost less weight
and displayed a slower weight-loss rate than those who consumed their lunch before
1500 hours in a weight-loss treatment (Garaulet, Gomez-Abellan et al. 2013). The late
dinner eating in Japanese adults is significantly associated with hyperglycemia (Nakajima
and Suwa 2015). In addition, in-laboratory late meal timing (lunch at 16:30) or large
dinner (60% energy consumed at dinner) worsens insulin sensitivity and reduces glucose
tolerance (Morgan, Shi et al. 2012, Bandin, Scheer et al. 2015). A recent published
clinical trial demonstrated that time-restricted feeding (a 6-hour feeding period before
1500 hours) in males with prediabetes improves insulin sensitivity, β cell
responsiveness, oxidative stress, appetite and lowers morning BP compared to the 12hour feeding controls (Sutton, Beyl et al. 2018). All these data suggest eating at the
“right” time is beneficial while eating at the “wrong” time is detrimental to metabolic
health.
1.3.3 Circadian rhythm and diabetes
Accumulated evidence from human and animal studies demonstrates that
circadian misalignment between environmental/behavioral cycles and the endogenous
circadian clock is associated with increased incidence of obesity and type 2 diabetes. In
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humans, results from epidemiology studies show that night or rotating shift workers
have a higher prevalence of type 2 diabetes (Gan, Yang et al. 2015). The social jet lag-mismatching sleep timing between workdays and freedays, is found to be associated
with increased body weight (Roenneberg, Allebrandt et al. 2012, Parsons, Moffitt et al.
2015, Wong, Hasler et al. 2015), elevated glycated hemoglobin in obese individuals
(Parsons, Moffitt et al. 2015), enhanced fasting plasma insulin and insulin resistance
(Wong, Hasler et al. 2015). Short duration and poor quality of sleep is associated with
increased risk of future diabetes (Cappuccio, D'elia et al. 2009, Nedeltcheva and Scheer
2014) (Holliday, Magee et al. 2013). Prolonged nighttime light exposure in an
uncontrolled home setting is associated with a significant increase in body weight,
triglyceride levels and low-density lipoprotein cholesterol levels (LDL-C) and a decrease
in high-density lipoprotein cholesterol (HDL-C) levels in elderly individuals (Obayashi,
Saeki et al. 2013). Laboratory human studies that mimic circadian misalignment also
reveal the association between circadian disruptions and diabetes. As described before,
late food consumption or a large dinner worsens insulin sensitivity and reduces glucose
tolerance (Morgan, Shi et al. 2012, Bandin, Scheer et al. 2015). In addition, sleep
restriction in normal subjects enhances plasma cortisol levels and sympathetic nervous
activity and reduces insulin sensitivity (Stamatakis and Punjabi 2010, Broussard,
Ehrmann et al. 2012). Sleep disturbance, such as sleep fragmentation and selective
suppression of slow-wave sleep, without changing the sleep duration, also decreases
glucose tolerance (Tasali, Leproult et al. 2008, Stamatakis and Punjabi 2010). Moreover,
laboratory circadian misalignment, achieved by forced desynchrony or 12-h reversed
38

eating and lighting protocols, uncouples behavioral cycles (fasting/feeding and
sleep/wake cycles) and/or light/dark cycles from the central circadian clock. Such
circadian misalignment causes increased postprandial glucose and BP, and reduced
leptin, sleep efficiency, glucose tolerance and insulin sensitivity (Scheer, Hilton et al.
2009, Buxton, Cain et al. 2012, Morris, Yang et al. 2015, Morris, Purvis et al. 2016). In
animals, as described before, time-restricted feeding only during the rest phase is
associated with accelerated weight gain (Arble, Bass et al. 2009) (Bray, Ratcliffe et al.
2013) and flattened fluctuation of plasma glucose (Bray, Ratcliffe et al. 2013). In
addition, light exposure significantly increases food intake and weight gain, reduces
glucose tolerance and impairs insulin sensitivity (Fonken, Workman et al. 2010,
Coomans, van den Berg et al. 2013). Imposing chronic jet-lag in mice is associated with
enhanced body weight and glucose intolerance (Oike, Sakurai et al. 2015) and leptin
resistance (Kettner, Mayo et al. 2015).
There seems be a reciprocal relationship between circadian disruptions and
diabetes as diabetes also alters circadian rhythm. As descripted before, diabetes
disrupts rhythms of BP and BP regulatory factors. In addition, people with prediabetes
or type 2 diabetes have disrupted 24-hour variation in body temperature (Gubin,
Nelaeva et al. 2017). In animal models of diabetes, altered circadian rhythms in body
temperature (Murakami, Horwitz et al. 1995, Grosbellet, Dumont et al. 2016),
locomotor activity (Kohsaka, Laposky et al. 2007, Su, Guo et al. 2008) (Kudo, Akiyama et
al. 2004) and food intake pattern (Kohsaka, Laposky et al. 2007, Grosbellet, Dumont et
al. 2016) are observed.
39

The mechanisms underlying the reciprocal relationship between circadian
misalignment and diabetes are not fully understood. Results from animal studies reveal
that alternations in clock genes participate in linking circadian rhythm disruptions and
diabetes. Genetic modulations of clock genes in animals lead to metabolic disorders. In
mice, either global (Rudic, McNamara et al. 2004, Kondratov, Kondratova et al. 2006,
Shi, Ansari et al. 2013) or tissue-specific Bmal1 deletion in liver (Lamia, Storch et al.
2008, Jacobi, Liu et al. 2015) or pancreas (Marcheva, Ramsey et al. 2010) causes
impaired glucose homeostasis and/or insulin resistance. Mutation of Clock, either
globally or in pancreas, leads to hyperglycemia and obesity (Turek, Joshu et al. 2005,
Marcheva, Ramsey et al. 2010). Deletion of Clock in primary myotubes decreases insulin
response to glucose and promotes lipid utilization (Perrin, Loizides-Mangold et al. 2018).
Both mPer1/2/3 triple-deficient and mPer3 single-deficient mice gain more weight on
high-fat diet than control mice (Dallmann and Weaver 2010). The mPer1/2-defecient
mice have significantly higher fat composition and leptin levels than wild type mice
(Kettner, Mayo et al. 2015). Mice with double knockout of Cry1/2 develop
hyperglycemia (Tanida, Yamatodani et al. 2007) while overexpression of Cry1 reduces
blood glucose concentration and improves insulin sensitivity in diabetic db/db mice
(Zhang, Liu et al. 2010). Dual depletion of Rev-erb-α/β in mice disrupts lipid hemostasis
(Cho, Zhao et al. 2012). On the other hand, circadian genes expressions are altered in
liver (Kudo, Akiyama et al. 2004, Ando, Oshima et al. 2006, Kohsaka, Laposky et al.
2007), adipose tissues (Kohsaka, Laposky et al. 2007, Caton, Kieswich et al. 2011), aorta
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(Su, Xie et al. 2011, Nernpermpisooth, Qiu et al. 2015), mesentery arteries (Su, Xie et al.
2011), heart (Su, Xie et al. 2011) and kidney (Su, Xie et al. 2011) in diabetic animals.
1.3.4 Clock genes in BP circadian rhythm
With the discovery of clock genes, the roles of clock genes in the regulation of BP
were investigated. In humans, genetic variations in Bmal1 are associated with
hypertension (Woon, Kaisaki et al. 2007) and non-dipping BP pattern in hypertensive
patients (Leu, Chung et al. 2015). Deletion of Bmal1 in mice, either embryonical (Bunger,
Wilsbacher et al. 2000) or tamoxifen inducible (Yang, Chen et al. 2016), leads to
decreased BP during the active-phase, resulting in flattened BP circadian rhythm (Curtis,
Cheng et al. 2007, Yang, Chen et al. 2016). In smooth-muscle-specific Bmal1 knockout
(SM-Bmal1–KO) mice, the circadian rhythm of BP is comprised, characterized mainly by
decreased SBP during the dark phase (Xie, Su et al. 2015). Deletion of mice Bmal1 in the
brown adipocytes (BA-Bmal1-KO) including perivascular adipose tissue (PVAT) reduces
the BP during the rest period, resulting in an extreme-dipping BP pattern (Chang, Xiong
et al. 2018).
The Clock is another component of the active arm of the clock molecular loop.
The BP in the Clock-KO mice preserves the circadian rhythm, but the levels are
significantly lower during both the light- and dark-phase compared with the wild type
mice (Zuber, Centeno et al. 2009). The Clock mutant (Clockmut) mice on different
backgrounds, including C57BL/6J (Curtis, Cheng et al. 2007), Jcl/ICR (Sei, Oishi et al.
2008) and BALB/c (Nakashima, Kawamoto et al. 2018), all exhibit increased BP during
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the light-phase, resulting in a non-dipping BP pattern. The cardiomyocyte-specific Clock
mutant (CCM) mice have a decreased heart rate (HR) during both the light- and darkphase, in which the decrease of HR is greater during the dark-phase than the lightphase, resulting in attenuated circadian variation of HR (Bray, Shaw et al. 2008).
However, the BP circadian rhythm and average levels are not significantly different
between the CCM and wild type mice.
Per is one of the components of the negative arm of the clock molecular loop. In
humans, the mRNA expression of Per1 in the renal medulla is significantly increased in
hypertensive patients compared to normotensive controls (Marques, Campain et al.
2011) and a tag single-nucleotide polymorphisms (SNPs) in Per2 are found to be
significantly associated with a non-dipping BP pattern in hypertensive patients (Leu,
Chung et al. 2015). The 129/sv mice lacking Per1 exhibit decreased BP during both lightand dark-phase, while the rhythm of BP is preserved (Stow, Richards et al. 2012). The
Per1-KO mice on the C57BL/6J background have normal BP level and circadian rhythm
on control diet, while they exhibit a non-dipping BP pattern on high-salt diet plus
desoxycorticosterone pivalate, a treatment that is used to generate salt-sensitivity
hypertension (Solocinski, Holzworth et al. 2017). Per2 mutant mice have increased 24hour HR, decreased 24-hour diastolic BP and attenuated the day and night difference in
HR and BP without changes in locomotor activity (Vukolic, Antic et al. 2010). The mice
lacking Per2 display normal BP and locomotor activity rhythm on normal diet in LD
condition, but have moderate increase in light-phase BP accompanied with loss of
locomotor activity rhythm in constant dark, and exogenous administration of Ang II on
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normal diet induces non-dipping BP in Per2-KO mice in constant dark (Pati, Fulton et al.
2016). In addition, low salt diet causes no-dipping BP in Per1/2/3 triple knockout (PerTKO) mice (Pati, Fulton et al. 2016).
Another component of the circadian repressor is Cry. Deletion of both Cry1 and
Cry2 leads to increased BP during the light phase, resulting in flattened BP circadian
rhythm (Masuki, Todo et al. 2005, Doi, Takahashi et al. 2010).
1.4 Diabetic mouse model-db/db mouse
The most widely used type 2 diabetic mouse model is the db/db mouse model.
The syndromes in db/db mice are similar to those in maturity-onset diabetes in humans,
characterized by obesity, infertility, hyperphagia and marked hyperglycemia (Ktorza,
Bernard et al. 1997). Diabetes in db/db mice is caused by a spontaneous point mutation
in the “leptin receptor” gene (lepr), resulting in abnormal splicing of the gene transcript,
leading to defective in leptin signaling (Chen, Charlat et al. 1996, Lee, Proenca et al.
1996). The BP level and its circadian rhythm in the db/db mice are preserved when they
are young (Senador, Kanakamedala et al. 2009). However, the db/db mice develop
hypertension, along with non-dipping BP around 12 weeks old (Su, Guo et al. 2008,
Senador, Kanakamedala et al. 2009). The diabetic and non-dipping BP phenotypes make
the db/db mouse a good animal model to study BP circadian rhythm disruption in
diabetes
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CHAPTER IA. STATEMENT OF THE PROBLEM
Diabetes affected approximately 422 million adults worldwide in 2014 (2016).
90-95% of these people are type 2 diabetes (T2D) in the US (Prevention 2017). People
with T2D suffer from short- and long-term complications, among which cardiovascular
disease (CVD) is the leading cause of mortality and morbidity associated with T2D
(Organization 2014). It is known that hypertension is a major risk factor for CVD.
Hypertension and T2D often coexist and the risk of CVD increases when both
hypertension and T2D are present (Gomes 2013).
With the use of ambulatory blood pressure monitoring (ABPM), people are
aware that blood pressure (BP) exhibits 24-h oscillation that is lowest at night and peaks
before awaking (Millar-Craig, Bishop et al. 1978). The BP during the nighttime mean is
normally 10-20% lower compared to the daytime mean, which is also called a dipping
pattern. In a large study that included 12765 hypertensive patients (2954 T2D patients),
more than 80% of hypertensive, type 2 diabetic patients were found to have an
abnormal BP circadian pattern (non-dipping or reserved-dipping) (Ayala, Moya et al.
2013). The abnormal BP circadian pattern is associated with increased risk of CVD and
target organ damages (described in chapter 1.2.2). Importantly, the dipping status of
systolic blood pressure (SBP) predicts all CVD outcomes independent of 24-hour SBP
levels (Roush, Fagard et al. 2014). Therefore, understanding the mechanisms and
restoring the disruption of BP circadian rhythm in T2D may help prevent or delay the
onset of CVD.
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The underlying mechanisms of diabetes associated BP circadian rhythm
disruption are not well-understood. As described in Chapter 1.2.4, BP circadian rhythm
is regulated by multiple factors, including the sleep-wake cycle, the ANS, the hormonal
systems (RAAS, glucocorticoid, thyroid and atrial natriuretic peptide), the vasculature
and the kidney. Alterations of any one of the above factors, along with diabetes induced
metabolic abnormalities, such as obesity, hyperglycemia and insulin resistance, may be
expected to contribute to diabetes associated BP circadian rhythm disruption.
With the identification of mammalian clock genes in the last two decades, the
molecular mechanisms of mammalian circadian clock are revealed. Investigations of
clock genes point out that the clock genes may also participate in diabetes associated BP
circadian rhythm disruption. For example, mutation or knockout of core clock genes,
such as Bmal1 (Curtis, Cheng et al. 2007, Yang, Chen et al. 2016), Clock (Curtis, Cheng et
al. 2007, Sei, Oishi et al. 2008, Nakashima, Kawamoto et al. 2018), Per (Vukolic, Antic et
al. 2010) and Cry (Masuki, Todo et al. 2005, Doi, Takahashi et al. 2010) leads to
abnormal BP circadian rhythm in rodents. On the other hand, the expressions of
circadian genes are altered in liver (Kudo, Akiyama et al. 2004, Ando, Oshima et al. 2006,
Kohsaka, Laposky et al. 2007), adipose tissues (Kohsaka, Laposky et al. 2007, Caton,
Kieswich et al. 2011), aorta (Su, Xie et al. 2011, Nernpermpisooth, Qiu et al. 2015),
mesentery arteries (Su, Xie et al. 2011), heart (Su, Xie et al. 2011) and kidney (Su, Xie et
al. 2011) in diabetic animals. However, the results of clock genes expressions in diabetes
are achieved using real-time PCR or Western blotting in tissues collected every 4 to 6 h
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in only one day. Consequently, the time resolution of circadian rhythm analysis is limited
by sampling intervals and duration.
To overcome this barrier, we crossed db/db mice, a widely used type 2 diabetic
mice, with mPer2Luc knock-in mice and generated a novel db/db-mPer2Luc mouse model.
The mPer2Luc mice have an in-frame 3’-end fusion of the luciferase reporter gene to the
endogenous

mPer2

gene,

which

allows

real-time

monitoring

of

mPer2Luc

bioluminescence ex vivo and in vivo (Yoo, Yamazaki et al. 2004, Tahara, Kuroda et al.
2012). Therefore, the db/db-mPer2Luc mice enable a novel, continuous monitoring of
Per2 oscillation under a diabetic condition.
Extensive research over the past decades has focused on how the components
of food (what we eat) and the amount of food (how much we eat) affect metabolic
diseases. Only recently has it become appreciated that the timing of food intake (when
we eat), independent of total caloric and macronutrient quality, is also critical for
metabolic health. Results from animal and human studies demonstrated that it is
beneficial to the metabolic health of an organism when the feeding time is in alignment
with the endogenous circadian clock and vice versa. However, it is not known whether
the timing of food intake affects BP circadian rhythm. It is also not known whether
active-time restricted feeding (ATRF, the feeding time is restricted to the active-phase)
is

able

to

restore

disrupted

BP
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circadian

rhythm

in

diabetes.

CHAPTER IB. HYPOTHESIS
Specific Aim 1: To real-time monitor clock gene oscillation in diabetes by generating
db/db-mPer2Luc mice.
Specific Ami 2: To examine the effects of active-time restricted feeding (ATRF) on BP
circadian rhythm in diabetic db/db mice and to explore underlying mechanisms.
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CHAPTER II. MATERIALS AND METHODS
2.1 Project 1: A Novel Diabetic Mouse Model for Real-time Monitoring of Clock
Gene Oscillation and Blood Pressure Circadian Rhythm.
2.1.1 Generation of the db/db-mPer2Luc mice
The heterozygous leptin receptor (Leprdb) mutation db/+ mice on the C57BL/KsJ
background (Stock No.: 000642; also known as C57BL/KsJ-db/+) and the homozygous
mPer2Luc mice on the C57BL/6J background (Stock No.: 006852; also known as C57BL/6JmPer2Luc) were purchased from the Jackson Laboratory. Since the homozygous
C57BL/KsJ-db/db mice are infertile, the heterozygous male C57BL/KsJ-db/+ mice and
homozygous female C57BL/6J-mPer2Luc mice were used as breeders to generate the
homozygous diabetic db/db-mPer2Luc mice and heterozygous non-diabetic db/+mPer2Luc control mice (Figure 2.1.1A). Of note, both db/db-mPer2Luc and db/+-mPer2Luc
control mice have a mixed C57BL/KsJ and C57BL/6J background. The genotyping
protocol for the db/db mice is listed in the Jackson Laboratory website. The genotyping
protocol for the mPer2Luc mice was described previously (Yoo, Yamazaki et al. 2004). The
representative agarose gels for PCR genotyping of the mPer2Luc and db/db mice are
shown in Figure 2.1.1B and 2.1.1C. The mice were fed normal chow diet and housed
under 12:12 light: dark condition. Only the 4-6 month-old male db/db-mPer2Luc and ageand gender-matched db/+-mPer2Luc control mice were used in the current study. All
animal procedures were approved by the Institutional Animal Care and Use Committee
at the University of Kentucky.
48

Figure 2.1.1
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Figure 2.1.1 Generation of the db/db-mPer2Luc mice. (A) Breeding strategy to generate
db/db-mPer2
mPer2

Luc

Luc

and control male mice. (B) Representative image for genotyping

mice. Of note, mouse # 1, 2, and 4 are homozygous mPer2
-/-

Luc

mice. (C)

Representative image for genotyping db/db (lepr ) mice. Of note, mouse #1, 7, and 8
are db/db mice whereas mouse # 2, 3, 4, and 6 are db/+ control mice.
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2.1.2 Metabolic characterization of animals
2.1.2.1 Body composition
Body composition (lean mass and fat mass) was assessed in the light phase by NMR
spectroscopy according to manufacturer’s instructions (Echo MRITM-100H, Houston, TX,
USA).
2.1.2.2 Blood glucose
Non-fasting blood glucose was measured between Zeitgeber Time (ZT; ZT0 is defined as
light on and ZT12 is defined as light off) ZT9 to ZT10 from the tail vein using StatStrip®
XepressTM glucometer (NOVA® biomedical, Waltham, MA, USA).
2.1.2.3 Plasma insulin
Blood was collected between ZT10 and ZT11 in EDTA-coated tubes. Then the blood was
centrifuged at 5000rpm for 10 mins and the supernatant was collected as plasma.
Plasma insulin was determined by ELISA according to manufacturer’s instructions
(Chrystal Chem, Elk Grove Village, IL, USA).
2.1.2.4 Intraperitoneal glucose tolerance test (IPGTT)
IPGTT was performed at ZT3 after 6-h fasting. The basal blood glucose was measured,
followed by intraperitoneal (i.p.) injection of 1 mg/kg body weight (BW) glucose
dissolved in 0.9% NaCl. The blood glucose was then measured at 15, 30, 60, 90 and 120
mins after glucose injection.
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2.1.3 Implantation of radiotelemetry
The radiotelemetry probe (TA11PA-C10, Data Sciences International, St. Paul, MN, USA)
was chronically inserted inside the left common carotid artery of the mice as described
previously (Su, Guo et al. 2008, Su, Xie et al. 2013, Xie, Su et al. 2015). Briefly, the mice
were anesthetized using isoflurane. Then the left carotid artery was isolated and the
catheter of the radiotelemetry probe was inserted into the isolated carotid artery and
tied. The body of the radiotelemetry was slipped subcutaneously to the flank close to
the left hindlimb. Then the neck incision was sutured. After the surgery, the mice were
watched closely until fully awake from anesthesia. After 7-10 days of recovery from the
surgery, blood pressure (BP), heart rate (HR), and locomotor activity were recorded in
conscious free-moving mice. The signals from the radiotelemetry were received to the
receiver (model RPC-1) and then transferred as described in the Acquisition software.
The data were sampled at 500Hz and analyzed using the Dataquest A.R.T. software. In
order to demonstrate the daily rhythms of BP, HR and locomotor activity, at least 72-h
continuous data were collected.
2.1.4 Baroreflex sensitivity analysis
Spontaneous baroreflex sensitivity (BRS) was analyzed by sequence techniques using
Hemolab

software

downloaded

from:

http://www.haraldstauss.com/HemoLab/HemoLab.html. The data collected from
radiotelemetry were generated into short (1-h) data sets. Then the short data sets were
filtered at fourth order, and corner frequency 40 Hz. For an effective BRS, at least four
consecutive sequences where the systolic arterial pressure and pulse interval were
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positively correlated (r2>0.80) were counted. Baroreflex sensitivity was calculated as the
average slope of the systolic pressure-pulse interval relationships with auto threshold at
3 beats in delay. The BRS were averaged in each corresponding hour over 3 days and
one 24-hour BRS was generated.
2.1.5 Metabolic chamber measurement of locomotor activity, food and water intake,
respiratory exchange ratio (RER) and energy expenditure (EE)
The locomotor activity, food and water intake, RER, and EE were determined by indirect
gas calorimetry LabMaster system (TSE System, Bad Homburg, Germany; also known as
metabolic chambers). The mice were kept under 12:12 light: dark cycle and were
individually housed in the acclimation cages for seven days before being transferred to
the metabolic chambers. The mice were put in the metabolic chamber to collect data
for at least three consecutive days. The concentrations of oxygen and carbon dioxide
inside the metabolic chambers, the weights of food and water containers and the
counts of locomotor activity were measured every 30 minutes. The data were calculated
by the accompanied TSE PhenoMaster software.
2.1.6 Real-time monitoring of mPer2 oscillations in explant tissues by LumiCycle
The procedure for real-time monitoring of mPer2 oscillations in explant tissues by
LumiCycle was adapted from previous report (Yamazaki and Takahashi 2005). Briefly,
the aorta, mesenteric artery (MA), kidney, liver, white adipose tissue (WAT), thymus,
lung, adrenal gland (AG), and brain were isolated from mice between ZT10 and ZT11.
The aorta was cleaned, cut open longitudinally, and denuded of endothelium cells. The

52

MA was dissected to remove fat tissues. The kidney, liver, WAT, thymus, and lung were
cut into small pieces, with a diameter varying between approximately 2 and 6 mm
depending upon the tissue. The total AG was used. The brain containing the SCN was cut
into 250 µm thick sections by using NVSL manual advance vibroslice (World Precision
Instruments, Sarasota, FL, USA). Each tissue was cultured in a well-sealed 35-mm Petri
dish containing Dulbecco’s Modified Eagle Medium (DMEM) and 0.1 mM D-luciferin
(Gold Biotechnology Inc., St. Louis, MO). Details of the medium constituent were
described previously (Yamazaki and Takahashi 2005). The light emission from the
cultured tissues was measured with photon-counting photomultiplier tubes that count
photons for 1 min over a 10 min interval using a LumiCycle 32 system (Actimetrics,
Wilmette, IL, USA) as described (Yamazaki and Takahashi 2005). The bioluminescence
data obtained from the explanted tissues were analyzed using LumiCycle Analysis
software (Actimetrics, Wilmette, IL, USA). To detrend the signal drift over time, the 24hour moving average was subtracted from the raw data. To eliminate the influence of
exposure to environmental lighting before recording, the first 12-hour data collected in
the explant culture were excluded. The data collected from 12 hours to 36 hours in the
culture were used to determine the oscillation amplitude and acrophase. The data
collected from 12 hours to 120 hours in the culture were used to determine the
oscillation period by the dampened sine-curve fitting method. The data with a goodness
of fit >0.8 were used for analysis in all the tissues except in kidney where data with a
goodness of fit > 0.7 were used due to the rapid dampening of the oscillation.
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2.1.7 In vivo imaging of mPer2 time-of-day variation in the kidney, liver, and
submandibular gland (SG)
The procedure for in vivo imaging of mPer2 time-of-day variation in the kidney, liver,
and SG was adapted from previous report (Tahara, Kuroda et al. 2012). Briefly, at ZT5,
11, 17 and 23, mice were anesthetized with 2.5-4% isoflurane and subcutaneously
injected with D-luciferin (15 mg/kg body weight in PBS). The mice were imaged 7
minutes later for dorsal side up and 10 minutes later for later ventral side up for 5
seconds by using the IVIS spectrum (IVIS spectrum in vivo imaging system, PerkinElmer,
Waltham, MA, USA). Bioluminescence from the liver of each mouse was quantified
(photon/s/cm2/sr) by setting the region of interest to the same shape and size using
Living Image software (IVIS Imaging System). The bioluminescence intensity was
expressed as an absolute value or as the percentage of the average value throughout
the day as described (Tahara, Kuroda et al. 2012).
2.1.8 Cosinor analysis of circadian rhythm
The daily rhythms of BP, HR, locomotor activity, food and water intake, RER and EE were
analyzed using Cosinor analysis as previously reported (Refinetti, Lissen et al. 2007).
Briefly, a cosine wave with a known period (24 hours) was fitted by the least squares to
the data as an estimate of the pattern of the smooth rhythm. The model equation was
written as xi=M+Acos (θi+φ), where M is mesor, A is amplitude, φ is acrophase, and θi is
trigonometric angles corresponding to the sampling time.
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2.1.9 Tissue collection and quantitative analysis of mRNA expression
2.1.9.1 Tissue collection
Mesenteric arteries (MA) were isolated at ZT5 and ZT17 and immediately placed in
RNAlater solution. Then the fat and adventitious tissues were carefully cleaned off
under microscope from the MA.
2.1.9.2 Quantitative analysis of mRNA expression
The cleaned tissues were homogenized using tissue homogenizer (Bullet Blender ® Next
Advance, Troy, NY) in RNase- DNase-free tubes, followed by total RNA extraction using
RNeasy® Mini Kit (Qiagen, Hilden, Germany). Then the total RNA was used to synthesize
cDNA by M-MLV reverse transcriptase kit (Invitrogen, Carlsbad, CA) using random
hexamers. The real-time PCR primers for each gene are described in Table 2.1.1.
Table 2.1.1. Real-time PCR primer information for project 1.
Gene

Primer

Bmal1

Forward

5'-ATCAGCGACTTCATGTCTCC-3'

Reverse

5'-CTCCCTTGCATTCTTGATCC-3'

Forward

5'-GACTGGGGACAGTTTTGAGAC-3

Reverse

5'-ATCCAAATCATAAACCAGGGCAT-3'

Forward

5’-TTTCTAAACATGCGAAGAATCTCATATG-3’

Reverse

5’-CTTCTACCCCATTTCTTCCAAGTC-3’

Forward

5'-GCACATTTTAACCGAGGTCCT-3'

Reverse

5'-CTGATGGTCGTATTTCTGGGC-3'

ROCK1

ROCK2

Calponin-1

Sequence
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Table 2.1.1 (continued)
Calponin-2

Calponin-3

Tropomyosin 1 (α)

Tropomyosin 2 (β)

SM22α

Forward

5'-GCGGGAACATGACACAGGT-3'

Reverse

5'-CATGGTGGCGTCGTCAAAGT-3'

Forward

5′-AGGCAGAATACCCCGATGAA-3′

Reverse

5′-GGTCGTCGCCATACTGGTACTC-3′

Forward

5'-CTGGTTGAGGAGGAGTTGGA-3'

Reverse

5'-ATGTGCTTGGCCTCTTTCAG-3'

Forward

5′-AGGCCACCGACGCTGAA-3′

Reverse

5′-CCTGTGCCCGATCCAACT-3′

Forward

5′-ACCGTGGAGATCCCAACTGGTTTA-3′

Reverse

5′-CATTTGAAGGCCAATGACGTGCT-3′

Bmal1: Brain and muscle aryl hydrocarbon receptor nuclear translocator-like protein 1;
ROCK1/2: Rho kinase 1/2; SM22α: Smooth muscle protein 22-α.
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2.1.10 Statistical analysis
All data were expressed as mean ± SEM. For comparison of 1 parameter between 2
strains of mice, unpaired 2-tail Student’s t-test was used. For comparison of one
parameter across a time period between 2 strains of mice, 2-way ANOVA with repeated
measures and Bonferroni’s post-test were performed. For comparison of multiple
parameters between 2 strains of mice, regular 2-way ANOVA with Bonferroni’s post-test
was

performed.

P

<

0.05

was
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defined

as

statistically

significant.

2.2 Project 2: Active-Time Restricted Feeding Restores Blood Pressure Circadian
Rhythm via Autonomic Nervous System in Type 2 Diabetic db/db Mice.
2.2.1 Experimental design
Experimental 1: To test if active-time restricted feeding (ATRF) can prevent db/db mice
from disruption of BP daily rhythm.

Experimental 2: To test if ATRF can restore the already disrupted BP daily rhythm in
db/db mice.

2.2.2 Animals
2.2.1.1 C56BL/6J and db/db mice
C56BL/6J mice were purchased from the Jackson Lab (Stock No.: 000664). Db/db on the
C57BL/KsJ background and age-, gender-matched nondiabetic db/+ mice were
purchased from the Jackson Lab (Stock No.: 000642; Bar Harbor, ME). Upon arrival, the
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mice were housed under 12:12 light: dark condition in a light-tight box and fed with
normal chow diet ad libitum.
2.2.1.2 Generation of the inducible global Bmal1 knockout (iG-Bmal1-KO) mice
The homozygous Bmal1flox/flox mice (Storch, Paz et al. 2007)(Stock No.: 007668) and
heterozygous UBC-Cre-ERT2+/- mice (Stock No.: 007001) were purchased from the
Jackson lab. The Bmal1flox/flox/UBC-Cre-ERT2+/- mice were generated by crossing
Bmal1flox/flox mice and UBC-Cre-ERT2+/- mice. The genotyping protocols for the
Bmal1flox/flox and UBC-Cre-ERT2+/- mice are listed in the Jackson Laboratory website. To
generate iG-Bmal1-KO mice, 100 ul 20mg/ml tamoxifen dissolved in sesame oil was i.p.
injected daily for 5 days.
2.2.3 Feeding schedule
All the mice were housed under 12:12 light: dark (LD) condition upon arrival and fed ad
libitum before being subjected to experiments. The mice were fed with normal chow
diet and had free access to water throughout the study.
Inactive-time restricted feeding (ITRF): the mice were allowed access to food for 10
hours between ZT2 and ZT12 during the light-phase.
8-h active-time restricted feeding (ATRF): the mice were allowed access to food for 8
hours from ZT13 to ZT21 during the dark-phase.
12-h ATRF: the mice were allowed access to food for 12 hours from ZT12 to ZT24 during
the dark-phase.
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2.2.4 Metabolic characterization of animals
2.2.4.1 Body composition
Please see chapter 2.1.2.1.
2.2.4.2 Blood glucose
Blood glucose was measured from the tail vein using StatStrip® XepressTM glucometer
(NOVA® biomedical, Waltham, MA, USA). For db/db and control mice that began 8-h
ATRF at 6-week-old, non-fasting blood glucose was measured every other week at ZT13
and ZT21. For the db/db and control mice that began 8-h ATRF at 16-week-old, nonfasting and fasting blood glucose was measured at ZT21, in which the fasting blood
glucose was measured after 4-h fasting started at ZT17.
2.2.4.3 Plasma insulin, non-esterified fatty acids (NEFA) and total cholesterol
measurement
Endpoint blood was collected at ZT5, ZT11, ZT17 and ZT23 in tubes with 10ul 0.5mM
EDTA and plasma was separated as described in chapter 2.1.2.3. Plasma insulin was
determined by ELISA kit (Chrystal Chem, Elk Grove Village, IL, USA). Plasma NEFA was
determined using NEFA kit (FUJIFILM Wako Diagnostics, Richmond, VA, USA). Total
cholesterol was determined by a commercial cholesterol reagent set (Pointe Scientific,
Canton, MI, USA).
2.2.4.4 Intraperitoneal insulin tolerance test (IPTTT)
IPITT was performed at ZT1 after 4-h fasting. The basal blood glucose was measured,
followed by i.p. injection of 1 unit/kg body weight of insulin dissolved in 0.9% NaCl. The
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blood glucose was then measured at 15, 30, 60, 90 and 120 mins after insulin injection.
Area under the curve (AUC) was calculated for the area between the basal and
decreased blood glucose after insulin injection over 120 mins in each mouse.
2.2.5 Implantation of radiotelemetry
Please see chapter 2.1.3.
2.2.6 Sleep-wake state monitoring
The sleep-wake state of the mice was monitored using PiezoSleep system (Signal
Solutions LLC, Lexington, KY, USA) (Flores, Flores et al. 2007). The PiezoSleep system
distinguishes between the sleep and wake state according to the body movements of
the mice. During sleep, the primary gross body movements are associated with
respiration and are rhythmic. During awake, the respiratory movements are masked by
other activity and are erratic. The PiezoSleep system detects the body movements using
a high-sensitive motion detector on the bottom of the animal cages. Control and db/db
mice were habituated to the piezo device in LD schedule with normal chow diet for 4
weeks. The sleep-wake state was recorded at 15-week-old for 7 days as baseline. Then
the mice were subjected to 8-h ATRF and sleep-wake state was continued to be
recorded for 5 days after ATRF.
2.2.7

Urine

collection

and

catecholamines,

aldosterone

and

corticosterone

measurement
Urine was collected using metabolic cages (Tecniplast, S.p.A.). The mice were acclimated
in the cage for over 12 hours, then the urine was collected during the periods ZT0 to 6,
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ZT6 to 12, ZT12 to 18 and ZT18 to 24. ELISA kits were used to determine the
concentrations of urinary epinephrine, norepinephrine and normetanephrine (Abnova,
Taiwan) and aldosterone (Enzo Life Sciences, Inc.). The urinary concentrations of
corticosterone were determined using EIA kit (Arbor Assay, Ann Arbor, MI). Total
contents of urinary epinephrine, norepinephrine, normetanephrine, aldosterone and
corticosterone were calculated as concentrations × urine volumes.
2.2.8 Effects of prazosin on BP
The 1-adrenergic receptor antagonist, prazosin, was i.p. injected at 1mg/kg body
weight in the mice. Radiotelemetry was recorded 1 hour before injection as baseline
and 2 hours after the injection (total three hours). The data were averaged over an
interval of 3 mins. Baseline BP was calculated as the average of 1h data before injection.
The values of BP after injection of prazosin were selected as the lowest points after
injection.
2.2.9 Baroreflex sensitivity analysis
Please chapter 2.1.4
2.2.10 Heart rate variability (HRV) analysis
HRV was analyzed from the radiotelemetry data by frequency domain and time domain
methods using Ponemah Software (DSI, version 6.32).
For frequency domain analysis, 2-min segments at 20-min interval over 72 hours were
selected and scanned to ensure they were free of artifacts. Each segment was
interpolated to 20Hz using quadratic method. Subsequently, the data were subdivided
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into 50 overlapping series and computed by Fast Fourier Transform (FFT) using Hanning
window method. The cut-off frequency range for low-frequency (LF) was 0.15-0.6Hz,
optimized by Baudrie's group (Baudrie, Laude et al. 2007). The high-frequency (HF)
range was 1.5-4Hz.
For time domain analysis, 5-min segments over 72 hours were calculated and the rootmean-square successive beat-to-beat difference (rMSSD) was plotted as the marker of
parasympathetic heart rate control.
For both the frequency and time domain data, The HRV were averaged in each
correspondent hour over 3 days and one 24-hour HRV was generated.
2.2.11 Tissue collection and quantitative analysis of mRNA expression
2.2.11.1 Tissue collection
The mice were euthanized at ZT5, 11, 17 and 23. The liver, mesenteric arteries (MA),
kidney, heart and adrenal gland were removed and immediately placed in RNAlater
solution. Then the fat and adventitious tissues of the MA were carefully cleaned off
under microscope. The real-time PCR primers for each gene are described in Table 2.2.1.
Table 2.2.1. Real-time PCR primer information for project 2.
Gene

Primer

Bmal1

Forward

5'-ATCAGCGACTTCATGTCTCC-3'

Reverse

5'-CTCCCTTGCATTCTTGATCC-3'

Forward

5'-GGCGTTGTTGATTGGACTAGG-3

Clock

Sequence
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Table 2.2.1 (continued)

Per1

Per2

Cry1

Cry2

Rev-erbα

Rorc

Th

Dbh

Pnmt

Comt

MaoA

Reverse

5'-GAATGGAGTCTCCAACACCCA-3'

Forward

5’-TCGAAACCAGGACACCTTCTCT-3’

Reverse

5’-GGGCACCCCGAAACACA-3’

Forward

5'-AAAGCTGACGCACACAAAGAA-3'

Reverse

5'-ACTCCTCATTAGCCTTCACCT-3'

Forward

5'-TCGCCGGCTCTTCCAA-3'

Reverse

5'-TCAAGACACTGAAGCAAAAATCG-3'

Forward

5′-CCTCGTCTGTGGGCATCAA-3′

Reverse

5′-GCTTTCTTAAGCTTGTGTCCAGATC-3′

Forward

5'-CCCTGGACTCCAATAACAACACA-3'

Reverse

5'-GCCATTGGAGCTGTCACTGTAG-3'

Forward

5′-TCCACTACGGGGTTATCACCT-3′

Reverse

5′-AGTAGGCCACATTACACTGCT-3′

Forward

5′-TCTCCTTGAGGGGTACAAAACC-3′

Reverse

5′-ACCTCGAAGCGCACAAAGT-3′

Forward

5’-CTGGGTGCCAAGGCATTTTAC-3’

Reverse

5’-GAACTTCCAGTCGGAGAAACG-3’

Forward

5’-AGACCTGAGCAACCCTGATG-3’

Reverse

5’-TGGTGATGTCCTCAAAGTGG-3’

Forward

5’-AACACGCAAAGCCTGGAGA-3’

Reverse

5’-CATGGTGAGAAGCCTGGCTC-3’

Forward

5’-GGTCCTCCTTGGGGATAAAG-3’
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Table 2.2.1 (continued)

MaoB

Angiotensinogen

Renin

Ace

Ace2

At1a

Reverse

5’-TCTCAGGTGGAAGCTCTGGT-3’

Forward

5’-ATGAGCAACAAAAGCGATGTGA-3’

Reverse

5’-TCCTAATTGTGTAAGTCCTGCCT-3’

Forward

5’-TCTCTTTACCCCTGCCCTCT-3’

Reverse

5’-CAGGCAGCTGAGAGAAACCT-3’

Forward

5’-TCAGGGAGAGTCAAAGGTTTCC-3’

Reverse

5’-ACAGTGATTCCACCCACAGTCA-3’

Forward

5’-AGCCCAAGTGTTGTTGAACGA-3’

Reverse

5’-TGGATACCTCCGTGCTTTTCT-3’

Forward

5’-TCCAGACTCCGATCATCAAGC-3’

Reverse

5’-TGCTCATGGTGTTCAGAATTGT-3’

Forward

5’-CCAAGAAAGCCATCACCAGATC-3’

Reverse

5’-TTTCTGGGTTGAGTTGGTCTCA-3’

Bmal1: Brain and muscle aryl hydrocarbon receptor nuclear translocator-like protein 1;
Clock: Circadian locomotor output cycles kaput; Per: Period; Cry: Cryptochrome; Rorc:
RAR-related orphan receptor c; Th: Tyrosine hydroxylase; Dbh: Dopamine beta (β)hydroxylase; Pnmt: Phenylethanolamine N-methyltransferase; Comt: Catechol-Omethyltransferase; MaoA and MaoB: Monoamine oxidase A and B; Ace: angiotensinconverting enzyme; At1a: angiotensin II receptor type 1a.
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2.2.11.2 Quantitative analysis of mRNA expression
Please see chapter 2.1.9.2.
2.2.12 Statistical analysis
All data were expressed as mean ± SEM. For comparison of 1 parameter between 2
groups of mice, paired 2-tail Student’s t-test was used. For comparison of 1 parameter
between more than 2 groups of mice, one-way ANOVA with Newman-Keuls’s post-test
was used. For comparison of two parameters between ≥2 groups of mice, 2-way ANOVA
with Bonferroni’s post-test were performed. P < 0.05 was defined as statistically
significant.
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CHAPTER III. RESULTS
3.1 Project 1: A Novel Diabetic Mouse Model for Real-time Monitoring of Clock
Gene Oscillation and Blood Pressure Circadian Rhythm.
(Published in J Biol Rhythms. 2018 Oct 2)
Authors: Tianfei Hou, Wen Su, Zhenheng Guo and Ming C. Gong
3.1.1 Db/db-mPer2Luc mice are obese and diabetic
The db/db mouse is an extensively used monogenic type 2 diabetic mouse model. The
syndrome in db/db mice is similar to that in maturity-onset diabetes in humans,
characterized by obesity, infertility, hyperphagia and marked hyperglycemia (Ktorza,
Bernard et al. 1997). The diabetic phenotype of the db/db mice, however, varies
depending on the genetic background. Currently, there are two db/db mouse models:
one is on the C57BL/KsJ background with severe hyperglycemia and temporarily
elevated plasma insulin; the other one is on the C57BL/6J background with transient
hyperglycemia and marked hyperinsulinemia (Hummel, Coleman et al. 1972). To study
the disruption of circadian rhythms in type 2 diabetes, we crossed the C57BL/KsJ-db/db
mice that have severe diabetes with the mPer2Luc mice that contain a knock-in luciferase
gene fused to mouse Period2 (mPer2) as a clock gene reporter (Yoo, Yamazaki et al.
2004), and generated a novel db/db-mPer2Luc mice. Since the mPer2Luc mice are on the
C57BL/6J background, the generated db/db-mPer2Luc mice have a mixed background
(C57BL/KsJ and C57BL/6J). It is unclear to what extent the db/db-mPer2Luc mice retain
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obesity and diabetes. Therefore we first characterized this novel mouse model with
respect to obesity, hyperglycemia, hyperinsulinemia and insulin resistance.
The db/db-mPer2Luc mice had significantly increased body weight when compared to
their littermate db/+-mPer2Luc control mice (Figure 3.1.1A). The body weight increase
was mostly attributable to an increased fat mass as the lean mass was comparable
between the db/db-mPer2Luc and control mice (Figure 3.1.1B). The non-fasting blood
glucose and plasma insulin levels in the db/db-mPer2Luc mice were also markedly
elevated relative to those in the control mice (Figure 3.1.1C and 3.1.1D). Moreover, the
db/db-mPer2Luc mice exhibited a severely impaired glucose tolerance (Figure 3.1.1E).
These results indicate that the db/db-mPer2Luc mice manifest the common
characteristics of type 2 diabetes, e.g. obesity, hyperglycemia, hyperinsulinemia, and
impaired glucose tolerance.
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Figure 3.1.1
A

B

D

C

E

Figure 3.1.1 The db/db-mPer2Luc mice are obese and diabetic. Body weight (A; n = 12),
body composition (B; n = 4-6), non-fasting blood glucose (C; n = 12), and plasma insulin
(D; n = 4-5) were measured between ZT9 and ZT11 in the db/db-mPer2Luc and control
db/+-mPer2Luc mice. Glucose tolerance test (E; n = 11-12) was performed at ZT3 after 6hour fasting. All data were expressed as mean ± SEM. *, P < 0.05; ***, P < 0.001; ns, not
significant.
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3.1.2 Db/db-mPer2Luc mice have a compromised BP daily rhythm that is associated
with the disruption of the daily rhythm in baroreflex sensitivity but not heart rate
To determine whether the BP daily rhythm is disrupted in the db/db-mPer2Luc mice, we
recorded BP by radiotelemetry under normal 12:12 light-dark cycle for 72 consecutive
hours. We found that the daily oscillations of mean arterial pressure (MAP), systolic
blood pressure (SBP), and diastolic blood pressure (DBP) were diminished in the db/dbmPer2Luc mice compared to that in the control mice (Figure 3.1.2A, 3.1.3A and 3.1.3D).
The compromised daily rhythms of the MAP, SBP, and DBP were primarily caused by the
decreased dipping during the inactive light phase with no change during the active dark
phase in the db/db-mPer2Luc mice relative to the control mice (Figure 3.1.2A, 3.1.3A and
3.1.3D). Quantitative analysis of the daily (24-hour) average of MAP, SBP, and DBP
showed no difference between the db/db-mPer2Luc and control mice (Figure 3.1.2B
3.1.3B and 3.1.3E), indicating that the db/db-mPer2Luc mice are normotensive, unlike the
C57BL/KsJ-db/db mice (Park, Bivona et al. 2008, Su, Guo et al. 2008, Goncalves, Tank et
al. 2009, Senador, Kanakamedala et al. 2009). Further quantitative analysis of the BP
during either the light or dark phase BP (12-hour) revealed a 50% reduction in the
difference between light phase and dark phase in the MAP, SBP, and DBP in the db/dbmPer2Luc mice compared to that in the control mice (Figure 3.1.2C, 3.1.3C and 3.1.3F).
Cosinor analysis of the oscillations showed that the amplitude (half of the range of
oscillation) and robustness of daily rhythms in the MAP, SBP, and DBP were significantly
attenuated in the db/db-mPer2Luc mice compared to that in the control mice (Figure
3.1.2D and 3.1.2E; Table 3.1.1). Interestingly, no differences were found in the
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acrophase (the time when the cycle peaks) between the db/db-mPer2Luc and control
mice (Figure 3.1.2F; Table 3.1.1).
Baroreflex is an important rapid negative feedback mechanism for maintaining normal
BP. Therefore we investigated whether the compromised BP daily rhythm in the db/dbmPer2Luc mice is associated with an alteration of the time-of-day variations in baroreflex
sensitivity. We analyzed spontaneous baroreflex sensitivity by sequence techniques in
the db/db-mPer2Luc and control mice as previously described (Xie, Su et al. 2015). In the
db/+-mPer2Luc control mice, baroreflex sensitivity was significantly higher during the
light-phase than during the dark-phase (Figure 3.1.4). In contrast, such time-of-day
variations of baroreflex sensitivity were abolished in the db/db-mPer2Luc mice. This
result implicates the loss of daily variation in baroreflex sensitivity in the compromised
BP daily rhythm.
Because heart rate is an important factor that determines the cardiac output and BP
level (Reule and Drawz 2012), we investigated whether the daily heart rate oscillation is
also altered in the db/db-mPer2Luc mice. We found that the daily heart rate, the
difference between light phase and dark phase heart rate, and its rhythmicity, including
amplitude, robustness, and acrophase, were not significantly altered in the db/dbmPer2Luc mice compared to that in the control mice (Figure 3.1.5A-3.1.5F).
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Figure 3.1.2
A

B

D

C

E

F

Figure 3.1.2 The daily rhythm of mean arterial pressure (MAP) is disrupted in the
db/db-mPer2Luc mice. MAP was recorded by radiotelemetry in the db/db-mPer2Luc and
control db/+-mPer2Luc mice. (A) The 72-hour recording of MAP. The light grey box
indicates the dark-phase and the length of the arrowhead lines indicates the BP
difference between the light and dark phase in the two mouse strains. (B) The 24-hour
MAP. (C) The 12-hour MAP during the light phase (L) and dark phase (D). (D-F) The
amplitude, robustness, and acrophase of the MAP daily oscillation. All data were
expressed as mean ± SEM (n = 6). *, P < 0.05; **, P < 0.01, ***, P < 0.001; ns, not
significant.
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Figure 3.1.3
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Figure 3.1.3 The daily oscillations of systolic blood pressure (SBP) and diastolic blood
pressure (DBP) are diminished in db/db-mPer2Luc mice. SBP (A-C) and DBP (D-F) were
recorded by radiotelemetry. The 72-hour recording of SBP (A) and DBP (D) where the
grey box indicates the dark phase and the length of the arrowhead lines indicate the
difference of BP between two strains of mice. The 24-hour average of SBP (B) and DBP
(E). The 12-hour SBP (C) and DBP (F) during the light phase (L) and dark phase (D). The
difference in the day and night BP was indicated in the figures. All data were expressed
as mean ± SEM (n = 6). Unpaired t test was used for (B and E). Two-way ANOVA was
used for (C and F). The difference between two mouse strains was indicated in the
figures. *, p<0.05; ns, p>0.05.
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Figure 3.1.4

Figure 3.1.4 The day and night variation of baroreflex is abolished in the db/dbmPer2Luc mice. Baroreflex was calculated every hour using the Hemolab software in the
db/db-mPer2Luc and control db/+-mPer2Luc mice. The light grey box indicates the darkphase. All data were expressed as mean ± SEM (n = 6). **, P < 0.01, ***, P < 0.001.
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Figure 3.1.5
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Figure 3.1.5 The daily oscillation of heart rate (HR) is not disrupted in db/db-mPer2Luc
mice. HR was recorded by radiotelemetry in the db/db-mPer2Luc and control db/+mPer2Luc mice. (A) The 72-hour recording of HR. The light grey box indicates the darkphase and the length of the arrowhead lines indicates the HR difference between the
light and dark phase in the two mouse strains. (B) The 24-hour HR. (C) The 12-hour HR
during the light phase (L) and dark phase (D). (D-F) The amplitude, robustness, and
acrophase of the HR daily oscillation. All data were expressed as mean ± SEM (n = 6). **,
P < 0.01; ns, not significant.
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Table 3.1.1 The daily oscillations in systolic blood pressure (SBP) and diastolic blood
pressure (DBP) were diminished in db/db-mPer2Luc mice.
Blood Pressure

SBP

DBP

Circadian Rhythm

db/+-mPer2

Luc

db/db-mPer2

Luc

P value

Amplitude (mmHg)

7.421±1.546

4.353±0.5485

0.001 *

Acrophase (ZT time)

18.34±0.5734

19.17±0.731

0.0555

Robustness (%)

67.93±7.997

44.17±9.646

0.0009 ***

Amplitude (mmHg)

6.596±1.425

3.728±0.4713

0.0004 ***

Acrophase (ZT time)

17.96±0.5435

18.54±0.8214

0.1741

Robustness (%)

66.58±10.39

46.22±9.543

0.0054 **

The SBP and DBP were recorded by radiotelemetry. The amplitude, acrophase, and
robustness were calculated by Cosinor analysis. *, P<0.05; **, p<0.01, ***, p<0.001.
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3.1.3 The compromised BP daily rhythm is associated with the disruption of daily
rhythms in locomotor activity and metabolism but not in food and water intake in the
db/db-mPer2Luc mice
Behavioral factors such as locomotor activity, food and water intake as well as
metabolism may affect central and peripheral clock function through the release of
neurotransmitters and hormones and thus impinge on BP circadian rhythm (Rudic and
Fulton 2009). Therefore, the daily rhythms in locomotor activity, food and water intake,
and metabolism were monitored by indirect calorimetry (also known as metabolic
chamber) in the db/db-mPer2Luc and control mice every 30 minutes over 72 consecutive
hours under 12: 12 light: dark condition. We also used radiotelemetry to monitor
locomotor activity independently to confirm the indirect calorimetry data. The results
from both indirect calorimetry and radiotelemetry data consistently showed that the
daily oscillation in locomotor activity was abolished in the db/db-mPer2Luc mice
compared with that in the control mice (Figure 3.1.6A, 3.1.6B, 3.1.6H and 3.1.6I). While
the absolute counts regarding the daily locomotor activity from indirect calorimetry
(Figure 3.1.6C) and radiotelemetry (Figure 3.1.6J) were not consistent, both methods
showed a loss of the locomotor activity daily oscillation in the db/db-mPer2Luc mice
(Figure 3.1.6D and 3.1.6K). Cosinor analysis revealed that the amplitude and robustness
of the locomotor activity daily oscillations were largely diminished in the db/db-mPer2Luc
mice (Figure 3.1.6E, 3.1.6F, 3.1.6L and 3.1.6M). Interestingly, in agreement with the
compromised BP daily rhythm in the db/db-mPer2Luc mice (Figure 3.1.2F), there were
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also no differences in the acrophase of the locomotor activity daily oscillation between
the db/db-mPer2Luc and control mice (Figure 3.1.6G and 3.1.6N).
In contrast to the locomotor activity, the food and water intake daily oscillations
appeared to be preserved in the db/db-mPer2Luc mice (Figure 3.1.7A and 3.1.7B; Figure
3.1.8A and 3.1.8B), although the db/db-mPer2Luc mice consumed more food and water
than the control mice (Figure 3.1.7C and 3.1.8C). Since the db/db-mPer2Luc mice
consumed more food and water proportionally during both the light and dark phase
than the control mice (Figure 3.1.7D and 3.1.8D), the percentages of daily food and
water intake during the light and dark phase were similar between two strains of mice
(Figure 3.1.7D and 3.1.8D). In accordance with these findings, there were also no
differences in robustness and acrophase in food and water intake daily oscillations
(Figure 3.1.7F, 3.1.7G, 3.1.8F and 3.1.8G). Interestingly, there was a trend towards an
increased daily oscillation amplitude in food intake (Figure 3.1.7E) and a significant
increase in water intake (Figure 3.1.8E) in the db/db-mPer2Luc mice.
The respiratory exchange ratio (RER) and energy expenditure (EE) daily oscillations were
acquired by the metabolic chamber. The RER is calculated as the ratio between the
volume of carbon dioxide (VCO2) produced and the volume of oxygen (VO2) used in
metabolism. It is an indicator of fuel sources (Even and Nadkarni 2012). The EE is
calculated as the total daily energy expenditure (calories) in the metabolic chamber,
including basal and physical activity expenditure, thermoregulation, and the thermic
effects of food (Even and Nadkarni 2012). The RER daily oscillation was disrupted in the
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db/db-mPer2Luc mice compared with the control mice (Figure 3.1.9A vs. 3.1.9B).
Although both strains of mice had a similar average RER (Figure 3.1.9C), the db/dbmPer2Luc mice lost the RER daily oscillation compared to the control mice (Figure
3.1.9D). In agreement with these findings, the amplitude and robustness of the RER
daily oscillation were suppressed (Figure 3.1.9E and 3.1.9F), and the acrophase was
delayed in the db/db-mPer2Luc mice (Figure 3.1.9G). In contrast, the EE daily oscillation
was preserved in both strains of mice (Figure 3.1.10A and 3.1.10B), although the daily EE
level was higher in the db/db-mPer2Luc than the control mice (Figure 3.1.10C). Both
strains of mice exhibited a similar EE daily oscillation pattern (Figure 3.1.10D). In
agreement with these findings, there was no difference in amplitude and acrophase
between the db/db-mPer2Luc and control mice (Figure 3.1.10E and 3.1.10F). However,
the robustness was suppressed in the db/db-mPer2Luc mice (Figure 3.1.10G).
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Figure 3.1.6
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Figure 3.1.6 The daily rhythm of locomotor activity is disrupted in the db/db-mPer2Luc
mice. Locomotor activity was recorded by indirect calorimetry (A-G) and radiotelemetry
(H-N). (A and H) The 72-hour recording of locomotor activity in the control mice by
indirect calorimetry (A) and radiotelemetry (H). The 72-hour recording of locomotor
activity in the db/db-mPer2Luc mice by indirect calorimetry (B) and radiotelemetry (I)
where the light grey box indicates the dark-phase. (C and J) The 24-hour locomotor
activity calculated from indirect calorimetry (C) and radiotelometry (J) data. (D and K)
The 12-hour locomotor activity during the light phase (L) and dark phase (D) calculated
from indirect calorimetry (D) and radiotelometry (K) data. (E-F and L-N): The amplitude,
robustness, and acrophase of locomotor activity daily oscillation calculated from indirect
calorimetry (E-F) and radiotelometry (L-N) data. All data were expressed as mean ± SEM
(n = 6). *, p<0.05, ***, P < 0.001; ns, not significant.
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Figure 3.1.7
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Figure 3.1.7 The daily rhythm of food intake is not diminished in the db/db-mPer2Luc
mice. Food intake was recorded by indirect calorimetry. (A and B) The 72-hour recording
of food intake in the control (A) and db/db-mPer2Luc (B) mice where the light grey box
indicates the dark-phase. (C) The 24-hour food intake. (D) The 12-hour food intake
during the light phase (L) and dark phase (D). (E-F): The amplitude, robustness, and
acrophase of food intake daily oscillation. All data were expressed as mean ± SEM (n =
6). *, P < 0.05; **, P < 0.01, ***, P < 0.001; ns, not significant.
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Figure 3.1.8
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Figure 3.1.8 The daily rhythm of water intake is not diminished in the db/db-mPer2Luc
mice. Water intake was recorded by indirect calorimetry. (A and B) The 72-hour
recording of water intake in the control (A) and db/db-mPer2Luc (B) mice where the light
grey box indicates the dark-phase. (C) The 24-hour water intake. (D) The 12-hour water
intake during the light phase (L) and dark phase (D). (E-F): The amplitude, robustness,
and acrophase of water intake daily oscillation. All data were expressed as mean ± SEM
(n = 6). *, P < 0.05; **, P < 0.01; ns, not significant.
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Figure 3.1.9
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Figure 3.1.9 The daily rhythm of respiratory exchange ratio (RER) is disrupted in the
db/db-mPer2Luc mice. RER was recorded by indirect calorimetry. (A and B) The 72-hour
recording of the RER in the control (A) and db/+-mPer2Luc (B) mice. The light grey box
indicates the dark-phase. (C) The 24-hour RER. (D) The 12-hour RER during the light
phase (L) and dark phase (D). (E and F) The amplitude, robustness, and acrophase of the
RER daily rhythm. All data were expressed as mean ± SEM (n = 6). *, P < 0.05; **, P <
0.01, ***, P < 0.001; ns, not significant.
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Figure 3.1.10
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Figure 3.1.10 The daily rhythm of energy expenditure (EE) is not disrupted in the
db/db-mPer2Luc mice. EE was recorded by indirect calorimetry. (A and B) The 72-hour
recording of the EE in the control (A) and db/+-mPer2Luc (B) mice. The light grey box
indicates the dark-phase. (C) The 24-hour EE. (D) The 12-hour EE during the light phase
(L) and dark phase (D). (E and F) The amplitude, robustness, and acrophase of the EE
daily rhythm. All data were expressed as mean ± SEM (n = 6). *, P < 0.05; **, P < 0.01,
***, P < 0.001; ns, not significant.
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3.1.4 Ex vivo LumiCycle recording reveals that the phases of mPer2 daily oscillation are
shifted to different extents in various peripheral tissues but not the SCN from the
db/db-mPer2Luc mice
Multiple systems coordinate to maintain the normal physiological BP circadian rhythm
(Coffman 2011). To investigate in which tissue the clock genes are altered in the db/dbmPer2Luc mice that may contribute to the compromised BP circadian rhythm, we
monitored mPer2 bioluminescence in real-time in peripheral and central SCN tissues in
explant organ culture in the db/db-mPer2Luc and control mice. In the various tissues
from the control mice, the acrophases of mPer2 oscillation varied but were orchestrated
in a specific order (Figure 3.1.11A through 3.1.11J), with the earliest peak shown by the
SCN (10.47 ± 0.82 hours) and later peaks shown by the lung (12.08 ± 0.24 hours), kidney
(14.23 ± 0.11 hours), liver (14.39 ± 0.77 hours), adrenal gland (15.59 ± 0.20 hours), white
adipose tissue (WAT; 15.59 ± 0.39 hours), aorta (16.17 ± 0.24 hours), thymus (19.61 ±
0.77 hours), and mesenteric arteries (MA; 19.69 ± 0.29 hours).
In the tissues from the db/db-mPer2Luc mice, the acrophases of mPer2 oscillations were
significantly advanced to different extents relative to the corresponding control in a
tissue-specific manner (Figure 3.1.11J). The aorta, MA, and kidney, which are crucial for
BP and cardiovascular homeostasis, had a 0.98 ± 0.40, 1.70 ± 0.42, and 2.21 ± 0.56 hour
phase advance, respectively (Figure 3.1.11A to 3.1.11C). The liver and WAT, two tissues
that are crucial for energy metabolism, had a 3.28 ± 0.77 and 4.65 ± 1.21 hour phase
advance (Figure 3.1.11D and 3.1.11E). The thymus, a primary lymphoid organ, had a
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4.24 ± 1.59 hour phase advance (Figure 3.1.11F). In contrast, the lung and adernal gland
had no significant phase shift (Figure 3.1.11G and 3.1.11H). Interestingly, the SCN that
has long been believed to be a major regulator of BP circadian rhythm, had also no
significant phase shift (Figure 3.1.11I). In contrast to the shift in the acrophase in tissues
from the db/db-mPer2Luc mice, no significant change was detected in period and
amplitude of mPer2 luciferase oscillations in most peripheral tissues from the db/dbmPer2Luc (Table 3.1.2).
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Figure 3.1.11(1)
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Figure 3.1.11(2)
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Figure 3.1.11 The phases of mPer2 protein daily oscillation are desynchronized in
various explanted peripheral tissues from the db/db-mPer2Luc mice. The
bioluminescence of mPer2 protein daily oscillation was recorded by LumiCycle in
explanted central SCN and peripheral tissues from the db/db-mPer2Luc and control db/+mPer2Luc mice. The mPer2 oscillation acrophase of the tissues was calculated using the
LumiCycle analysis software. In the representative mPer2 bioluminescence real-time
recording (left panel), the solid vertical line indicates the acrophase of the non-diabetic
db/+-mPer2Luc control mice, whereas the dotted vertical line indicates the acrophase of
the diabetic db/db-mPer2Luc mice. In the acrophase (right panel), the number above the
symbol indicates the difference of the acrophase between two strains of mice. All data
were expressed as mean ± SEM from the aorta (A; n= 7-11), mesentery artery (MA; B; n
= 8-12), kidney (C; n = 4-5), liver (D; n = 6-12), white fat tissue (WAT; E; n = 3-4), thymus
(F; n = 3-5), lung (G; n = 4-6), adrenal gland (H; n = 3-6), and suprachiasmatic nucleus (I;
SCN; n = 6-11). (J) The acrophase of various tissues in control and db/db-mPer2Luc mice.
*, P < 0.05; **, P < 0.01, ***, P < 0.001; ns, not significant.
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Table 3.1.2 No significant changes were detected in the period and amplitude of
mPer2 oscillations in most explanted peripheral tissues from the db/db-mPer2Luc mice.
Tissues

Luc

Luc

Circadian Rhythm

db/+-mPer2

db/db-mPer2

P value

Period (h)

23.76±0.2235

24.05±0.186

0.3409

Amplitude (counts)

139.3±29.33

208.3±21.45

0.0706

Period (h)

24.41±0.2349

24.4±0.1887

0.9672

Amplitude (counts)

26.6±2.005

28.11±3.485

0.7458

Period (h)

24.5±0.5553

23.78±0.2905

0.2608

Amplitude (counts)

8.072±2.38

25.06±3.207

0.0049 **

Period (h)

21.08±0.3492

21.01±0.2061

0.8555

Amplitude (counts)

44.42±10.53

55.54±11.6

0.5471

Period (h)

24.41±0.2349

24.4±0.1887

0.9672

Amplitude (counts)

26.6±2.005

28.11±3.485

0.7458

Period (h)

25.23±0.9905

23.96±0.6772

0.3133

Amplitude (counts)

23.83±10.15

20.5±5.679

0.7641

Period (h)

23.9±0.7106

23.85±0.3052

0.9431

Amplitude (counts)

22.37±2.039

33.32±2.855

0.0233 *

Period (h)

22±0.4155

20.67±1.014

0.1821

Amplitude (counts)

5.882±1.914

16.16±7.113

0.1004

Period (h)

23.47±0.1764

23.88±0.273

0.311

Amplitude (counts)

11.4±2.262

11.82±2.781

0.9212

Aorta

MA

Kidney

Liver

WAT

Thymus

Lung

AG

SCN

The aorta, mesentery artery (MA), kidney, liver, white adipose tissues (WAT), thymus,
lung, adrenal gland (AG), and suprachiasmatic nucleus (SCN) were isolated from the
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db/db-mPer2Luc and db/+-mPer2Luc control mice and cultured in organ culture. The
mPer2 bioluminescence was monitored and recorded by the LumiCycle system. The
period and amplitude of these tissues were analyzed by using the LumiCycle analysis
software. *: p<0.05; **: p<0.01
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3.1.5 In vivo imaging verifies that the phase of mPer2 oscillation is also advanced in
the kidney, liver, and submandibular gland (SG) in the db/db-mPer2Luc mice
To investigate whether the phase advance of the mPer2 oscillation observed in explant
tissue culture manifests the in vivo tissue oscillation, we used IVIS spectrum and
monitored the mPer2 oscillations of the kidney, liver, and SG by IVIS spectrum in the
intact db/db-mPer2Luc and control mice. The in vivo mPer2 bioluminescence images
were obtained with 6 hours interval at ZT5, ZT11, ZT17, and ZT23, respectively. In
accordance with the result from the ex vivo LumiCycle recording (Figure 3.1.11C and
3.1.11D), the in vivo mPer2 bioluminescence of the kidney, liver, and SG exhibited
apparent time-of-day variations. The lowest absolute bioluminescence intensity was
detected at ZT5 and the highest absolute bioluminescence intensity was detected at
ZT17 in all three tissues (Figure 3.1.12A and 3.1.12B). The absolute bioluminescence
intensities were significantly higher in the db/db-mPer2Luc mice as compared to the
control mice at ZT11 and ZT17 in the kidney (Figure 3.1.12C), at ZT11, ZT17, and ZT23 in
the liver (Figure 3.1.12F) and at ZT17 in the SG (Figure 3.1.12I).
To better quantify the mPer2 oscillation in all three tissues between the two mouse
strains, we normalized the absolute mPer2 bioluminescence intensities to the average
of the four ZT time points absolute mPer2 bioluminescence intensities, in accordance
with a previous report (Tahara, Kuroda et al. 2012). The resulting analysis revealed that
the relative mPer2 bioluminescence signal from the db/db-mPer2Luc mice peaked earlier
in all three tissues than those of the control mice (Figure 3.1.12D, 3.1.12G, and 3.1.12J).
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Moreover, cosinor analysis further illustrated that the phase of the mPer2 oscillation
was significantly advanced in all three tissues in the db/db-mPer2Luc mice compared with
that in control mice, with 2.60 ± 0.82, 1.54 ± 0.59, and 1.571 ± 0.61 hour advance in the
kidney, liver, and SG (Figure 3.1.12E, 3.1.12H, and 3.1.12K), respectively.
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Figure 3.1.12(1)
A

B

C

D
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Figure 3.1.12(2)
F

G

H

I

J

K

Figure 3.1.12 The in vivo imaging shows a phase shift in the kidney, liver, and
submandibular gland (SG) in the db/db-mPer2Luc mice. The in vivo imaging of mPer2
bioluminescence by the IVIS spectrum show a time-of-day variation in the kidney, liver,
and SG. (A) Representative in vivo imaging of the mPer2 bioluminescence in the kidney
in the db/db-mPer2Luc (upper panel) and control mice (lower panel). (B) Representative
in vivo imaging of the mPer2 bioluminescence in the SG and liver in the db/db-mPer2Luc
(upper panel) and control mice (lower panel). The absolute bioluminescence intensity
detected in the kidney (C), liver (F), and SG (I). The relative bioluminescence intensity
obtained by normalizing to the average of the four-time points’ data in the kidney (D),
liver (G), and SG (J). The brown color solid vertical line indicates the acrophase of the
control db/+-mPer2Luc mice, whereas the blue dotted vertical line indicates the
acrophase of the db/db-mPer2Luc mice. The acrophase of the two strains of mice in the
kidney (E), liver (H), and SG (K) where the number above the symbol indicates the
difference of the acrophase between the two strains of mice. All data were expressed as
mean ± SEM (n = 4-5). *, P < 0.05; ***, P < 0.001.
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3.1.6 Altered time-of-day variations of gene expressions in the mesenteric arteries
from the db/db-mPer2Luc mice
Db/db mice exhibit alterations in the daily mRNA expressions of clock and clockcontrolled genes that are involved in the regulation of BP, as we have previously shown
(Su, Xie et al. 2012). In addition, we have demonstrated that smooth muscle BMAL1
participates in the control of the BP daily rhythm by regulating one of the contraction
regulatory proteins Rho-kinase 2 (ROCK2) in wild-type mice (Xie, Su et al. 2015). To test
whether any putative clock-controlled BP-associated genes are dysregulated in db/dbmPer2Luc mice, we determined mRNA expressions of Bmal1 and several contractile
regulatory genes in the MA at ZT5 and ZT17. As shown in Figures 3.1.13A through
3.1.13I, Bmal1, ROCK1, calponin-1, tropomyosin-2, and smooth muscle protein-22α
(SM22α) mRNA expression exhibited a significant time-of-day variation. Importantly, an
attenuation or loss of the time-of-day variations was found in the db/db-mPer2Luc mice
compared with the control mice. In contrast, no time-of-day variations were detected in
ROCK2, calponin-2, calponin-3, and tropomyosin-1 mRNA in either genotype (Figure
3.1.13C, 3.1.13E, 3.1.13F, and 3.1.13G).
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Figure 3.1.13
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Figure 3.1.13 Altered time-of-day variations of gene expressions in the mesenteric
arteries from the db/db-mPer2Luc mice. Control and db/db-mPer2Luc mice were
euthanized at ZT5 and ZT17 and mesenteric arteries were harvested. Mesenteric
arteries mRNAs were quantified using real-time PCR. (A) Bmal1. (B) ROCK1. (C) ROCK2.
(D) calponin-1. (E) calponin-2. (F) calponin-3. (G) tropomyosin-1. (H) tropomyosin-2. (I)
smooth muscle protein 22-α (SM22α). n = 4-5 for each mouse strain at each time point.
Data were analyzed by 2-way ANOVA. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not
significant.
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3.2 Project 2: Active-Time Restricted Feeding Restores Blood Pressure Circadian
Rhythm via Autonomic Nervous System in Type 2 Diabetic db/db Mice
(Manuscript in preparation)
Authors: Tianfei Hou, Wen Su, Chanuang Wang, Shreyas Joshi, Bruce O’Hara, Zhenheng
Guo and Ming C. Gong
3.2.1 Investigation of the effect of timing of food intake on BP circadian rhythm.
3.2.1.1 The disruption of BP daily rhythm is associated with altered food intake
rhythm in the db/db mice.
To investigate whether the disruption of BP daily rhythm in the db/db mice is associated
with an altered food intake rhythm, we simultaneously monitored the daily rhythms of
BP and food intake using radiotelemetry and Bio-DAQ system in 12-week-old freely
moving control and db/db mice. Consistent with previous studies (Su, Guo et al. 2008) :
the control mice exhibited apparent 24-hour oscillation in the mean arterial pressure
(MAP); whereas the db/db mice showed diminished daily rhythm in the MAP, mainly
due to a reduced MAP fall during the light-phase (Fig. 3.2.1.1A). The 12-hour average of
MAP during the light- and dark-phase showed that although the levels of MAP during
both the light- and dark-phase were higher in the db/db mice than those of the control
mice, the extent of increase from db/db mice compared to control mice in the lightphase MAP was greater than that of the dark-phase MAP, resulting in diminished
difference between the light- and dark-phase in the MAP of the db/db mice compared
to that of the control mice (Fig. 3.2.1.1B).
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The food intake was monitored at 1-min interval using the Bio-DAQ system. As
illustrated in figure 3.2.1.1C and 3.2.1.1D, the food consumption in the control mice was
concentrated during the dark-phase, while only sporadic consumption occurred during
the light-phase; however, the food consumption in the db/db mice was distributed
throughout the whole day. When calculating the accumulative food intake during the
light- and dark-phase, the db/db mice consumed more food during both the light- and
dark- phase than that of the control mice (Fig 3.2.1.1E). In addition, a significant higher
percent of food out of the daily food intake was consumed during the light-phase in the
db/db mice compared to that of the control mice (11.3±4.2% in the control mice vs.
36.0±2.9% in the db/db mice, p<0.0001).
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Figure 3.2.1.1 The disruption of blood pressure daily rhythm is associated with altered
food intake rhythm in the db/db mice. (A) 2-hour average mean arterial pressure
(MAP) in the control and db/db mice. The light grey box indicates the dark-phase. (B) 12hour average MAP during the light-phase (L) and dark-phase (D). (C and D)
Representative figures of food intake collected at 1-min interval using the Bio-DAQ
system in the control (C) and db/db (D) mice. (E) Food intake during the light- (L) and
dark- (D) phase. (F) Percents of food intake during the light- (L) and dark- phase (D). n=4.
**, p<0.01; ****, P<0.0001.
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3.2.1.2 Inactive-time restricted feeding (ITRF) altered the BP daily rhythm in the
healthy mice.
To investigate whether the alternation of food intake daily rhythm contributes to the
disruption of BP daily rhythm, we fed the healthy C57BL/6J mice, whose BP daily rhythm
is normal, on an ITRF regimen, in which the food was only available between ZT2 and
ZT12 (i.e., during the inactive-phase (light-phase)). As shown in figure 3.2.1.2A, the MAP
daily rhythm was apparent in the healthy C57BL/6J mice at baseline. After 4 days of
ITRF, although the MAP started to rise at the beginning of the dark-phase, it was not
sustained at that level during the late dark-phase and dropped to the level that was
similar to the light-phase MAP. In agreement with that, the dark-phase MAP after ITRF
was significantly lower than that at baseline (Fig. 3.2.1.2B). Cosine analysis of the MAP
oscillation revealed the amplitude and robustness were significantly decreased after
ITRF (Fig. 3.2.1.2C and 3.2.1.2D). In addition, the acrophase of MAP oscillation was
advanced (Fig. 3.2.1.2E).
The effect of ITRF on the level and daily rhythm of SBP was similar to that on the MAP
(Fig. 3.2.1.3A-3.2.1.3D), except the acrophase of SBP was not significantly altered after
ITRF (Fig. 3.2.1.3E). Interestingly, besides the similar effects of ITRF on the level of darkphase and the oscillation of DBP as those of the SBP (Fig. 3.2.1.3F-3.2.1.3J), ITRF also
significantly increased the DBP level during the light-phase (Fig. 3.2.1.3F and 3.2.1.3G).
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Figure 3.2.1.2
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Figure 3.2.1.2 Inactive-time restricted feeding (ITRF) altered the MAP daily rhythm in
the healthy mice. (A) 2-hour average MAP in the C57BL/6J mice at baseline and after 4
days of ITRF. The light grey box indicates the dark-phase. (B) 12-hour average MAP
during the light-phase (L) and dark-phase (D). (C-E) The amplitude (C), robustness (D)
and acophase (E) of MAP oscillation. n=6. *, p<0.05; **, p<0.01; ***, p<0.001; ****,
P<0.0001; ns, not significant.
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Figure 3.2.1.3(1)
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Figure 3.2.1.3 ITRF altered the systolic blood pressure (SBP) and diastolic blood
pressure (DBP) daily rhythm in the healthy mice. (A and F) 2-hour average SBP (A) and
DBP (F) in the C57BL/6J mice at baseline and after 4 days of ITRF. The light grey box
indicates the dark-phase. (B and G) 12-hour average SBP (B) and DBP (G) during the
light-phase (L) and dark-phase (D). (C-E and H-J) The amplitude, robustness and
acrophase of SBP (C-E) and DBP (H-J) oscillation. n=6. *, p<0.05; **, p<0.01; ***,
p<0.001; ****, p<0.0001; ns, not significant.
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3.2.2 Determination of whether active-time restricted feeding (ATRF) restores BP
circadian rhythm in diabetes.
3.2.2.1 ATRF prevented the disruption of BP daily rhythm in the db/db mice
To investigate whether ATRF prevents the disruption of BP daily rhythm, we fed the
db/db and control db/+ mice on an ATRF regimen, in which the food was only available
between ZT13 and ZT21 during the active-phase (dark-phase). The ATRF was started at
the age of 6-weeks-old when the normal BP daily rhythm was preserved in the db/db
mice, as the disruption of BP daily rhythm in the male db/db mice begins around 12weeks of age (Senador, Kanakamedala et al. 2009). As a control for the ATRF feeding
paradigm, a group of age-matched db/db and control mice received ad libitum feeding
(ALF). The BP was measured after 10-weeks of ATRF or ALF. As shown in Figure 3.2.2.1A
and 3.2.2.1B, the ad libitum fed-control mice (Ctrl-ALF) exhibited 24-hour oscillation in
mean arterial pressure (MAP): the MAP is lower during the light-phase than that during
the dark-phase. In contrast, the ad libitum fed db/db mice (db/db-ALF) exhibited a nondipping BP pattern: the decrease of MAP during the light-phase was severely
compromised when compared with the control mice. ATRF had no apparent effect on
the MAP in the control mice (Ctrl-ATRF vs. Ctrl-ALF), but effectively prevented the
disruption of BP daily rhythm in the db/db mice (db/db-ATRF vs. db/db-ALF). As shown
in Figure 3.2.2.1C, the MAP was increased in the db/db-ALF mice compared to the
control mice during both the light- and dark-phase, but the extent of increase was larger
during the light-phase than during the dark-phase, which resulted in a non-dipping
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phenotype in the db/db mice. The ATRF selectively reduced the MAP during the lightphase thus preserved the normal MAP dipping in the db/db-ATRF mice (Fig. 3.2.2.1C).
Cosine analysis of the MAP daily oscillation revealed that the oscillation amplitude (Fig.
3.2.2.1D) and robustness (Fig. 3.2.2.1E) were significantly decreased in the db/db-ALF
mice compared to the Ctrl-ALF mice. Importantly, the ATRF fed db/db mice maintained
near normal oscillation amplitude and robustness as in the control mice (Fig. 3.2.2.1D
and 3.2.2.1E). In contrast, the oscillation acrophase was not significantly altered in the
db/db-ALF mice and ATRF did not modify it significantly (Fig. 3.2.2.1F).
ATRF had similar effects on the daily oscillations of systolic blood pressure (SBP) (Fig.
3.2.2.2A-3.2.2.2E) and diastolic blood pressure (DBP) (Fig. 3.2.2.2F-3.2.2.2J) as observed
in the MAP (Fig. 3.2.2.1).
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Figure 3.2.2.1 Active-time restricted feeding (ATRF) prevented db/db mice from the
disruption of mean arterial pressure (MAP) daily rhythm. (A) Continuous 72-hour MAP
in the control and db/db mice with ad libitum feeding (ALF) or ATRF. The grey box
indicates the dark-phase. (B) 2-hour average MAP in the control and db/db mice with
ALF or ATRF. (C) 12-hour average MAP during the light-phase (L) and dark-phase (D). (DF) The amplitude (D), robustness (E) and acrophase (F) of MAP oscillation. Ctrl-ALF:
n=13; Ctrl-ATRF: n=12; db/db-ALF: n=12; db/db-ATRF: n=5. *, p<0.05; **, p<0.01; ***,
p<0.001; ****, p<0.0001; ns, not significant.
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Figure 3.2.2.2(1)
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Figure 3.2.2.2 ATRF prevented the disruption of systolic blood pressure (SBP) and
diastolic blood pressure (DBP) daily rhythm in the db/db mice. (A and F) 2-hour
average SBP (A) and DBP (F) in the control and db/db mice with ALF or ATRF. The grey
box indicates the dark-phase. (B and G) 12-hour average SBP (B) and DBP (G) during the
light-phase (L) and dark-phase (D). (C-E and H-J) The amplitude, robustness and
acrophase of SBP (C-E) and DBP (H-J) oscillation. Ctrl-ALF: n=13; Ctrl-ATRF: n=12; db/dbALF: n=12; db/db-ATRF: n=5. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; ns,
not significant.
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3.2.2.2 ATRF restored the already disrupted BP daily rhythm in the db/db mice
To test whether ATRF can restore the already disrupted BP daily rhythm, which is highly
relevant to human situations, we administered ATRF to 16-week-old db/db mice when
their BP daily rhythm is severely disrupted. BP was recorded at baseline with ALF and
after 9 days of ATRF. As expected, db/db mice lost the normal MAP daily oscillation at
baseline (Fig. 3.2.2.3A and 3.2.2.3B). Importantly, ATRF restored the MAP daily
oscillation mainly by reducing the light-phase MAP (Fig. 3.2.2.3A and 3.2.2.3B). Cosine
analysis demonstrated that the amplitude (Fig. 3.2.2.3C) and robustness (Fig. 3.2.2.3D)
of the db/db mice MAP oscillation were increased after ATRF. Moreover, ATRF had
similar effects on the SBP (Fig. 3.2.2.4A-3.2.2.4E) and DBP (Fig. 3.2.2.4F-3.2.2.4J) as that
on the MAP (Fig. 3.2.2.3).
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Figure 3.2.2.3 ATRF restored the disrupted MAP daily rhythm in the db/db mice. (A) 2hour average MAP in the db/db mice at baseline and after 9 days of ATRF. (B) 12-hour
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p<0.001; ****, P<0.0001; ns, not significant.
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Figure 3.2.2.4 ATRF restored the disrupted daily rhythms of SBP and DBP in the db/db
mice. (A and F) 2-hour average SBP (A) and DBP (F) in the db/db mice at baseline and
after 9 days of ATRF. (B and G) 12-hour average SBP (B) and DBP (G) during the lightphase (L) and dark-phase (D). (C-E and H-J) The amplitude, robustness and acrophase of
SBP (C-E) and DBP (H-J) oscillations. n=5. *, p<0.05; ****, p<0.0001; ns, not significant.
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3.2.2.3 The effects of ATRF on the diabetic symptoms of the db/db mice
To investigate that in addition to the striking benefits in the BP daily rhythm, whether
the ATRF improves the diabetic symptoms in the db/db mice, we measured the body
weight, lean and fat body mass, blood glucose at ZT 13 and ZT 21 in the four groups of
mice who started ATRF at 6-weeks of age. Neither the body weight (Fig. 3.2.2.5A) nor
the lean- or fat-body mass (Fig. 3.2.2.5B) were altered by the 10-week-long ATRF when
compared to the ALF fed groups. Of note, the body weight and fat mass remained
significantly higher in the db/db than in the control mice throughout the entire feeding
regimen (Fig. 3.2.2.5A and 3.2.2.5B). When measured at ZT13, a time point immediately
after the fasting period for the ATRF fed groups; the blood glucose levels were
significantly lower in the db/db-ATRF vs. db/db-ALF and in the Ctrl-ATRF vs. Ctrl-ALF
groups respectively (Fig. 3.2.2.5C). In contrast, when measured at ZT21, a time point
immediately after the active-phase feeding in the ATRF fed mice, the blood glucose was
not different between the db/db-ATRF vs. db/db-ALF mice and between the controlATRF vs. control-ALF mice respectively (Fig. 3.2.2.5D). Of note, the blood glucose
remained at much higher levels in the db/db mice than in the control mice under both
ATRF and ALF regimens (Fig. 3.2.2.5C and 3.2.2.5D).
We also investigated whether the recovery of BP daily rhythm in 16-week-old mice by
ATRF is associated with improvements of body weight, body composition and blood
glucose, insulin sensitivity, plasma insulin and non-esterified fatty acid (NEFA) and total
cholesterol. The results demonstrated no significant improvements in the body weight,
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body composition or fasting and non-fasting blood glucose (Fig. 3.2.2.5E-3.2.2.5H). For
insulin sentivity, we carried out an intraperitoneal insulin tolerance test at ZT1 after 4hour fasting. While insulin induced prompt blood glucose decrease in the control mice,
there was a minimal decrease in the blood glucose of the db/db mice, indicating a
severe insulin resistance in the db/db mice (Fig. 3.2.2.5I and 3.2.2.5J). Importantly, ATRF
did not improve the insulin sensitivity in the db/db or the control mice (Fig. 3.2.2.5I and
3.2.2.5J). Plasma insulin, NEFA and total cholesterol were significantly higher in the
db/db-ALF than in the Ctrl-ALF mice (Fig. 3.2.2.5K-3.2.2.5M). While ATRF significantly
decreased plasma insulin and total cholesterol levels in the control mice (Ctrl-ALF vs.
Ctrl-ATRF), it had no significant effects on the plasma NEFA levels in either the control or
db/db mice, nor on insulin or total cholesterol levels in the db/db mice (db/db-ALF vs.
db/db-ATRF) (Fig. 3.2.2.5K-3.2.2.5M).
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Figure 3.2.2.5 The effects of ATRF on the diabetic symptoms of the db/db mice. (A-D)
data collection in the mice started with ATRF at 6-week-old. (A) Body weight; Ctrl-ALF:
n=10; Ctrl-ATRF: n=14; db/db-ALF: n=8; db/db-ATRF; n=17. (B) Body composition; n=5 in
each group; (C and D) Blood glucose at ZT13 (C) and at ZT21 (D); n=7-10. (E-M) data
collected in the mice started with ATRF at 16-week-old. (E) Body weight; n=8-10; (F)
Body composition; n=8-10; (G and H) Non-fasting blood glucose (G) and fasting blood
glucose (H) measured at ZT21; Ctrl-ALF: n=3-8; Ctrl-ATRF: n=12; db/db groups: n=5-8; (I)
Insulin resistance test was performed at ZT1 by i.p. injection of 1 unit/kg insulin after 4hour fasting and the blood glucose was measured at indicated times; n=7-9; (J) Areas
under the curve of insulin resistance test; (K-M) Plasma insulin (K), non-esterified fatty
acid (NEFA, L) and cholesterol (M); control groups: n=4-7; db/db groups: n=3-5. *,
p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; ns, not significant.
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3.2.2.4 ATRF improved the daily rhythm of energy metabolism in the db/db mice
We had previously shown that the diabetic mice had disrupted daily rhythm in the
energy metabolism (Fig 3.1.9 and 3.1.10). It is not known, however, whether ATRF
improves the oscillation in the energy metabolism of the db/db mice. The respiratory
exchange ratio (RER) and energy expenditure (EE) were recorded using indirect
calorimetry in the four groups of mice which started ATRF at 6-weeks of age. The results
demonstrated that the daily rhythm of RER seen in the Ctrl-ALF mice was lost in the
db/db-ALF mice (Fig. 3.2.2.6A). ATRF induced an even more robust RER oscillation in the
control mice by decreasing the light-phase RER and increasing the dark-phase RER (Fig.
3.2.2.6A and 3.2.2.6B) and established a modest RER oscillation in the db/db mice by
decreasing the light-phase RER (Fig. 3.2.2.6A and 3.2.2.6B). Of note, the average RER
during the light- and dark-phase and 24-hour day was lower in the db/db mice
compared with the control mice in both feeding regimens (Fig. 3.2.2.6C and 3.2.2.6D). In
agreement with the observed oscillation, cosine analysis revealed that the RER
oscillation amplitude (Fig. 3.2.2.6E) and robustness (Fig. 3.2.2.6F) were significantly
decreased in the db/db-ALF mice compared with the Ctrl-ALF mice. ATRF increased the
oscillation amplitude and robustness in both the control and db/db mice (Fig. 3.2.2.6E
and 3.2.2.6F). In addition, the delayed acrophase of RER oscillation in the db/db mice
was corrected with ATRF (Fig. 3.2.2.6G). Regarding the EE, ATRF significantly decreased
the mean EE in the db/db mice during the light phase (Fig. 3.2.2.7B and 3.2.2.7C) and
consequently the 24-hour energy expenditure (Fig. 3.2.2.7D). In contrast, ATRF did not
significantly modify the EE in the control mice (Fig. 3.2.2.7A to 3.2.2.7D). Cosine analysis
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revealed that ATRF significantly enhanced the daily oscillations of EE amplitude (Fig.
3.2.2.7E) and robustness (Fig. 3.2.2.7F) in both the control and db/db mice. In addition,
ATRF corrected the delayed acrophase in the daily oscillation of EE in the db/db mice
(Fig. 3.2.2.7G).
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Figure 3.2.2.6
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Figure 3.2.2.6 ATRF improved the daily rhythm of respiratory exchange ratio (RER) in
the db/db mice. RER was recorded by indirect calorimetry. (A and B) The 72-hour
recording of the RER in the control and db/db mice with ALF (A) or ATRF (B). The light
grey box indicates the dark-phase. (C) 12-hour average RER during the light-phase (L)
and dark-phase (D). (D) Daily RER. (E-G) The amplitude (E), robustness (F) and
acrophase (G) of RER oscillation; control groups: n=10; db/db groups: n=5-6. *, p<0.05;
**, p<0.01; ***, p<0.001; ****, P<0.0001; ns, not significant.
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Figure 3.2.2.7
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Figure 3.2.2.7 ATRF improved the daily rhythm of energy expenditure (EE) in the db/db
mice. EE was recorded by indirect calorimetry. (A and B) The 72-hour recording of the
EE in the control and db/db mice with ALF (A) or ATRF (B). The light grey box indicates
the dark-phase. (C) 12-hour average EE during the light-phase (L) and dark-phase (D). (D)
Daily EE. (E-G) The amplitude (E), robustness (F) and acrophase (G) of EE oscillation;
control groups: n=10; db/db groups: n=5-6. *, p<0.05; **, p<0.01; ***, p<0.001; ****,
P<0.0001; ns, not significant.
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3.2.3 Exploration of possible mechanisms underlying ATRF initiated protection of BP
circadian rhythm in the db/db mice.
3.2.3.1 ATRF improved the daily rhythms in the sleep and locomotor activity
Since the daily cycles of sleep/wake and activity/rest significantly influence BP daily
oscillation; we monitored the effects of ATRF on these behaviors. As shown in Fig.
3.2.3.1A and 3.2.3.1B, ALF-fed control mice slept about 65% of the time during the lightphase and 25% of the time during the dark-phase. ATRF did not significantly modify the
sleep time distribution in the control mice. In contrast, ALF-fed mice slept significantly
less (~55%) during the light-phase and more (~37%) during the dark-phase sleep
compared with the ALF-fed control mice (Fig. 3.2.3.1A and 3.2.3.1B). Importantly, ATRF
significantly increased the sleep time during the light-phase and significantly decreased
the sleep during the dark-phase, resulting in a restoration of the sleep time distribution
during the light- and dark-phase similar to the control mice (Fig. 3.2.3.1A and 3.2.3.1B).
Interestingly, there is no difference in the total daily sleeping time between the control
and db/db mice (Fig. 3.2.3.1C). To investigate the sleep quality, we determined the the
sleep bout length during the light- and dark-phase. In both the db/db and control mice,
the sleep bout length was longer during the light-phase than during the dark-phase (Fig.
3.2.3.1D and 3.2.3.1E). Interestingly, while ATRF did not alter the sleep bout length
during the dark-phase in either the db/db and control mice, ATRF significantly increased
the sleep bout length during the light phase starting on the second day of ATRF and
reached a plateau around the third day of ATRF (Fig. 3.2.3.1D).
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With ALF, the daily rhythms in locomotor activity in the control mice, as demonstrated
in Fig. 3.2.3.2A, were lost in the db/db mice (Fig. 3.2.3.2B). ATRF significantly decreased
the locomotor activity during the light-phase and significantly increased the locomotor
activity during the dark-phase. ATRF thus restored a light-dark phase locomotor activity
difference in the db/db-ATRF group (Fig. 3.2.3.2C) without altering the mean locomotor
activity during the 24-hour day (Fig. 3.2.3.2D). Surprisingly, ATRF also significantly
increased the locomotor activity in the control mice during the dark-phase (Fig.
3.2.3.2C), which resulted in an increase in the mean locomotor activity during the 24hour day in the control mice (Fig. 3.2.3.2D). Analysis of the daily locomotor activity
oscillation demonstrated that, in the db/db mice, ATRF significantly enhanced the daily
activity oscillation robustness (Fig. 3.2.3.2F) and forward shifted the acrophase (Fig.
3.2.3.2G) without changing the amplitude (Fig. 3.2.3.2E). Interestingly, in control mice,
ATRF significantly increased the daily oscillation amplitude (Fig. 3.2.3.2E) and robustness
(Fig. 3.2.3.2F) without shifting the acrophase (Fig. 3.2.3.2G).
The ATRF induced an increase in the sleep percentage and decrease in the locomotor
activity during the light-phase, and had the opposite effects on the sleep percentage
and locomotor activity during the dark-phase in the db/db mice; this shift likely
contributed to the prevention/restoration of the BP daily rhythm in the db/db mice.
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Figure 3.2.3.1(1)

Light and Dark Sleep
Percent (%)

A
dark

light

80
60
40
20
0

Day on ATRF

0

1

2

3

4

5

0

1

2

B

C

Light and Dark Sleep
Percent (%)

****
80

ns
ns

****
****

60

****

40
20
0

L D
L D
Ctrl
db/db
Baseline

4

5

db/db

L D
L D
Ctrl
db/db
ATRF

Total Daily Sleep Percent (%)

Ctrl

3

60

ns

40
20
0
Ctrl db/db

Ctrl db/db

ALF

ATRF

Light and Dark Sleep
Bout Length (sec)

D
dark

light

1200
900
600
300
0

Day on ATRF

0

1

2

3

4

5

Ctrl

0

1

2

3
db/db

125

4

5

Figure 3.2.3.1(2)
F
*

1200
900
600

***

ns
ns

300
0

L D
L D
Ctrl
db/db
Baseline

L D
L D
Ctrl
db/db
ATRF

Daily Sleep Bout Length (sec)

Light and Dark Sleep
Bout Length (sec)

E

ns

800
600
400
200
0

Ctrl db/db

Ctrl db/db

ALF

ATRF

Figure 3.2.3.1 ATRF improved the daily rhythm of sleep time in the db/db mice. Sleep
was monitored using the PiezoSleep system. (A and D) The time course of the
percentage of sleep time (A) and sleep bout length (D) during the light- and dark-phase
in the control (Ctrl) and db/db mice before and after ATRF. (B and E) The baseline and
the average of day 3 to day 5 sleep time percentage (B) and sleep bout length (E) after
ATRF during the light- and dark-phase. (C and F) The baseline and the average of day 3
to day 5 sleep time percentage (C) and sleep bout length (F) after ATRF during the 24hour day. n=6-8. *, p<0.05; ***, p<0.001; ****, P<0.0001; ns, not significant.
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Figure 3.2.3.2
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Figure 3.2.3.2 ATRF improved the daily rhythm of locomotor activity in the db/db
mice. The locomotor activity was recorded by indirect calorimetry. (A and B) The 72hour recording of the locomotor activity in the control (A) and db/db (B) mice with ALF
or ATRF. The light grey box indicates the dark-phase. (C) 12-hour average locomotor
activity during the light-phase (L) and dark-phase (D). (D) Daily locomotor activity. (E-G)
The amplitude (E), robustness (F) and acrophase (G) of locomotor activity oscillation;
control groups: n=4-5; db/db groups: n=3. *, p<0.05; **, p<0.01; ***, p<0.001; ****,
P<0.0001; ns, not significant.
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3.2.3.2 The effects of ATRF on the BP-regulatory hormones
The BP-regulatory hormones play an important role in the BP homeostasis. We first
explored the renin-angiotensin system (RAS) by determining the mRNA levels in the four
groups of mice (Ctrl-ALF; db/db-ALF; Ctrl-ATRF and db/db-ATRF) at 6-hour intervals of
the following genes: angiotensinegin [Fig. 3.2.3.4A (liver) and Fig. 3.2.3.4B (kidney)],
renin (Fig. 3.2.3.4C, kidney), angiotensin converting enzyme [Fig. 3.2.3.4D (ACE, kidney),
Fig. 3.2.3.4E (ACE2, kidney) and Fig. 3.2.3.4F (ACE/ACE2, kidney)], angiotensin II receptor
1a [Fig. 3.2.3.4G (kidney) and Fig. 3.2.3.4H (and renal gland)]. The results demonstrated
that the kidney ACE was significantly diminished (Fig. 3.2.3.4D) while the kidney
angiotensinogen (Fig. 3.2.3.4B) was significantly increased in the db/db mice when
compared with that in the control mice in all four time points of the day. However, no
dramatic effects were observed by ATRF in either the control or the db/db mice,
suggesting the RAS does not play a critical role in the ATRF initiated protection of BP
daily rhythm.
We then measured three hormones that are important for BP regulation: aldosterone,
corticosterone, and epinephrine in urine samples collected every 6 hours from the
db/db-ALF and db/db-ATRF groups. The results showed that in the db/db-ALF mice, all
three hormones retained the time-of-day variations with a peak at the sample collected
between ZT12-18 (Fig. 3.2.3.5A-3.2.3.5C). ATRF significantly improved the time-of-day
variation by decreasing the aldosterone (Fig. 3.2.3.5A) and corticosterone (Fig. 3.2.3.5B)
at the ZT6-12 sample and by enhancing the epinephrine (Fig. 3.2.3.5C) at the ZT12-18
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sample. While these improvements of the time-of-day variations in humoral factors may
participate in the protective effects of ATRF on the BP daily oscillation, additional factors
are likely involved for the striking effective protection.
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Figure 3.2.3.4
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Figure 3.2.3.4 ATRF had no effect on the renin-angiotensin-system (RAS). Control and
db/db mice with ALF or ATRF were euthanized at ZT5, ZT11, ZT17 and ZT23 and the
time-of-day mRNA expression of RAS components were detected by real-time PCR. (A
and B) Agt in the liver (A) and kidney (B). (C-F) Renin (C), Ace (D), Ace2 (E) and Ace/Ace2
ratio (F) in the kidney. (G and H) At1a in the kidney (G) and adrenal gland (H). Agt:
angiotensinogen; Ace: angiotensin-converting enzyme; At1a: angiotensin II receptor type
1a. At each time point, Ctrl-ALF: n=6-7; Ctrl-ATRF: n=4-5; db/db-ALF: n=4-5, db/db-ATRF:
n=3-5. *, p<0.05; **, p<0.01; ***, p<0.001; ns, not significant.
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Figure 3.2.3.5

200

ZT

-2
4
18
ZT

ZT

-2
4

06

0

18

-1
8
12
ZT

612
ZT

ZT

06

0

**

-1
8

20

400

12

*

ZT

40

db/db-ALF
db/db-ATRF

600

612

db/db-ALF
db/db-ATRF

60

ZT

Corticosterone (ng)

B
Aldosterone (ng)

A

Epinephrien (ng)

C
db/db-ALF
db/db-ATRF

60

*

40
20

-2
4
ZT
18

-1
8
ZT
12

-1
2
ZT
6

ZT
0-

6

0

Figure 3.2.3.5 ATRF improved the time-of-day variations in the urinary excretion of
aldosterone, corticosterone and epinephrine. Urine was collected every 6 hours at ZT6,
ZT12, ZT18 and ZT0 from the db/db-ALF and db/db-ATRF mice. The urinary contents of
aldosterone (A), corticosterone (B) and epinephrine (C) were calculated by the
concentration times the urine volume. n=4-5. *, p<0.05; **, p<0.01.
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3.2.3.3 The autonomic nervous system (ANS) mediates, at least in part, the protective
effects of ATRF on BP daily rhythm
We next investigated the ANS as it is the prominent regulator of the BP circadian
rhythm. Several approaches were employed to investigate the involvement of the ANS.
Firstly, we determined the circadian rhythm of heart rate (HR) as the HR is primarly
determined by the ANS. As shown in Fig. 3.2.3.6A and 3.2.3.6B, in mice that started the
ATRF regimen at 6-weeks-old, the ALF-fed db/db mice had a similar HR oscillation as the
ALF-fed control mice. Interestingly, ATRF had no effect on the light-phase HR in the
control mice (Ctrl-ALF vs. Ctrl-ATRF), but dramatically decreased the light-phase HR in
the db/db mice (db/db-ALF vs. db/db-ATRF)(Fig. 3.2.3.6A and 3.2.3.6B). Cosine analysis
revealed the amplitude and robustness of the HR oscillation were significantly increased
in the db/db-ATRF mice compared to the db/db-ALF mice (Fig. 3.2.3.6C and 3.2.3.6D). In
addition, the HR oscillation amplitude of the db/db-ATRF mice was even greater than
the Ctrl-ATRF mice (Fig. 3.2.3.6C). Similar effects of ATRF on the HR were observed in
the db/db mice started on the ATRF regimen at 16-weeks-old (Fig. 3.2.3.7).
Secondly, we calculated the spontanous baroreflex sensitivity (BRS) across the 24-hour
day in the consious and free-moving mice using the sequence method (Di Rienzo, Parati
et al. 2001) . As shown in Fig. 3.2.3.8A, in the Ctrl-ALF group, there was a time-of-day
variation in the BRS, as we and others have reported (Hossmann, Fitzgerald et al. 1980,
Di Rienzo, Parati et al. 2001, Xie, Su et al. 2015). Such variation was abolished in the
db/db-ALF group (Fig. 3.2.3.8A). ATRF induced the time-of-day variation of BRS in the
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db/db mice that were on the ATRF regimen at both 6-weeks-old (Fig. 3.2.3.8B) and 16weeks-old (Fig. 3.2.3.8C).
Thirdly, we determined the heart rate variability (HRV) across the 24-hour day as HRV is
considered as an indication of autonomic function in some studies. The HRV was
calculated by frequency domain and time domain. For frequency domian, there are
inconsistent cut-offs of the low frequency (LF) and high frequency (HF) ranges for mice
between different literatures. We chose the cut-off at 0.15-0.6Hz for the LF, as
optimized by (Baudrie, Laude et al. 2007). The HF cut-off we used was 1.5-4Hz since
Thireau et al found this cut-off allows for a better evaluation of parasympathetic
modulation in mice (Thireau, Zhang et al. 2008). We first used atropine, a muscarinic
receptor antagonist that inhibits parasympathetic nervous system (PNS) and
metoprolol, a β1-adrenergic receptor antagonist that inhibits sympathetic nervous
system (SNS) function to the heart, to test the cut-offs of the LF and HF. We found that
when the cut-off was defined at 0.15-0.6Hz for the LF and 1.5-4Hz for the HF, atropine
decreased both the LF and HF (Fig. 3.2.3.9A) and metoprolol only decreased the LF (Fig.
3.2.3.9B). This is consistent with the indications of LF and HF in humans, that the LF is
determined by both the SNS and PNS, and the HF is dominated by the PNS (Draghici and
Taylor 2016). Next we calculated the hourly LF and HF using the above cut-offs. As
shown in Fig. 3.2.3.10A and 3.2.3.10C, there were time-of-day variations in both the LF
and HF in the ALF-fed control mice: both the LF and HF tended to be higher during the
light-phase and lower during the dark-phase; however, such variations were lost in the
ALF-fed db/db mice. When the ATRF was started at 6-weeks-old, the ATRF increased the
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light-phase LF and HF in the db/db mice, resulting in the time-of-day variations in the LF
and HF in the db/db mice that were equivalent to those of the control mice (Fig.
3.2.3.10B and 3.2.3.10D). The LF/HF was lower in the db/db-ALF mice than in the CtrlALF mice (Fig. 3.2.3.10E), and the difference persisted after ATRF (Fig. 3.2.3.10F). For the
time domain, the root mean square of successive RR interval differences (rMSSD), which
is demonstrated to be associated with HF, exhibited similar trend and response to ATRF
as the HF of the db/db mice (Fig. 3.2.3.10G and 3.2.3.10H). Equivalent effects of ATRF on
the HRV were observed in the db/db mice started on the ATRF regimen at 16-weeks-old
(Fig. 3.2.3.11). These results suggest that at least, the day and night difference in the
PNS activity was restored in the db/db mice when they were on the ATRF regimen.
Fourthly, we measured the sympathetic neurotransmitter norepinephrine (NE) and its
metabolite normetanephrine in the 6-hour urine samples collected across a 24-hour
day. As shown in Fig. 3.2.3.12A and 3.2.3.12B, no time-of-day variations in the NE and
normetanephrine were detected in the ad libitum fed db/db mice (p>0.05 by JTKCYCLE). The JTK-CYCLE is a algorithm that can distinguishes between rhythmic and nonrhytmic transcripts (Hughes, Hogenesch et al. 2010). The ATRF effectively recovered the
time-of-day variations of the urinary NE and normetanephrine mostly by decreasing
their excretion during the light-phase. The correlation between the decrease in urinary
excretion of sympathetic transmitter and the decrease in BP during the light-phase
suggest that modulation of sympathetic tone is involved in the ATRF’s protection of the
BP daily oscillation. The change in the urinary excretion of NE is unlikely due to the
alternations of the biosynthesis and/or the disposition of NE, as the mRNA expression of
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adrenal tyrosine hydroxylase (Th) and dopamine beta (β)-hydroxylase (Dbh), enzymes
resposible for the NE biosynthesis did not differ between the control and db/db mice
with either ALF or ATRF (Fig. 3.2.3.13A and 3.2.3.13B). For the diposition of NE, the
mRNA expression of the adrenal phenylethanolamine N-Methyltransferase (Pnmt), an
enzyme that methylates NE to form epinephrine, was higher at ZT11 in db/db-ATRF mice
compared with the db/db-ALF mice (Fig. 3.2.3.13C). However, the Pnmt expression was
still at a high level at ZT5 and increased PNMT is shown to be associated with increased
BP (Nguyen, Peltsch et al. 2009), therefore, the increase in the Pnmt expression unlikely
accounts for the ATRF initiated BP decrease during the light-phase.
Fifthly, to further explore a potential cause and effect relationship between the
sympathetic activity and BP daily oscillation, we determined the extent of BP drop in
response to the bloackade of sympathetic vascular function by α1 adrenergic receptor
antagonist prazosin at ZT5 and ZT 17 respectively. As shown in Fig. 3.2.3.14A and
3.2.3.14B, the control mice had higher BP at ZT17 than at ZT5; prazosin decreased the
BP to similar levels. These data indicated a major role of higher sympathetic vascular
tone underlying the higher BP during the dark-phase than during the light-phase in the
control ALF-fed mice. In contrast, in the db/db-ALF mice, no difference in the BP was
detected between ZT5 and ZT 17, and prazosin induced comparable extents of BP drop
(Fig. 3.2.3.14C and 3.2.3.14D). Importantly, the ATRF restored the BP day and night
difference in the db/db-ATRF mice and the prazosin decreased the BP to similar levels
(Fig. 3.2.3.14E and 3.2.3.14F), indicating a prominent role of sympathetic vascular tone
in the restoration of the BP difference between the light- and dark-phase.
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Figure 3.2.3.6
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Figure 3.2.3.6 ATRF improved the heart rate (HR) oscillation in the db/db mice started
on the ATRF regimen at 6-week-old. (A) 2-hour average HR in the control and db/db
mice with ALF or ATRF. (B) 12-hour average HR during the light-phase (L) and dark-phase
(D). (C-E) The amplitude (C), robustness (D) and acrophase (E) of HR oscillation. CtrlALF: n=13; Ctrl-ATRF: n=12; db/db-ALF: n=12; db/db-ATRF: n=5. *, p<0.05; **, p<0.01;
***, p<0.001; ****, p<0.0001; ns, not significant.
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Figure 3.2.3.7
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Figure 3.2.3.7 ATRF improved the HR oscillation in the db/db mice started on the ATRF
regimen at 16-week-old. (A) 2-hour average HR in the db/db mice at baseline and after
9 days of ATRF. (B) 12-hour average HR during the light-phase (L) and dark-phase (D).
(C-E) The amplitude (C), robustness (D) and acrophase (E) of HR oscillation. n=5. *,
p<0.05; **, p<0.01; ***, p<0.001; ****, P<0.0001; ns, not significant.
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Figure 3.2.3.8
B
Ctrl-ALF
db/db-ALF

Interaction
Time
Strain

Interaction

*
****
ns

Baroreflex Sensitivity
(ms/mmHg)

Baroreflex Sensitivity
(ms/mmHg)

A
4
3
2
1
0

0

6
12
18
ZT Time (hour)

Baseline
ATRF

4

ns
ns
****

4
3
2
1
0

24

C
Baroreflex sensitivity
(ms/mmHg)

Ctrl-ATRF
Strain
db/db-ATRF Time

0

Interaction
Time
Feeding

6
12
18
ZT Time (hour)

24

****
****
*

** * * **** *
**
* *

3
2
1
0

0

6
12
18
ZT Time (hour)

24

Figure 3.2.3.8 ATRF induced the time-of-day variation of baroreflex sensitivity (BRS) in
the db/db mice. The hourly average BRS was calculated using the sequence method. (A)
BRS in the Ctrl-ALF and the Ctrl-ATRF mice that started the ATRF regimen at 6-week-old.
(B and C) BRS in the db/db mice that started the ATRF regimen at 6-week-old (B) and at
16-week-old (C). Ctrl-ALF, n=4; db/db-ALF, n=10; Ctrl-ATRF, n=5; db/db-ATRF, n=6;
baseline and ATRF, n=4. *, p<0.05; **, p<0.01; ****, P<0.0001; ns, not significant.
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Figure 3.2.3.9
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Figure 3.2.3.9 The effects of atropine and metoprolol on the low frequency (LF) and
high frequency (HF) range of heart rate variability (HRV). (A) The LF and HF of HRV
before and after i.p. injection of 1mg/kg atropine. (B) The LF and HF of HRV before and
after i.p. injection of 4mg/kg metoprolol. The cut-off for the LF is 0.15-0.6Hz and for the
HF is 1.5-4Hz. n=5-6. *, p<0.05; **, p<0.01; ****, P<0.0001; ns, not significant.
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Figure 3.2.3.10(1)
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Figure 3.2.3.10(2)
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Figure 3.2.3.10 ATRF induced the time-of-day variations of the HRV in the db/db mice
started on the ATRF regimen at 6-week-old. (A-B) LF of the control and db/db mice with
ALF (A) or ATRF (B). (C-D) HF of the control and db/db mice with ALF (C) or ATRF (D). (EF) LF/HF of the control and db/db mice with ALF (E) or ATRF (F). (G-H) The rMSSD of the
control and db/db mice with ALF (G) or ATRF (H). rMSSD: root mean square of
successive RR interval differences. n=6-8. **, p<0.01; ***, P<0.001; ****, P<0.0001; ns,
not significant.
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Figure 3.2.3.11
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Figure 3.2.3.11 ATRF induced the time-of-day variations of the HRV in the db/db mice
started on the ATRF regimen at 16-week-old. (A to D) LF (A), HF (B), LF/HF (C) and
rMSSD (D) of the db/db mice before and after 9 days of ATRF. rMSSD: root mean square
of successive RR interval differences. n=3-4. **, p<0.01; ***, P<0.001; ****, P<0.0001;
ns, not significant.
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Figure 3.2.3.12
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Figure 3.2.3.12 ATRF improved the time-of-day variations in the urinary excretion of
norepinephrine (NE) and normetanephrine. Urine was collected every 6 hours at ZT6,
ZT12, ZT18 and ZT0 from the db/db-ALF and db/db-ATRF mice. The urinary contents of
NE (A) and normetanephrine (B) were calculated by the concentration times the urine
volume. n=4-5. *, p<0.05; **, p<0.01.

143

Figure 3.2.3.13(1)
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Figure 3.2.3.13 The effects of ATRF on the mRNA expression of the enzymes
responsible for NE biosynthesis and disposition. Control and db/db mice with ALF or
ATRF were euthanized at ZT5, ZT11, ZT17 and ZT23 and the time-of-day mRNA
expressions of the enzymes responsible for NE biosynthesis and disposition were
detected by real-time PCR. (A-F) The mRNA expressions of Th (A), Dbh (B), Pnmt (C),
Comt (D), MaoA (E) and MaoB (F) in the adrenal gland. Th: tyrosine hydroxylase; Dbh:
dopamine beta (β)-hydroxylase; Pnmt: phenylethanolamine N-methyltransferase; Comt:
catechol-O-methyltransferase; MaoA and MaoB: monoamine oxidase A and B. At each
time point, Ctrl-ALF: n=6-7; Ctrl-ATRF: n=4-5; db/db-ALF: n=4-5, db/db-ATRF: n=3-5. *,
p<0.05; **, p<0.01; ***, p<0.001; ns, not significant.
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Figure 3.2.3.14
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Figure 3.2.3.14. ATRF induced the day and night difference in prazosin induced BP
reduction in the db/db mice. (A, C and E) The MAP response to prazosin (1mg/kg) i.p.
injection at ZT5 and ZT17 in the control mice at baseline (A) and the db/db mice at
baseline (C) and after ATRF (E). (B, D and F) Average peak response of MAP to prazosin
injection at ZT5 and ZT17 in the control mice at baseline (B) and the db/db mice at
baseline (D) and after ATRF (F). control-basal, n=8; db/db-basal, n=9; db/db-ATRF, n=4.
*, p<0.05, **, p<0.01, ns, not significant.
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3.2.4 Investigation of whether the clock genes participate in the ATRF initiated
protection of BP circadian rhythm in the db/db mice.
3.2.4.1 ATRF restored the clock gene Bmal1 mRNA daily oscillations in multiple tissues
in the db/db mice.
Clock genes are the molecular mechanisms underlying the intrinsic biological rhythms.
We and others have demonstrated that the clock gene daily oscillations were altered in
the db/db mice (Su, Xie et al. 2012). To investigate whether ATRF restores the daily
oscillation of clock genes in the db/db mice, we determined the mRNA expressions of
clock genes Bmal1, Clock, Per1, Per2, Cry1, Cry2, Rev-erbα and Rorc at ZT5, ZT11, ZT17
and ZT23 in the liver, mesentery arteries (MA), kidney, heart and adrenal gland from the
control and db/db mice fed ALF or ATRF. We found that the time-of-day expression of
several clock genes showed tissue-dependent alternations in the db/db-ALF mice
compared with the Ctrl-ALF mice (Fig 3.2.4.1-3.2.4.5). Moreover, ATRF recovered some
of the altered clock genes in most of the tissues in the db/db-ATRF mice (Fig. 3.2.4.13.2.4.5). Among all the clock genes investigated, Bmal1 mRNA showed the most
consistent alterations in the db/db-ALF group and recovery in the db/db-ATRF group
(Fig. 3.2.4.1A, 3.2.4.2A, 3.2.4.3A, 3.2.4.4A and 3.2.4.5A). The JTK cycle analysis showed
the oscillations of Bmal1 mRNA expressions were retained in the db/db-ALF and –ATRF
mice (P<0.05); however, the oscillation acrophase was shifted forward by 6.32 hours in
liver, 3.78 hours in the MA, 5.13 hours in the kidney, 5.51 hours in the heart and 4.73
hours in the adrenal gland in the db/db-ALF mice when compared with that in the Ctrl-
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ALF mice (Table 3.2.4.1). ATRF nearly completely shifted the acrophase phase back to
control mice in all the tissues investigated (Table 3.2.4.1). Another consistent change in
Bmal1 oscillation is the suppressed amplitudes of the oscillations, which are also nearly
restored by ATRF (Table 3.2.4.1).
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Figure 3.2.4.1
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Figure 3.2.4.1 The mRNA expression of clock genes in the liver. Control and db/db mice
with ALF or ATRF were euthanized at ZT5, ZT11, ZT17 and ZT23 and the time-of-day
mRNA expressions of the clock genes were detected by real-time PCR. (A) Bmal1, (B)
Clock, (C) Per1, (D) Per2, (E) Cry1, (F) Cry2, (G) Rev-erbα and (H) Rorc. At each time
point, Ctrl-ALF: n=6-7; Ctrl-ATRF: n=4-5; db/db-ALF: n=4-5, db/db-ATRF: n=3-5. *,
p<0.05; **, p<0.01; ***, p<0.001; ns, not significant.
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Figure 3.2.4.2
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Figure 3.2.4.2 The mRNA expression of clock genes in the mesentery arteries (MA).
Control and db/db mice with ALF or ATRF were euthanized at ZT5, ZT11, ZT17 and ZT23
and the time-of-day mRNA expressions of the clock genes were detected by real-time
PCR. (A) Bmal1, (B) Clock, (C) Per1, (D) Per2, (E) Cry1, (F) Cry2, (G) Rev-erbα and (H)
Rorc. At each time point, Ctrl-ALF: n=6-7; Ctrl-ATRF: n=4-5; db/db-ALF: n=4-5, db/dbATRF: n=3-5. *, p<0.05; **, p<0.01; ***, p<0.001; ns, not significant.
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Figure 3.2.4.3
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Figure 3.2.4.3 The mRNA expression of clock genes in the kidney. Control and db/db
mice with ALF or ATRF were euthanized at ZT5, ZT11, ZT17 and ZT23 and the time-ofday mRNA expressions of the clock genes were detected by real-time PCR. (A) Bmal1,
(B) Clock, (C) Per1, (D) Per2, (E) Cry1, (F) Cry2, (G) Rev-erbα and (H) Rorc. At each time
point, Ctrl-ALF: n=6-7; Ctrl-ATRF: n=4-5; db/db-ALF: n=4-5, db/db-ATRF: n=3-5. *,
p<0.05; **, p<0.01; ***, p<0.001; ns, not significant.
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Figure 3.2.4.4
B
1.5

Ctrl-ALF
db/db-ALF
Ctrl-ATRF
db/db-ATRF

1

0
5

11
17
ZT Time (hour)

1.0

0.5

5

23

D

11
17
ZT Time (hour)

5

11
17
ZT Time (hour)

4
3
2
1

23

G

11
17
ZT Time (hour)

23

11
17
ZT Time (hour)

23

2.5

Heart Cry2 mRNA

0

0

F
Heart Cry1 mRNA

Heart Per2 mRNA

5

5

5

5

10

10

23

E
15

5

11
17
ZT Time (hour)

23

5

11
17
ZT Time (hour)

23

2.0
1.5
1.0
0.5
5

H
1.5

3
Heart Rorc mRNA

Heart Rev-erb mRNA

Heart Per1 mRNA

2

C
Heart Clock mRNA

Heart Bmal1 mRNA

A

1.0
0.5
0.0
5

11
17
ZT Time (hour)

23

2

1

Figure 3.2.4.4 The mRNA expression of clock genes in the heart. Control and db/db
mice with ALF or ATRF were euthanized at ZT5, ZT11, ZT17 and ZT23 and the time-ofday mRNA expressions of the clock genes were detected by real-time PCR. (A) Bmal1,
(B) Clock, (C) Per1, (D) Per2, (E) Cry1, (F) Cry2, (G) Rev-erbα and (H) Rorc. At each time
point, Ctrl-ALF: n=6-7; Ctrl-ATRF: n=4-5; db/db-ALF: n=4-5, db/db-ATRF: n=3-5. *,
p<0.05; **, p<0.01; ***, p<0.001; ns, not significant.
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Figure 3.2.4.5
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Figure 3.2.4.5 The mRNA expression of clock genes in the adrenal gland. Control and
db/db mice with ALF or ATRF were euthanized at ZT5, ZT11, ZT17 and ZT23 and the
time-of-day mRNA expressions of the clock genes were detected by real-time PCR. (A)
Bmal1, (B) Clock, (C) Per1, (D) Per2, (E) Cry1, (F) Cry2, (G) Rev-erbα and (H) Rorc. At each
time point, Ctrl-ALF: n=6-7; Ctrl-ATRF: n=4-5; db/db-ALF: n=4-5, db/db-ATRF: n=3-5. *,
p<0.05; **, p<0.01; ***, p<0.001; ns, not significant.
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Table 3.2.4.1 ATRF recovered the amplitude and acrophase of Bmal1 mRNA time-ofday expressions in multiple tissues.
Tissue

Groups

Amplitude

Acrophase

ADJ.P

Ctrl-ALF

1.1153

23.08

1.32E-08

Ctrl-ATRF

1.1393

23.06

9.94E-05

db/db-ALF

0.9791

17.48

1.99E-06

db/db-ATRF

1.6204

22.44

7.13E-06

Ctrl-ALF

0.6011

1.4

5.80E-06

Ctrl-ATRF

0.9758

0.81

4.85E-07

db/db-ALF

0.375

21.62

0.013453

db/db-ATRF

0.7463

0.4

9.94E-05

Ctrl-ALF

2.0724

22.59

5.61E-09

Ctrl-ATRF

2.0812

22.89

1.49E-05

db/db-ALF

1.7639

17.46

0.000556

db/db-ATRF

2.8298

22.23

5.55E-06

Ctrl-ALF

0.8144

0.91

1.43E-11

Ctrl-ATRF

0.9091

0.64

3.73E-08

db/db-ALF

0.5121

19.4

0.00265

db/db-ATRF

0.9676

23.42

1.49E-05

Ctrl-ALF

4.0315

21.4

5.27E-11

Ctrl-ATRF

4.0976

21.72

4.85E-07

db/db-ALF

3.4306

16.67

0.000228

db/db-ATRF

3.7691

20.64

0.015956

Liver

Mesentery
Artery

Kidney

Heart

Adrenal gland
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The amplitude, acrophase and ADJ.P of Bmal1 mRNA expressions in the liver, mesentery
arteries, kidney, heart and adrenal gland.

155

3.2.4.2 Bmal1 is partially required for ATRF initiated protection of BP daily rhythm
To further test whether the clock gene Bmal1 is required for the protection of BP daily
rhythm by ATRF, we investigated the BP daily rhythm in an inducible global Bmal1
knockout mouse model (iG-Bmal1-KO). As shown in Fig. 3.2.4.6A and 3.2.4.6B, the
normal BP daily rhythm was abolished by global deletion of Bmal1, which is associated
with a complete loss of food intake rhythm (Fig. 3.2.4.7). Imposing ATRF resulted in
partial recovery of BP daily rhythm (Fig. 3.2.4.6A and 3.2.4.6B). Cosine analysis revealed
the BP daily oscillation amplitude (Fig. 3.2.4.6C), robustness (Fig. 3.2.4.6D) and
acrophase (Fig. 3.2.4.6E) in the iG-Bmal1-KO mice under ATRF condition remained
significantly suppressed when compared with the control mice under ALF, indicating
that Bmal1 is essential for the normal BP daily rhythm.
Since the daily rhythm of locomotor acitivity was associtated with ATRF induced
protection of BP oscillation, we tested the locomotor activity in the iG-Bmal1-KO mice
before and after ATRF. As expected, the locomotor activity daily rhythm was abolished
in the iG-Bmal1-KO-ALF mice; however, ATRF restored the oscillation almost completely
(Fig. 3.2.4.8A and 3.2.4.8B). The locomotor activity oscillation amplitude (Fig. 3.2.4.8C)
and robustness (Fig. 3.2.4.8D) were restored to the levels that are similar to the Flox
mice, although there was still a shift in the acrophase (Fig. 3.2.4.8E). As ANS plays a
critical role in ATRF induced protection of BP daily rhythm, we then tested whether the
time-of-day variations in the HR, BRS and urinary NE excretion are recoved by ATRF in
the iG-Bmal1-KO mice. As shown in Fig. 3.2.4.9A-3.2.4.9F, the deletion of Bmal1
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abolished oscillations of HR (Fig. 3.2.4.9A-3.2.4.9E), BRS (Fig. 3.2.4.9F) and attenuated
the day and night difference in the urinary NE excretion (Fig. 3.2.4.9G) in the iG-Bmal1KO-ALF mice. When the iG-Bmal1-KO mice were fed on the ATRF regimen, the
oscillations of HR (Fig. 3.2.4.9A-3.2.4.9E) and BRS (Fig. 3.2.4.9F) were completely
restored, except the overall level of HR was lower in the iG-Bmal1-KO-ATRF mice than
the Flox-ALF mice (Fig. 3.2.4.9A and 3.2.4.9B). On the contrary, no significant difference
of NE was found in the iG-Bmal1-KO mice between ALF and ATRF in either the light- or
dark-phase (Fig. 3.2.4.9G).
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Figure 3.2.4.6
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Figure 3.2.4.6 ATRF partially restored the abolished MAP oscillation in the iG-Bmal1KO mice. (A) 2-hour average MAP in the Flox-ALF, iG-Bmal1-KO-ALF and iG-Bmal1-KOATRF mice. (B) 12-hour average MAP during the light-phase (L) and dark-phase (D). (CE) The amplitude (C), robustness (D) and acrophase (E) of MAP oscillation. n=12. **,
p<0.01; ***, p<0.001; ****, P<0.0001; ns, not significant.
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Figure 3.2.4.7 The daily rhythm in the food intake was disrupted in the iG-Bmal1-KO
mice. (A and B) The daily rhythm of food intake measured using indirect calorimetry in
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Figure 3.2.4.8
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Figure 3.2.4.8 ATRF completely restored the abolished locomotor activity oscillation in
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p<0.001; ****, P<0.0001; ns, not significant.
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Figure 3.2.4.9
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3.2.4.3 ATRF improves daily oscillations of RER and EE in mice lacking Bmal1.
We have demonstrated that the oscillations of RER and EE in the db/db mice were
improved with ATRF. To determine if the improvements were dependent upon the
presence of require Bmal1, we monitored the RER and EE using indirect calorimetry
system in Flox and iG-Bmal1-KO mice before and after ATRF. As shown in Fig. 3.2.4.10A,
the RER daily oscillation was altered in the iG-Bmal1-KO-ALFmice with an increased
light-phase RER (Fig. 3.2.4.10B). ATRF significantly improved the oscillation of RER in
both the Flox-ATRF and iG-Bmal1-KO-ATRF mice (Fig. 3.2.4.10B). Interestingly, the
oscillation of RER in iG-Bmal1-KO-ATRF mice is even more robust than the Flox-ATRF
mice (Fig. 3.2.4.10B), which was reflected by greater amplitude in the iG-Bmal1-KOATRF than Flox-ATRF mice (Fig. 3.2.4.10E). The advanced acrophase of RER oscillation in
the iG-Bmal1-KO-ALF mice was corrected (Fig. 3.2.4.10G). Of note, the 24-h RER in the
iG-Bmal1-KO mice was higher than the Flox mice in both feeding regimens (Fig.
3.2.4.10D). Regarding EE, the deletion of Bmal1 altered the EE oscillation (Fig.
3.2.4.11A), characterized by increased light-phase EE (Fig. 3.2.4.11C). ATRF increased EE
oscillation in both the Flox and iG-Bmal1-KO mice (Fig. 3.2.4.11B). Cosinor analysis
revealed the amplitude and robustness of EE oscillation was enhanced in both strains of
mice after ATRF compared to ALF; however, the amplitude and robustness was still
significantly lower in the iG-Bmal1-KO-ATRF mice than that of the Flox-ATRF mice (Fig.
3.2.4.10E and F). The advanced acrophase was corrected in the iG-Bmal1-KO-ALF mice
(Fig. 3.2.4.10G). No differences were found in 24-h EE between Flox and iG-Bmal1-KO
mice with either ALF or ATRF (Fig. 3.2.4.10D).
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Figure 3.2.4.10 ATRF drives robust daily rhythm of respiratory exchange ratio (RER) in
the iG-Bmal1-KO mice. RER was recorded by indirect calorimetry. (A and B) The 72-hour
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Figure 3.2.4.11
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Figure 3.2.4.11 ATRF improves the daily rhythm of energy expenditure (EE) in the iGBmal1-KO mice. EE was recorded by indirect calorimetry. The plotted EE is normalized
to lean mass in each mouse. (A and B) The 72-hour recording of the RER in the Flox and
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significant.
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3.2.5 Determination of whether the 8-hour ATRF induced protection of BP daily
rhythm is attributable to time-restriction or calorie-restriction.
3.2.5.1 8-hour ATRF decreased total calorie intake in the db/db mice.
When calculating the total food intake in the control and db/db mice on the ALF or ATRF
regimens, we found the db/db-ALF mice consumed a significant greater amount of food
than the Ctrl-ALF mice (Fig 3.2.5.1A). The 8-hour ATRF had no effect on the amount of
daily food intake in the control mice (Ctrl-ALF vs. Ctrl-ATRF, Fig 3.2.5.1A); however, it
significantly decreased the daily food consumption in the db/db mice (db/db-ALF vs.
db/db-ATRF, Fig 3.2.5.1A). Since calorie restriction is known to be beneficial to the
health (Heilbronn and Ravussin 2003), it is important to understand whether timerestriction itself is able to induce the protective effects.
3.2.5.2 The 12-hour ATRF restored the BP daily rhythm in the db/db mice without
reducing calorie intake.
In order to test whether time-restriction alone restores the BP daily rhythm in the db/db
mice, we increased the food available time from 8-hour to 12-hour (this experiment was
done by Wen Su). As shown in Fig. 3.2.5.1B, the food intake in the db/db mice with 12hour ATRF was comparable to that on the ALF regimen. Importantly, we found the
disrupted BP daily rhythm in the db/db mice can be recovered with 12-hour ATRF (Fig.
3.2.5.2, this experiment was done by Wen Su), indicating the time-restriction without
reducing calorie intake is able to restore BP daily rhythm.
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Figure 3.2.5.1
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Figure 3.2.5.2
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3.2.6 Investigation of the effects of aldosterone and phenylephrine on the clock gene
expression.
3.2.6 Aldosterone induced time-dependent phase shift in Per2::luc expression in the
aorta and mesentery artery explants.
We have shown that the altered time-of-day expressions of clock genes mRNA were
restored in the db/db mice with ATRF. However, the underlying mechanisms for this
restoration are not clear. Although the ATRF improved the time-of-day variations in the
urinary excretion of glucocorticoid (corticosterone), mineralocorticoid (aldosterone) and
sympathetic transmitter (NE) in the db/db mice; and although glucocorticoid is a known
factor to induce the phase shift of clock genes, it is not known whether the
mineralocorticoid and sympathetic neurotransmitter also induce the phase shift of clock
gene. To determine the effect of mineralocorticoid and sympathetic neurotransmitter
on the clock gene, we treated the explants of aorta and mesentery arteries (MA)
isolated from the mPer2Luc mice with 100nM aldosterone and 100nM phenylephrine
(PE) at 3-hour interval across 24 hours and generated a phase response curve (PRC). We
also treated the aorta and MA with 1nM dexamethasone as positive controls. As
expected, dexamethasone induced a time-dependent phase shift of Per2::luc in the
aorta and MA (Fig. 3.2.6A and 3.2.6B). In both the aorta and MA, the phase of Per2::luc
advanced when the dexamethasone was added at 0-hour, 3-hour, and 21-hour relative
to the Per2::luc peak, delayed at 6-hour, 9-hour and 12-hour and shifted relative less at
15-hour and 18-hour (Fig. 3.2.6A and 3.2.6B). To our surprise, aldosterone also induced
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a similar time-dependent phase shift as dexamethasone in the aorta and MA (Fig. 3.2.6C
and 3.2.6D). However, the PE did not induce a clear PRC in either the aorta or MA (Fig.
3.2.6E and 3.2.6F).
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CHAPTER IV. GENERAL DISCUSSION
4.1 Summary
In project 1, we generated a novel type 2 diabetic db/db-mPer2Luc mouse model
to explore the role of clock genes in the disruption of BP circadian rhythm in diabetes.
Using this model, we found: 1) the db/db-mPer2Luc mice are obese, hyperglycemic, and
glucose-intolerant and thus resemble type 2 diabetic patients; 2) the db/db-mPer2Luc
mice are normotensive but exhibite a compromised BP daily rhythm, which is associated
with the disruption of daily rhythms in baroreflex sensitivity, locomotor activity, and
metabolism, but not heart rate or food and water intake; 3) a desynchrony of peripheral
tissue oscillation is caused by various extents of phase advances of the mPer2 oscillation
ex vivo of many tissues except the central SCN pacemarker; 4) the similar desynchrony
of mPer2 phase is also observed in vivo in the kidney, liver, and submandibular gland.
In project 2, we tested the effects of active-time restricted feeding on BP
circadian rhythm to explore a potential theraputic strategy for the disrupted BP
circadian rhythm in diabetes. The major findings are: 1) the disruption of BP daily
rhythm is associated with altered food intake rhythm in the db/db mice; 2) inactive-time
restricted feeding (ITRF) alters BP daily rhythm in the healthy C57BL/6J mice; 3) activetime restricted feeding (ATRF) prevents and restores the disruption of BP daily rhythm in
the db/db mice; 4) ATRF has minimal effects on body weight, body composition, blood
glucose, plasma insulin and fatty acid, and insulin sensitivity in the db/db mice; 5) ATRF
improves the rhythms of energy metabolism, sleep-wake cycle, BP-regulatory hormones
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and of the autonomic nervous system in the db/db mice; 6) ATRF improves the time-ofday variations in the mRNA expression of clock genes, especially Bmal1; 7) Bmal1 is
partially required for ATRF to protect the BP circadian rhythm.

4.2 The db/db-mPer2Luc mouse models
The db/db mice have been used extensively for studying the pathogenesis of
obesity and diabetes. Interestingly, the diabetic phenotype of db/db mice varies
depending on the genetic background. The hyperglycemia is more severe when the
leptin receptor mutation is expressed on a C57BL/KsJ background than on a C57BL/6J
background (Leiter, Coleman et al. 1981). Probably because of its severe diabetic
phenotype, the C57BL/KsJ-db/db mice are most commonly used. Interestingly, the
db/db-mPer2Luc mice have significantly higher body weight than the age-matched
C57BL/KsJ-db/db mice (65.72 ± 1.38 g vs. 47.07 ± 1.05 g; n=12; P<0.001). However, the
hyperglycemia in the db/db-mPer2Luc mice is much less severe than that in the
C57BL/KsJ-db/db mice (320.3 ± 18.46 mg/dl vs. 585.9 ± 9.163 mg/dl; n=12; P<0.001).
These results suggest that while the C57BL/KsJ-db/db mice are more like the maturityonset condition of diabetic patients with obesity and marked hyperinsulinemia, while
the db/db-mPer2Luc mice more closely resemble the C57BL/6J-db/db mice (Hummel,
Coleman et al. 1972) and more closely mimic diabetic patients with obesity, moderate
hyperglycemia, and glucose intolerance.
In agreement with the severity of the diabetic phenotypes, the db/db-mPer2Luc
mice are normotensive, which contrasts with the hypertensive C57BL/KsJ-db/db mice
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(Park, Bivona et al. 2008, Su, Guo et al. 2008, Goncalves, Tank et al. 2009, Senador,
Kanakamedala et al. 2009). Despite this difference, the db/db-mPer2Luc mice also
exhibite non-dipping BP, similar to the C57BL/KsJ-db/db mice (Park, Bivona et al. 2008,
Su, Guo et al. 2008, Goncalves, Tank et al. 2009, Senador, Kanakamedala et al. 2009),
which is typified by a lack of BP fall during the inactive light phase.

4.3 Mechanisms underlying diabetes induced BP circadian rhythm disruption
As described in Chapter 1.2.4, the BP circadian rhythm is regulated by multiple
factors. However, the mechanisms by which diabetes induces BP circadian rhythm
disruption are not well understood. Using the db/db-mPer2Luc mice, we have
demonstrated that, in the absence of any change in the phase of SCN, the phase of the
mPer2 protein daily oscillation was advanced to various extents in a tissue-specific
manner in peripheral tissues. This finding was revealed by monitoring mPer2 protein
oscillation in real-time in our novel db/db-mPer2Luc mice. In agreement with the
important role of Bmal1 in the renal, smooth muscle, and fat tissues in the regulation of
BP rhythm under physiological conditions (Tokonami, Mordasini et al. 2014, Xie, Su et al.
2015, Chang, Xiong et al. 2018), we found that the phase of mPer2 protein oscillation
was advanced in the WAT, kidney, MA, and aorta from the db/db-mPer2Luc mice to 4.6,
2.21, 1.71, and 0.99 hours, respectively. These results are also consistent with previous
studies reporting mPer2 mRNA daily oscillation was altered in these tissues from db/db
mice (Su, Guo et al. 2008, Caton, Kieswich et al. 2011, Su, Xie et al. 2012,
Nernpermpisooth, Qiu et al. 2015). In contrast, it was surprising that the phase of mPer2
protein daily oscillation in the adrenal gland, an important source of hormones that
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regulate the BP circadian rhythm, was not significantly changed in the db/db-mPer2Luc
mice relative to control mice. It was also surprising that the phase of mPer2 protein
daily oscillation in the thymus, an important organ that produces T lymphocytes, was
advanced up to 4.23 hours. This result is consistent with a previous report that T
lymphocytes play a critical role in angiotensin II-induced hypertension (Guzik, Hoch et al.
2007), and suggests that clock genes in T lymphocytes may be crucially involved in the
disruption of the BP circadian rhythm in diabetes.
It has been long believed that the BP circadian rhythm, just like other
physiological and behavioral circadian rhythms, is mostly controlled by the master
pacemaker in the SCN. However, the current study demonstrated that the phase of
mPer2 protein daily oscillation was not significantly altered in the SCN tissue from the
db/db-mPer2Luc mice compared to controls. These results confirm previous reports that
there is little or no change of the SCN mPer2 mRNA daily oscillation in db/db mice
(Kudo, Akiyama et al. 2004, Nernpermpisooth, Qiu et al. 2015, Grosbellet, Dumont et al.
2016). These results are also consistent with previous reports that peripheral clock gene
oscillations are altered in some tissues from diabetic patients (Ando, Takamura et al.
2009, Pappa, Gazouli et al. 2013) and db/db mice (Kudo, Akiyama et al. 2004, Caton,
Kieswich et al. 2011, Su, Xie et al. 2012, Nernpermpisooth, Qiu et al. 2015). In addition,
in db/db mice, the alternations of peripheral clock expression occur as early as 6-8
weeks of age (Kudo, Akiyama et al. 2004, Caton, Kieswich et al. 2011) whereas the
disruption of BP circadian rhythm is not detectable in db/db mice until 11-weeks or
older, indicating that peripheral clock impairment precedes the disruption of the BP
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circadian rhythm. Taken together, these results suggest that the peripheral oscillators,
in contrast to the master SCN pacemaker, are strongly affected by diabetes and may
ultimately be responsible for the disruption of BP circadian rhythm.
Besides the desynchrony of peripheral clocks, we also examined other factors
that may contribute to diabetes associated BP circadian rhythm disruption. The results
from both the db/db-mPer2Luc and db/db mice demonstrate for the first time that the
disrupted BP daily rhythm in the diabetic mice is associated with loss of daily rhythm in
spontaneous baroreflex sensitivity.

The baroreflex is a critical mechanism for

maintaining BP homeostasis, and baroreflex sensitivity exhibits daily variations in
humans (Hossmann, Fitzgerald et al. 1980, Di Rienzo, Parati et al. 2001). Interestingly,
the observed loss of daily variation in baroreflex sensitivity resembles the loss of
baroreflex sensitivity daily variation we reported in the smooth muscle Bmal1 knockout
mice (Xie, Su et al. 2015); this indicates that loss of baroreflex sensitivity daily variation
in the diabetic mice may contribute to the decreased nocturnal BP decline phenotype.
The sleep-wake cycle is critical to BP circadian rhythm. In this dissertation, we
have demonstrated that db/db mice have decreased daytime sleep and increased
nighttime sleep compared to control mice. The sleep bout lengths are significantly
shortened during the daytime. Previous study also revealed an altered diurnal rhythm of
sleep time and increased sleep fragmentation in db/db mice (Laposky, Bradley et al.
2008). This earlier study demonstrated that the NREM sleep is increased during the
nighttime; the REM sleep is increased during the daytime and decreased during the
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night. Although the sleep stages cannot be distinguished in the present dissertation, the
overall decreased daytime sleep may contribute to the increase of BP during this period.
In addition, the shortened sleep bout length during the daytime suggests increased
sleep fragmentation. In humans, sleep fragmentation index is associated with increased
awake arterial BP (Morrell, Finn et al. 2000). Although these are no investigations on
sleep fragmentation and BP circadian rhythm, it is possible that sleep fragmentation is
associated with abnormal BP circadian rhythm since sleep fragmentation is a major
characterization of obstructive sleep apnea (OSA) (Kimoff 1996). Previous study has
demonstrated that the severity of OSA is an independent predictor of BP circadian
rhythm (Nabe, Lies et al. 1995). Therefore, changes in sleep fragmentation may
contribute to the non-dipping BP in db/db mice.
The daily rhythm of locomotor activity is abolished in both the db/db-mPer2Luc
and db/db mice. This finding is consistent with previous reports that the daily locomotor
activity rhythm is lost in the C57BL/KsJ-db/db mice (Su, Guo et al. 2008). We speculate
that the loss of locomotor activity rhythm in both strains of db/db mice results from
their severe obesity, i.e., that they are too heavy to move around. Although the loss of
locomotor activity rhythm may potentially contribute to the loss of the BP daily rhythm,
the loss of locomotor activity mainly occurred during the night in the db/db-mPer2Luc
mice, whereas the loss of BP dipping occurred during the day. Therefore, it is unlikely
that the loss of locomotor activity accounts for the disrupted BP daily rhythm in the
diabetic mice.

176

The neuroendocrine system is prominently involved in the generation of the BP
circadian rhythm. We have determined the mRNA expression of renin-angiotensinsystem (RAS) at four time points in control and db/db mice. We found no apparent timeof-day variations in the mRNA expression of RAS in either control or db/db mice,
suggesting that the variation of BP may not be regulated at transcription level of RAS.
Numerous studies have demonstrated that plasma renin activity (PRA) exhibits circadian
variation (Gordon, Wolfe et al. 1966, KATZ, ROMFH et al. 1975, Modlinger, Sharif-Zadeh
et al. 1976, Cugini, Manconi et al. 1980, Beilin, Deacon et al. 1983, Cugini, Salandi et al.
1983, Kawasaki, Uezono et al. 1983, Stern, Sowers et al. 1986, Kawasaki, Cugini et al.
1990, Portaluppi, Bagni et al. 1990, Brandenberger, Follenius et al. 1994). Therefore, it is
possible the BP circadian rhythm is achieved by the oscillation of PRA. Further
experimentation on the oscillation of PRA in db/db mice is needed. We observed
apparent daily variations in urinary aldosterone and corticosterone excretion in db/db
mice. However, due to limited sample collection in control mice, we were not able to
measure aldosterone and corticosterone in control mice. Consequently, it is not known
whether there is a difference between control and db/db mice regarding the variations
of urinary aldosterone and corticosterone excretion. For the autonomic nervous system
(ANS), we have reported indirect, but compelling evidence that db/db mice have
increased sympathetic nervous activity and decreased parasympathetic nervous activity
compared to control mice. These findings are consistent with previous studies and
confirmed the critical role of ANS in BP circadian rhythm.
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The db/db mice have a leptin receptor mutation. One may speculate that
impaired leptin signalling contributes to the disruption of BP circadian rhythm in db/db
mice, particularly given the fact that leptin signaling is implicated in obesity associated
hypertension (Simonds, Pryor et al. 2014). However, several considerations suggest that
it is unlikely that the abnormal BP daily rhythm in the db/db mice is directly mediated by
the loss-of-function mutation in the leptin receptor. First, the leptin is demonstrated to
increase arterial BP. In the human, the level of plasma leptin is positively associated with
the BP level (Barba, Russo et al. 2003), and the loss-of-function mutations in the gene
encoding leptin are associated with low BP (Simonds, Pryor et al. 2014). In diet-induced
obese (DIO) mice, increasing the level of leptin significantly elevates BP, while blocking
the actions of leptin reverses the effect (Simonds, Pryor et al. 2014). However, the lossof-function mutation of leptin receptor in db/db mice does not lower BP, but rather
increases BP, indicating the change in the BP of the db/db mice is not due to the leptin
signaling deficiency. Second, the circulating leptin levels in humans have a 24-hour
oscillation that is higher during the night and lower during the day (Sinha, Ohannesian et
al. 1996). This pattern is opposite to the BP circadian rhythm. Since leptin is positively
associated with BP, it is unlikely that the circadian rhythm of BP is mediated by the
oscillation of leptin. Third, while the leptin receptor mutation is present thoughout the
life of the db/db mice, the disruption of BP circadian rhythm in the db/db mice is only
detectable in mice older than 11-weeks (Senador, Kanakamedala et al. 2009). These
indicate the loss of BP circadian rhythm in diabetes is not due to deficiency of leptin
signialling.
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4.4 Mechanisms of diabetes induced clock gene disruption
In this dissertation, we found the shifts of mPer2 phase observed in vitro from
tissues explanted from the db/db-mPer2Luc mice reflect phase shifts observed in vivo.
This raises the question as to whether the mPer2 phase shifts in the db/db mice might
be caused directly by leptin receptor mutation within cells or indirectly by hyperphagia,
obesity, and diabetes. Although it is currently uncertain, there is some evidence to
support all possibilities. First, leptin is an adipocyte-derived hormone that binds to the
leptin receptor and promotes weight loss by reducing appetite and food intake and by
increasing energy expenditure (Kelesidis, Kelesidis et al. 2010). Circulating leptin levels
display diurnal variations in both humans and rodents (Sinha, Ohannesian et al. 1996,
Ahren 2000, Cha, Chou et al. 2000). There is also evidence that leptin can directly
regulate clock gene oscillations. For example, leptin can phase advance the electrical
activity rhythm in the rat SCN in vitro (Prosser and Bergeron 2003). Thus, leptin receptor
mutation in various tissues may directly advance the mPer2 oscillations in vivo. Second,
consistent with a previous report (Ktorza, Bernard et al. 1997), the current study
demonstrated that both the db/db-mPer2Luc and db/db mice consumed more food than
the control mice. It is possible that increased food intake due to impaired leptin
signaling alters circadian rhythms. In fact, evidence that increased food intake affects
behavioral, metabolic, and molecular circadian rhythms has been demonstrated in HF
diet-fed mice (Kohsaka, Laposky et al. 2007, Hatori, Vollmers et al. 2012, Pendergast,
Branecky et al. 2013, Branecky, Niswender et al. 2015) and db/db mice (Kennedy,
Ellacott et al. 2010).
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associated phase advance of the mPer2 oscillation in vivo. Third, the current dissertation
has demonstrated hyperglycemia, hyperinsulinemia, and glucose intolerance in the
db/db-mPer2Luc mice. Both glucose and insulin have been shown to alter clock gene
expression rhythms in vitro and in vivo. For example, glucose down-regulates Per1 and
Per2 mRNA expression in rat-1 fibroblasts (Hirota, Okano et al. 2002). The amplitude of
circadian expression of REV-ERBα and DBP was enhanced with 0.5mM glucose
compared to 25mM glucose in fibroblasts (Lamia, Sachdeva et al. 2009). Decreasing the
amount of glucose in the medium significantly increased the circadian period length and
decreased the circadian amplitude of U2OS cells stably expressing Bmal1-luciferase
(Lamia, Sachdeva et al. 2009) and also increased the circadian period of Per2-luciferase
expression in mouse fibroblasts cells (Putker, Crosby et al. 2018). 5.5mM glucose
significantly shortened the period and delayed the phase of Per2 mRNA levels compared
to 0.5mM glucose in cultured mHypoE-37 neurons (Oosterman and Belsham 2016).
Insulin is able to induce phase-dependent bi-directional phase shifts in diabetic rat livers
(Yamajuku, Inagaki et al. 2012). In addition, insulin suppresses Bmal1 transcriptional
activity by promoting postprandial Akt-mediated Ser42-phosphorylation of Bmal1,
which affects its intracellular localization in mouse liver (Dang, Sun et al. 2016).
Therefore, it is likely that diabetes resulting from leptin receptor mutation may also
have an indirect effect on the mPer2 phase advances in peripheral tissues in vivo.
Nevertheless, future studies are required to distinguish these potential mechanisms.
Another interesting finding is that there are some similarities with respect to the
effects of high-fat diet and leptin receptor mutation (db/db-mPer2Luc mice) on the
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mPer2 rhythm. For example, using ex vivo bioluminescent analyses, Pendergast et al
demonstrated that mice fed a high-fat diet for 1 week display about a 4 hour phase
advance in the mPer2 rhythm of the liver but not in the SCN or lung (Pendergast,
Branecky et al. 2013). Using the same ex vivo assay, the current study demonstrated the
db/db-mPer2Luc mice also exhibit more than 3 hours phase advance in the mPer2
rhythm in the liver, while no phase shift is found in the SCN or lung. These results
suggest that the liver clock is sensitive whereas the SCN and lung are resistance to both
high-fat diet and leptin receptor mutation. Both the high-fat diet and leptin receptor
mutation are associated with alternations in food intake. In particular, a high-fat diet
changes the food intake pattern such that more food is consumed during the light-phase
when fed high-fat diet than when fed the chow diet (Pendergast, Branecky et al. 2013).
Leptin receptor mutation in the db/db-mPer2Luc mice leads to increased total food
intake throughout the day and night without changing the food intake pattern.
Therefore, increased food intake during the light-phase may be a primary determinate
of the liver clock. Despite these similarities, there were some differences with respect to
the effects of high-fat diet and leptin receptor mutation on the mPer2 rhythm. For
example, the mPer2 rhythm in the white adipose tissue (WAT) and aorta explants show
more than 4 hour and 1 hour phase advance, respectively, in the db/db-mPer2Luc mice,
but no change is seen in the high-fat diet fed mice (Pendergast, Branecky et al. 2013).
These results indicate that either the high-fat diet has no effect on Per2 expression in
WAT and aorta or that one week of high-fat feeding is not long enough to change Per2
expression in WAT and aorta. It is probably the latter possibility since attenuated Per2
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mRNA expression in WAT is observed after 6 weeks of high-fat diet (Kohsaka, Laposky et
al. 2007). However, due to the limitation of sampling, the phase of Per2 was not
calculated (Kohsaka, Laposky et al. 2007).

4.5 Effects of ATRF on BP
Multiple studies have investigated the effects of time-restricted feeding on
metabolic health. However, no study has examined the relationship between food
intake pattern and BP circadian rhythm. In this dissertation, we first monitored food
intake pattern and BP circadian rhythm simultaneously in free-moving mice and
demonstrated that non-dipping db/db mice have an altered food intake pattern. In
addition, when imposing the abnormal feeding rhythm (i.e. the inactive-time restricted
feeding; ITRF) on healthy mice, their BP daily rhythm is significantly altered. Importantly,
active-time restricted feeding (ATRF) significantly decreased the light-phase (i.e., resting
phase) BP, resulting in the restoration of BP daily rhythm in the db/db mice. These
results demonstrate that the altered food intake pattern is associated with the loss of
BP circadian rhythm. However, whether there is a cause-effect of this food intake
pattern and the BP circadian rhythm is not known. Interestingly, the db/db-mPer2Luc
mice have similar non-dipping BP as the db/db mice. However, the food intake rhythm
of db/db-mPer2Luc mice remains normal, that they eat similar percents of food during
both the light- and dark-phase compared to the control mice. However, other regulatory
factors of the BP circadian rhythm, such as the daily rhythms of locomotor activity and
baroreflex sensitivity and the time-of-day variations of clock genes, are similarly affected
in both the db/db-mPer2Luc and db/db mice. Therefore, it is possible the diabetes182

associated circadian rhythm disruptions in other aspects rather than the food intake
rhythm contribute to the abnormal BP circadian rhythm.
Despite the difference in the food intake rhythm between the db/db-mPer2Luc
and db/db mice, both strains of the mice consume significantly greater amounts of food
compared to their controls. In addition, the ATRF regimen not only reduces food intake
time, but also decreases total amount of food intake. These results raise the possibility
that change in calorie intake (overfeeding or fasting) may contribute to the BP circadian
rhythm disruption, especially given the results that calorie restriction achieved by
decreasing the calorie intake every day or intermittent fasting is able to reduce BP level
in humans and laboratory animals (Nakano, Oshima et al. 2001, Wan, Camandola et al.
2003, Mager, Wan et al. 2006, Harvie, Pegington et al. 2011). However, in human
studies, since both the daytime and nighttime SBP is reduced after calorie restriction, it
is not known whether the circadian variation of BP is also changed (Nakano, Oshima et
al. 2001, Harvie, Pegington et al. 2011). In animal studies, the calorie restriction is
always accompanied with time restriction as the food was given at a certain time of the
day (Wan, Camandola et al. 2003, Mager, Wan et al. 2006). And again, the circadian
variation of BP has not been examined in the calorie-restricted animals (Wan,
Camandola et al. 2003, Mager, Wan et al. 2006). In this dissertation, we performed time
restriction without calorie restriction by prolonging the duration of food available time.
We found the db/db mice consumed similar amounts of food with 12-h ATRF compared
to ALF. Importantly, the BP daily rhythm can also be restored. These data indicate time
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restriction without calorie restriction is able to restore BP circadian rhythm in db/db
mice.
We further explored the mechanisms underlying ATRF induced BP circadian
rhythm restoration in db/db mice. We found ATRF significantly improves the rhythm of
the sleep-wake cycle and increases the sleep bout length during the light-phase. Few
studies have examined the effects of food intake pattern on sleep. Afaghi et al found the
meal given 4-h before bedtime significantly shortened sleep onset latency (SOL)
compared to the same meal given 1-h before bedtime (Afaghi, O'Connor et al. 2007).
Another study demonstrated that caloric intake at night in women (represented as
percent of total caloric intake, %) positively correlates with sleep latency and negatively
correlates with sleep efficiency (Crispim, Zimberg et al. 2011). These results are
consistent with the present study and indicate that an early dinner time and less calorie
intake during dinner are associated with increased sleep quality. The daily variations of
urinary aldosterone and corticosterone excretion are also improved with ATRF. The
effects of time-restricted feeding on aldosterone rhythm have not been reported
previously. However, the rhythm of corticosterone in response to time-restricted
feeding was documented as early as 1970s. The peak of corticosterone shifts in
response to food available time: when feeding only occurs during the light-phase of rat,
the peak of corticosterone has a 12-h shift (KRIEGER 1974). The most dramatic change
with ATRF is time-of-day variation in autonomic nervous system (ANS) activity. We have
demonstrated indirect evidence that ATRF significantly decreases sympathetic nervous
system (SNS) activity and increases parasympathetic nervous system (PNS) activity
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during the fasting period compared to ALF, resulting in restored ANS daily variation in
db/db mice. ATRF is a repeated switching between feeding and fasting state every 24 h.
Although there is no study of the effects of time-restricted feeding on ANS rhythm,
various studies have demonstrated that fasting is able to suppress the sympathetic
nervous system (SNS) (Young and Landsberg 1977, Prinz, Halter et al. 1979, Young,
Saville et al. 1982, Young, Rosa et al. 1984) and the suppression is reversed by feeding
(Young and Landsberg 1977). However, the effect of fasting on SNS in previous studies
was tested after 2 days of fasting, which is impractical in any clinical application. In this
dissertation, we have demonstrated that 16-h of fasting is able to suppress the SNS and
subsequently lower BP during the fasting period, resulting in the restoration of BP
circadian rhythm in db/db mice. Previous studies proposed that the mechanism
underlying dietary mediated modulation of SNS might be through the alternation of
insulin secondary to changes in carbohydrate intake (Landsberg 1986). For example:
alterations in carbohydrate and fat enhance SNS activity without increasing total calorie
intake (Young and Landsberg 1977, Schwartz, Young et al. 1983, Walgren, Young et al.
1987); and a diet with low carbohydrate decreases SNS (Jung, Shetty et al. 1979,
DeHaven, Sherwin et al. 1980). In addition, insulin infusion increases SNS activity in the
absence of a glucose change (Rowe, Young et al. 1981). In this dissertation, we found
ATRF decreases SNS activity during the fasting period without changing plasma insulin
level, indicating that other mechanisms may have participated. Using the iG-Bmal1-KO
mice, we have demonstrated that the urinary norepinephrine (NE) excretion is not
decreased during the fasting period after ATRF compared to ALF, and importantly, that
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ATRF cannot completely restore the BP in iG-Bmal1-KO mice. In addition, study from the
embryonic Bmal1-KO mice showed that the sympathoadrenal function is impaired as
the plasma NE and epinephrine (Epi) levels are significantly reduced in the embryonic
Bmal1-KO mice at both ZT2 and ZT14 compared to control mice (Curtis, Cheng et al.
2007). These data indicate that Bmal1 may play an important role in dietary induced
modulation of SNS as well as of BP. Studies of the effects of time-restricted feeding on
parasympathetic nervous system (PNS) function are rare. Results from dietary
restriction, achieved by intermittent fasting or calorie restriction, have been shown to
increase PNS activity in rats (Mager, Wan et al. 2006). In humans, 6-months of calorie
restriction also increases PNS activity (de Jonge, Moreira et al. 2010). In this dissertation,
we first demonstrated that the PNS activity is increased during the fasting period of
ATRF. The mechanisms underlying dietary induced PNS modulation need further
investigation.

4.6 Effects of ATRF on metabolism
Results from previous studies demonstrate that ATRF is beneficial to metabolic
health in high-fat fed mice, including decreased body weight, total cholesterol,
triglyceride, glucose intolerance, insulin and insulin resistance (Hatori, Vollmers et al.
2012, Sherman, Genzer et al. 2012, Tsai, Villegas-Montoya et al. 2013, Chaix, Zarrinpar
et al. 2014, Yasumoto, Hashimoto et al. 2016). The mechanisms of the beneficial effects
of ATRF on metabolism are implicated in multiple pathways. Hatori et al and Chaix et al
from the Panda group revealed that ATRF have profound effects on the enzymes and
proteins involved in the regulation of nutrient hemostasis (Hatori, Vollmers et al. 2012,
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Chaix, Zarrinpar et al. 2014). In the liver, the mRNA expression of fatty acid synthase
(Fasn), stearoyl coA desaturase1 (Scd1) and elongation of very long chain fatty acids
protein 5 (Elovl5) are reduced upon ATRF. The Fasn, Scd1 and Elovl5 genes encode
enzymes involved in lipid synthesis, desaturation and elongation respectively.
Conversely, the expression of hepatic lipase (Lipc) gene, which encodes the enzyme that
catalyzes the hydrolysis of triglyceride, is enhanced, along with increased expression of
3-hydroxybutyrate (BHBA), one of the end products of β-oxidation. Therefore, ATRF
shifts lipid toward degradation. In addition, the expression of peroxisome proliferatoractivated receptor gamma (Ppar), a key regulator of lipid storage, is significantly
repressed in the liver and brown adipose tissues (BAT), which may explain reduced
hepatic steatosis and BAT lipid droplets. Since hepatic lipid homeostasis contributes to
cholesterol and bile acid metabolism, Hatori et al and Chaix et al determined the mRNA
expressions of squalene epoxidase (Sqle) and 7-dehydrocholesterol reductase (Dhcr7),
two key enzymes involved in de novo cholesterol biosynthesis. They found both the Sqle
and Dhcr7 mRNA expressions are enhanced, along with increased protein levels of sterol
regulatory element-binding proteins (SREBPs), suggesting increased cholesterol
biosynthesis. On the other hand, the peak expression of cholesterol 7 alpha-hydroxylase
(Cyp7a1), a gene that encodes the rate limiting enzyme in cholesterol breakdown to bile
acid, is also elevated. Consequently, the overall levels of cholesterol are decreased. For
glucose hemostasis, the mRNA expressions of pyruvate carboxylase (Pcx) and glucose-6phosphatase (G6pc), genes that encode enzymes that mediate the committing step in
gluconeogenesis, are reduced. On the contrary, the expressions of glucose-6-phosphate
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dehydrogenase (G6pdx), a gene that encodes the rate-limiting enzyme of the pentose
phosphate cycle (PPC) and the levels of its substrate, glucose-6-phosphate (G6-P), are
elevated, suggesting increased activity of the PPC. Since PPC pathway is in parallel with
glycolysis, the elevated activity of the PPC indicates increased glycolysis. Therefore,
ATRF reprograms glucose metabolism away from gluconeogenesis toward glycolysis.
ATRF also improves protein homeostasis in the liver. In high-fat fed mice under ad
libitum, the oscillation of phospho-ribosomal protein S6 (pS6), an indicator of protein
synthesis, is blunted while ATRF restores the oscillation. Energy homeostasis is also
improved with ATRF. The levels of 5' adenosine monophosphate-activated protein
(AMP) and phospho- acetyl CoA carboxylase (ACC) (pACC, relative to total ACC) are
increased, which reflects increased activity of AMP-kinase (AMPK), a key regulator of
energy metabolism. AMPK also plays an important role in diabetes as the net effects of
AMPK activation inhibit lipogenesis, stimulate fatty acid oxidation, lipolysis and glucose
uptake, and modulate insulin secretion from pancreatic beta-cells (Winder and Hardie
1999). In addition, the expressions of uncoupling protein 1/2/3 (UCP1/2/3), which
encodes proteins participate in thermogenesis, are increased in the BAT, suggesting
increased energy expenditure. In summary, the alternations in nutrient and energy
homeostasis participate in the beneficial effects of ATRF on high-fat fed mice.
In this dissertation, however, we did not observe significant improvements of
ATRF on nutrient hemostasis of the db/db mice, including fat body mass, non-fasting
blood glucose, insulin sensitivity, plasma insulin, NEFA or cholesterol. These results are
in contrast to the effects of ATRF on high-fat fed mice. A possible explanation for the
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discrepancy between db/db and high-fat fed mice is that effective impacts of ATRF on
metabolism may require intact leptin signaling, given the consideration that the db/db
mice have a loss-of-function mutation of the leptin receptor. Actually, in high-fat fed
mice under ATRF, the leptin levels are significantly decreased compared to ad libitum
feeding (Hatori, Vollmers et al. 2012, Chaix, Zarrinpar et al. 2014). As reviewed by Stern
et al (Stern, Rutkowski et al. 2016), leptin interacts with glucose and lipid metabolism in
multiple tissues. For example, leptin increases glucose uptake and glycogen synthesis in
vivo (Barzilai, She et al. 1999) and in vitro in soleus muscle (Ceddia, William Jr et al.
1999), cultured L6 muscle cells (Bates, Gardiner et al. 2002), C2C12 myotubes (Kellerer,
Koch et al. 1997) and adipocytes (Müller, Ertl et al. 1997). It also inhibits glycogenolysis
and gluconeogenesis in hepatocytes (Ceddia, Lopes et al. 1999). In addition, leptin
modulates function of the pancreas by inhibiting insulin secretion in the pancreatic β
Cell (Ceddia, William Jr et al. 1999, Seufert, Kieffer et al. 1999, Laubner, Kieffer et al.
2005) and glucagon secretion in the α Cell (Soedling, Hodson et al. 2015) (Tudurí,
Marroquí et al. 2009). For lipid metabolism, leptin has been shown to inhibit lipogenesis
and increase fatty acid oxidation and triglyceride hydrolysis in adipocytes (William,
Ceddia et al. 2002), liver (Huang, Dedousis et al. 2006, Huynh, Neumann et al. 2013) and
skeletal muscles (Minokoshi, Kim et al. 2002). Reduced body weight with ATRF in highfat fed mice has consistently been observed in other studies (Arble, Bass et al. 2009,
Hatori, Vollmers et al. 2012, Sherman, Genzer et al. 2012, Tsai, Villegas-Montoya et al.
2013, Chaix, Zarrinpar et al. 2014, Yasumoto, Hashimoto et al. 2016). However, the body
weight of the db/db mice is not significantly decreased following ATRF, despite less food
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consumption vs. ALF. One explanation for the unchanged body weight is that ATRF
decreases energy expenditure (EE) in the db/db mice. Therefore, we monitored the EE
and found that ATRF significantly decreases the 12-h light-phase EE, but leaves the 12-h
dark-phase EE unchanged in the db/db mice; therefore, the 24-h daily EE is reduced.
Lowered light period EE is also observed in dark-phase high-fat fed mice; however, darkphase high-fat feeding also significantly increases their EE during the dark period,
therefore resulting in unaltered 24-h EE (Bray, Ratcliffe et al. 2013). Interestingly, in the
current study, there is a trend of decrease in the light-phase EE and increase in the darkphase EE in chow-fed control mice with ATRF, while the 24-h daily EE is unchanged,
which is consistent with high-fat fed mice. Therefore, the different EE response to ATRF
between control and db/db mice may be attributable to impaired leptin signaling due to
leptin receptor mutation in the db/db mice. Actually, leptin is known to stimulate EE
through its action on the hypothalamus (Meier and Gressner 2004), and plays a critical
role in the regulation of body weight (Halaas, Gajiwala et al. 1995, Friedman and Halaas
1998). However, whether the improved nutrient homeostasis and increased EE during
the dark-phase with ATRF in high-fat fed mice is dependent upon leptin signaling need
further investigations.
Another intriguing finding of this dissertation is that both the db/db-mPer2Luc
and db/db mice lose their rhythms in RER, and ATRF partially restores the RER oscillation
in the db/db mice. In normal mice, there are apparent time-of-day variations in RER,
with higher values during the active-phase indicating the preferential use of
carbohydrates and lower values during the inactive-phase indicating the preferential use
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of fats. This is consistent with previous observations in humans (van Moorsel, Hansen et
al. 2016) and rodents (Bray, Ratcliffe et al. 2013, Oosterman, Foppen et al. 2015, Sun,
Wang et al. 2015). Previous studies also demonstrated RER in the db/db mice is
decreased at one specific time of the day (Osborn, Sanchez-Alavez et al. 2010, Choi, Kim
et al. 2015). However, it is surprising that it has not been reported whether the daily
rhythm of RER is disrupted in the db/db mice. The current study first demonstrated that
the leptin receptor mutant mice, regardless of gene background, lose the RER time-ofday variations. These results suggest that the flexibility to use different sources of fuel is
compromised in diabetic mice. Importantly, imposing ATRF partially restores the RER
oscillation in the db/db mice. However, it is not clear whether the attenuated RER daily
rhythm is associated with compromised BP dipping and whether the recovery of RER
oscillation after ATRF contributes to the restoration of BP rhythm.
We further investigated whether the improved oscillation of RER and EE upon
ATRF is Bmal1-depenent. In contrast to the partial recovery of BP daily rhythm with
ATRF in iG-Bmal1-KO mice, ATRF dramatically improves the RER oscillation that is even
more robust than the flox mice. These results are comparable with the results of a
recent published paper that ATRF drives the rhythms of RER in mice lacking clock genes
(Chaix, Lin et al. 2018). In that paper, the authors monitored the RER in three different
strains of clock gene knockout mice, the liver-specific Bmal1 knockout mice (Bmal1LKO), liver-specific Rev-erbα/β double knockout mice (Rev-erb α/β LDKO) and Cry1/2
double knockout (CDKO) mice. The oscillations of RER are blunted in all the three strains
of mice and ATRF restores the rhythms, suggesting the feeding and fasting cycle is able
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to drive the rhythm of RER in mice lacking clock genes. Regarding EE, ATRF also
significantly increased the EE oscillation in both the iG-Bmal1-KO and Flox mice;
however, the amplitude and robustness were still lower in the iG-Bmal1-KO mice. In
addition, the 24-h EE in the iG-Bmal1-KO mice are not significantly different between
ATRF and ALF. These results are in contrast to the results of the Chaix et al study, which
showed increased EE upon ATRF in high-fat fed Bmal1-LKO, Rev-erb α/β LDKO and CDKO
mice (Chaix, Lin et al. 2018). One possible explanation for this difference is the mice in
Chaix et al study were fed with high-fat diet while the iG-Bmal1-KO mice were fed with
chow diet. It is possible that the EE responses to ATRF are different between different
diets, especially considering the fact that high-fat diet itself has been shown to decrease
EE (Choi, Kim et al. 2015). In addition, the body weight in the mice with ATRF is lower
than the mice fed ad libitum; therefore when the EE is normalized to body weight, the
resulting EE will be higher in the mice with smaller body weight if assuming the EE
before normalization are equal between ALF and ATRF. However, the body weights
between ATRF and ALF in the iG-Bmal1-KO mice fed chow diet are not significantly
different; hence the normalized EE with ATRF is the same as the mice with ALF. An
alternate explanation is that the deletion of Bmal1 in this dissertation is global, in both
SCN and peripheral tissues, while the Bmal1 KO mice in Chaix et al study is liver-specific.
The SCN has been shown to control EE (Coomans, van den Berg et al. 2012). Therefore,
the EE responses to ATRF might be different in mice with and without intact central
clock.
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4.7 Limitations and Future directions
The major limitation of this dissertation is the diabetic mouse model. The
diabetic phenotypes of the db/db mice are caused by the leptin receptor mutation.
However, the leptin receptor mutation in humans is rare, and it is not known whether
the protective effect of ATRF on the BP circadian rhythm in the db/db mice also
applicable to the diabetic patients whose the diabetic symptoms are often induced by a
change of lifestyle. Therefore, testing the effect of ATRF on the BP circadian rhythm is
needed in different diabetic animal models, such as the high-fat diet induced diabetic
mouse.
The second limitation of this dissertation is all the experiments were done in
male mice. It is not known whether there is a gender difference in the mechanisms of
diabetes-associated BP circadian rhythm disruption and whether ATRF is equally
applicable to female diabetic animals.
We have demonstrated that the ANS participates, in part, in the protection of
ATRF on the BP circadian rhythm; however, we did not find any changes with ATRF in
the time-of-day mRNA expressions of the norepinephrine biosynthesis/ disposition
enzymes or the adrenergic receptors in the vascular. It is possible that the effects of
ATRF on the enzymes and receptors are at translational, or post-translational, levels. It
could also be that the ATRF affects the activities of the enzymes, rather than on their
expressions. In addition, the effects of ATRF on the autonomic nervous system may act
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in the brain. Therefore, further experiments are needed to understand the underlying
mechanisms of the ATRF on the ANS.
Using the iG-Bmal-KO mice we have demonstrated that Bmal1 partially
participates in the protection of ATRF on the BP circadian rhythm. It is not known
whether other clock genes, such as Cry1, also play a role. Previous studies have reported
that Cry1/2 double knockout mice exhibit abnormal BP circadian rhythm (Masuki, Todo
et al. 2005, Doi, Takahashi et al. 2010). Importantly, the time-of-day expression of Cry1
is also altered in the db/db mice and recovered with ATRF. Therefore, it is interesting to
test the role of Cry1 in the protection of ATRF on the BP circadian rhythm.
We have demonstrated that ATRF effectively prevented and restored the
disrupted BP circadian rhythm in diabetic mice. It would be interesting to test whether
ATRF is also able to prevent or restore the BP circadian rhythm in diabetic patients.

4.8 Concluding remarks
Findings from this dissertation demonstrate that the desynchronization of
peripheral tissues participates in the compromised BP circadian rhythm in diabetes.
Moreover, the active-time restricted feeding may serve as a novel and effective therapy
against the disruption of BP circadian rhythm in diabetes.
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